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ABSTRACT 
 The DDS/+ mouse is a model for glomerulosclerosis in Denys Drash Syndrome 
(DDS). The mutation results in a 20% reduction in nephron number that triggers a 
compensatory cascade of events leading to glomerulosclerosis. However, the 
mechanisms controlling the rate of maturation of nephrons and determining final 
nephron number within a kidney are not fully known. Stereological examinations on 
newborn kidneys were performed for glomerular count. Microarray analysis of foetal 
kidneys was carried out to reveal differentially expressed genes. 1136 differentially 
expressed genes were identified by microarray, of which the top 5 genes encoded 
mitochondrial tRNAs. Ingenuity Pathway Analysis indicated the involvement of renal 
developmental and tRNA splicing in the underlying mechanisms. Cross-database 
analyses revealed at least 216 genes that contain intragenic WT1 target sequence 
therefor represent potential direct targets of WT1 that are mis expressed due to the 
mutation. Given the expression changes of apoptosis related genes, TUNEL staining to 
identify apoptosis was carried out to reveal insignificant differences between genotypes. 
Given abnormal expression of mitochondrial tRNAs, immunofluorescence and western 
blotting were carried out and confirmed the presence of WT1 protein in mitochondrial 
isolates. Furthermore, metabolic profiling revealed abnormalities in the oxidative 
phosphorylation system in WT1 mutant cells compared with wild type.  
This study identified a list of genes that are associated with WT1 induced nephron 
underdosing, many of which have not previously been linked with nephrogenesis. The 
data suggests a role for apoptosis in nephron underdosing, however, more strikingly, the 
differentially expressed genes point to more complex molecular interactions involving 
mitochondria and WT1. To date, there are no reports of WT1 involvement in any aspect 
of mitochondrial biology. Molecular analyses verified WT1 protein is found in 
mitochondria indicating the potential for direct involvement of WT1 in mitochondria and, 
therefore, a potential for mitochondrial involvement in nephron development and 
endowment. These data suggest a previously unrecognised component of 
nephrogenesis that should be considered in future investigations to further uncover the 
various pathways involved in final nephron endowment. 
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CHAPTER 1. INTRODUCTION 
1.1 - Wilms Tumor 1 gene:  
Located at chromosome 11p13, the WT1 gene spans across 10 exons (Hammes 
et. al., 2001). Exons 5 and exon 9 provide the location of the main alternative splice 
donor sites. Exon 7-10 encodes four zinc finger (ZF) domains. It is postulated that WT1 
plays a role in RNA processing by binding to both GC-rich and TC repeat elements, in 
addition to the well-established role as a transcriptional regulator (Morrison et. al., 2008). 
Consistent with these functional differences, WT1 antibody staining shows localization 
within the nucleus that appears as diffuse, typical of transcription factors, or speckles, 
typical of splicing factors (Discenza et. al., 2004). In normal kidney development, WT1 is 
important for metanephric mesenchyme survival and ureteric-bud induction (Miguel et al. 
2005). WT1 gene plays a crucial role in urogenital system normal development and in 
some tumours such as Wilms tumour when mutated or misregulated. It exhibits a 
complex interaction in different tissues, with monoallelic and biallelic expression of both 
parents, tissue-specific and can be polymorphic imprinting pattern. There are multiple 
WT1 transcript reported of WT1 with evidence suggesting a non-AUG (CUG) translation 
initiation codon in some cases. Example of diseases related to mutation of WT1 is 
Denys-Drash Syndrome (DDS). In the kidney, when the WT1 related pathway is 
dysregulated, is can contribute to development of glomerulosclerosis, and specifically 
related to a specific type Primary Focal Segmental Glomerulosclerosis (FSGS). As a 
transcriptional factor, WT1 is important for cell survival and cellular development. 
(Hamilton et al., 1995), and recognize the sequence 5-GCG(T/G)GGGCG-3 (Stoll et al., 
2007, Hashimoto et al., 2014) for DNA binding. Among the genes that were found to be 
the target for WT1 are Bmp7 that is essential for kidney development and Sulf1 which 
important in glomerular filtration.  
WT1 is crucial for the urogenital development, and it also been shown to have tumour 
suppressor role. This is thought to be isoform specific. WT1 is a zinc finger DNA binding 
protein. WT1 isoforms without KTS (-KTS) motif are seen to have transcription factors 
functions (Smolen et al., 2004). WT1 isoforms having KTS (+KTS) motif have the ability 
to bind to mRNA and involve in mRNA metabolism and spicing (Markus et al., 2006). 
Intron 9 of WT1 provides the most important splice site, the +KTS and -KTS are different 
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due to the insertion of 3 amino acids difference, lysine, threonine, and serine, located 
between zinc fingers 3 and 4, in +KTS which is crucial for kidney and gonad 
development (Hammes et. al., 2001). Exon 5 of WT1 provide site for insertion of an 
alternatively spliced 17-amino acid segment (Hossain and Saunders, 2001). These 4 
isoforms were the main form of WT1 proteins, and interaction of these 4 isoforms are 
thought to control the differentiation and cellular proliferation with their own target (Haber 
et al., 1991).  
 
Figure 1.1.1. Figures show the exons of WT1 gene and the protein with 4 zinc 
finger (ZF) motifs at the C-terminus and a proline/glutamine-rich DNA-binding 
domain at the N-terminus. 
 
 
Call et al. (1990) and Gessler et al. (1990) were the first to isolate WT1 protein when 
postulating the causative factors in Wilms tumour. Disruption of the DNA binding motif of 
WT1 either by somatic or constitutional mutation will result in a dominant negative 
phenotype. The WT1 (-KTS) isoforms was seen to be localised inside the nucleus in 
diffuse pattern, whereas WT1(+KTS) shows speckled pattern within the nucleus. 
Although different isoforms and mutations may show distinct patterns of subnuclear 
localisation, WT1 dominant negative protein interacting with other WT1 wild type 
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associated proteins may result in protein complex formation that concentrated within 
nucleus. Since then, Scharnhorst et al. (1999) described further 32 WT1 isoforms, 
further the complexity of WT1 activity and expression.  
Davies et al. (2000) showed in a site-directed mutational experiment that only the 
disruption of the zinc fingers was sufficient to generate proteins with different properties 
in vitro. +/- KTS isoforms of WT1 retain their balance of expression when not interacting 
with targeted DNA. Introducing DNA of its target would disrupt the interactions of linkers 
and zinc fingers, and would bind to specific sites, with -KTS involved in a C-terminal 
helix-capping. Following this, Laity et al. (2000) generated different WT1 isoforms 
interacting with different locations allowing it to act at both the transcriptional and 
posttranscriptional levels. Mitsuya et al. (1997) study on fibroblast and lymphocyte 
shows biallelic expression nature of WT1, complementing the findings by Jinno et al. 
(1994) biallelic WT1 in more than half of the cells of preterm placental villus and foetal 
brain, suggesting tissue specific and individual-specific modifier.  
In a study by Niksic et al. (2004), up to half of Wt1 protein was shown to localized in 
cytoplasm. Wt1 proteins were continuously shuttled between cytoplasm and nucleus, 
including WT1 (+/-KTS) isoforms. Cytoplasmic WT1 proteins are mostly associated with 
ribonucleoprotein particles (RNPs) and are involved in regulation of translation.  
 
 
1.2 – Kidney: Normal structure and function 
In a normal developed adult, grossly kidneys are paired organs, have a general shape of 
a bean measuring about 6cm wide, 11cm long and 3cm thick. Each kidney weighs 
approximately 150grams, positioned at the level of T12-L3, with the right kidney 
positioned slightly lower than the left kidney due to the surrounding organs. Blood is 
supplied to the kidney via a pair of renal arteries and exit via a renal vein from each 
kidney. From the renal pelvis, urine is drained through the ureter to the urinary bladder. 
Each of the kidneys are enclosed by renal capsule that made of thin fibrous connective 
tissues as a protective against injuries and infections. The renal capsule is surrounded 
by a layer of adipose tissue, which in turn enclosed by renal fascia.  
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Figure 1.2.1: Figures showing the general location and the cross section of the kidney. 
The cross-section showing the capsule, cortex, and medulla. The Cortex consists of 
renal corpuscles (glomerulus) and convoluted tubules. Medulla is the innermost layer, 
consisting loops of tubules and collecting ducts, and clustered into renal pyramids 
(pyramid-like appearance) separated by renal columns, that concentrate to become 
calyces that formed funnel, called renal pelvis that funnel out urine to the ureter. Image, 
guniita©123RF.com.  
Capsule 
Cortex 
Medulla 
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Figure 1.2.2: Figures showing the A) cross-sectioned kidney and zoomed-in at the 
border between cortex and medulla and B) the structure of the functional unit of the 
A ) 
B ) 
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kidney, the nephron.  Cortex is the area of the kidney where most glomerulus are 
located. Glomerulus is the part which filters the plasma. Image, guniita©123RF.com. 
 
The kidneys as a paired organ serve the human body with multiple important functions. 
Inside the kidney, the most important structural and functional unit is the nephron. On 
average, each adult kidney has about 1 million nephrons and this can vary between 
individuals. The nephron regulates the contents of the plasma that flows through the 
kidney via the processes of filtration, reabsorption, secretion, and excretion. The most 
obvious function of the kidneys is the excretion of waste metabolites from the body, 
including but not limited to, urea, creatinine, uric acid and others such as drugs and 
toxins in the urine. The kidneys also selectively reabsorb the required elements back 
such as required electrolytes, water, amino acids and glucose in the renal tubules, and 
regulates pH balance. By regulating the fluid and electrolyte balance, kidneys regulate 
the body osmotic pressure, termed osmoregulation. They also serve as an endocrine 
organ, in which an enzyme, renin, is secreted which is involved in regulating blood 
pressure, production of erythropoietin, which is essential for normal red blood cell 
formation, and in converting vitamin D precursor to its active form, 1, 25-
dihydroxycholecalciferol (calcitriol).  
 
 
1.3 – Normal Kidney Development 
During normal embryogenesis, at e8-e9.5 of mice foetal development, the first 
hint of kidney formation is the appearance of a pair of nephric ducts (ND) (a.k.a Wolffian 
duct) which dorsally grows from the intermediate mesoderm (IM) just under the 5th 
somite. This duct grows reaching the cloaca, sequentially forming pronephric than 
mesonephric tubules. The anterior end of pronephric duct consists of a transient 
rudimentary structure called pronephros that is non-functional in mammals, that rapidly 
degenerates. As the ND grows, the middle part, made up of mesenchymal cells (a.k.a. 
mesonephric duct), condenses to give rise to mesonephric tubules. These tubules 
having the mesonephros anteriorly are transient and degenerate as the duct develop 
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caudally, until the metanephric kidneys develop from induction with metanephric 
mesenchyme (MM) (Saxén and Sariola, 1987, Dressler G, 2006). 
At e10.5-11, at the hind limb of the nephric duct just under the 25th somite, 
outgrows an epithelial tissue budding, the ureteric bud (UB). The initiation of kidney 
development requires reciprocal and sequential interaction of intermediate mesoderm 
(IM) derived tissue, an outgrowth of epithelial tissue from the nephric duct, when the 
ureteric bud (UB) emerge and invading the adjacent metanephric mesenchyme (MM) 
(Figure 1.3.1) (Saxén, 1987). After the initial budding, signals from the metanephric 
mesenchyme (MM) direct the subsequent branching of the ureteric bud tips, forming a 
polarized renal vesicle (RV) (Costantini and Kopan., 2010) further generating an 
arborized network of collecting duck system, that concentrates and transports urine out 
from glomeruli to the ureter and bladder.  
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Figure 1.3.1: Stages of normal for kidney development in mouse. Schematic 
representation of kidney development showing maturation from condensed 
mesenchyme to comma shaped body, then S-shaped body, then mature glomerulus.  
WT1 expression levels are represented by the lowest bar. WT1 is expressed at low 
levels throughout the metanephric mesenchyme, in the adult WT1 expression is 
restricted to podocytes but is expressed at high levels.  
 
As the polarized RV grows, the distal part grows, attaches and links to the 
bordering UB forming a connected structure. The connected RV quickly grow and 
advance to form comma-shaped bodies (CSB) and grow further to be S-shaped bodies 
(SSB). SSB is retain the polarized attribute, having proximal, intermediate and distal 
segments that connects to the UB. The most proximal segment subsequently expands 
into two layers of epithelial of visceral and parietal, respectively later known as 
Bowman’s capsule and podocytes. The segmentation of SSB further evolves to become 
the mature nephron composed of glomerulus (proximally), proximal tubule, loop of Henle 
and distal tubule (distally) that connected to the collecting duct. The mature nephron is 
seen as early as E16.5 however various stages of nephron development can still be 
seen until postnatal. All the nephron development stages coexist at the same time 
(Hartman et al., 2007). This actually one of the reasons why with presence of non-fatal 
factors that affect kidney development, the range of reduction of nephron number is not 
very profoundly different from wildtype, nonetheless important long term.   
WT1 gene plays central role in initiating nephrogenesis as shown in a gene 
knockout experiment in transgenic mice (Kreidberg et al., 1993). WT1 was shown to be 
expressed in the condensing mesenchyme (cap mesenchyme, CM) and also 
specializing cells in glomerular formation (visceral epithelial/podocytes) (Pritchard-Jone 
et al., 1990, Rackley et al., 1993, Yeger et al., 1992), with the expression was 
documented to be lowest in metanephric mesenchyme with generalized expression 
throughout developing kidney, becoming more concentrated as specialization continues 
with the highest in the S-tubular forms, then the expression gradually lowers as 
maturation of glomerular progresses, which WT1 expression absent from tubules and 
concentrated in specialized cells of the mature glomeruli uniformly express WT1, the 
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podocytes cells which only can be seen to actively express WT1 in mature glomerulus 
(Yeger et al., 1996).  
The expression pattern of WT1 is restricted in general embryogenesis and the 
intracellular expression pattern in renal development contribute to the possibility of WT1 
having specific and dedicated roles in specific tissues and cell specific differentiation. It 
is also likely that it serves as main regulator of glomerular and nephron differentiation 
and to some extent functional maturation (Yeger et al., 1996). The expression of WT1 
persists into the postnatal period at relatively high levels with concurrent continuation of 
growth and maturation processes of mouse kidney (Armstrong et al., 1993, Buckler et 
al., 1991, Rackley et al., 1993., Saxen et al., 1987) which is later followed by a steady 
decrease to low level adult expression 2 weeks after birth (Yeger et al., 1996) once the 
kidney tissues are differentiated to functional specialization and the glomeruli mature 
and losses it’s proliferative ability.  
 
 
Figure 1.3.2: Significant turn points of lineage relationship of cells in developing kidney 
(adapted from Little and McMahon, 2012) 
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During kidney developmental processes, three main progenitor populations have 
been proposed from cell-fate studies (reviewed by Little and McMahon 2012), those are 
the cap mesenchyme (CM), vascular progenitors and stromal progenitors.  
It is thought that notwithstanding the slightly different of starting time of each 
individual nephron, the local expression of nephron development is the same. 
Embryonic nephron shows patterns of origin underneath the ureteric tip while final 
nephron push post birth resulting in multiple direct connecting nephron per ureteric tip 
(Rumballe et al., 2011).  
 
 
1.4 - Chronic Kidney Disease (CKD) 
 1.4.1 – Background  
Chronic renal disease is a reduction of renal function attributed to structural 
abnormalities as evidenced by changes in glomerular filtration rate (GFR) or pathological 
examinations (National Kidney Foundation, 2002).  
Chronic kidney disease (CKD) is an irreversible loss of renal function for at least 
three months. It is a major public health issues and is a significant burden on health care 
funding. The prevalence of CKD and end-stage renal disease (ESRD) is high in 
advanced countries and is increasing worldwide. It is estimated that the prevalence of 
CKD in the US was 16.8% while in Asia the prevalence ranged from 12.1% to 17.5%, 
data were collected in 2007-2008 and 2006-2007 respectively (Ingsathit et al., 2010, 
Chen et al., 2009). In Malaysia, the incidence and prevalence of patients with ESRD on 
dialysis had increased from 88 and 325 per million population (pmp) respectively in 2001 
to 170 and 762 pmp respectively in 2009. The increase in ESRD was largely driven by 
the increasing incidence of diabetic kidney disease (DKD) accounting for 58% of new 
patients accepted for dialysis (Lim et al., 2011). The increasing incidence is attributed to 
the increasing population of ageing people and chronic non-communicable disease 
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(non-infectious in origin) such as hypertension and diabetes mellitus as the main cause, 
with the projection of exceeding 2 million people will be on dialysis for CKD by 2030 
(Szczech and Lazar 2004).  
However, for paediatric cases, the causes of CKD are a bit different. The North 
American Paediatric Renal Trials and Collaborative Studies (NAPRTCS) registry 
collected data on paediatric CKD patient, including below 21 years old since 1994, 
providing a number of causes of CKD in children (Fivush et al., 1998, NAPRTCS 2008). 
In the NAPRTCS report, it is documented that the most common causes included 
congenital anomalies of the kidney and urinary tract (CAKUT) (48%) followed by 
hereditary nephropathies (10%), followed by others such as glomerulonephritis, 
haemolytic uremic syndrome, congenital nephrotic syndrome and others (Harambat et 
al., 2011). The cases and incidence of individual diseases varies with age accordingly. 
All these diseases contribute to development of CKD in children, which in most cases 
contributes to glomerulosclerosis and varies across races. For example, in African 
American children the incidence of glomerulosclerosis is 3 times higher (19% versus 
6%) than Caucasian children (NAPRTCS 2008). These causes of CKD were found to be 
similar in registries in Belgium and Italy (Ardissino et al., 2003, Mong et al., 2010).  
The growing number of cases of ESRD places an enormous burden in both 
economic and social terms and on the healthcare system. In an economic evaluation 
among the Ministry of Health dialysis centres in Malaysia, the cost of dialysis and 
erythropoietin was RM2,500 per month for a patient (Hooi et al., 2005). In the US, the 
cost of medical care was 1.7 times higher in patients with CKD stage 3 and 2.6 times 
higher in those with stage 4 CKD compared with controls (Smith et al., 2004). Early 
kidney disease is largely asymptomatic and patients often present late with 
complications of CKD. As such, targeted screening and early intervention will be 
necessary to reduce the burden of the disease. Primary care providers play a key role in 
the early identification, treatment and improving the outcome of patients with CKD. 
Awareness of CKD among primary care providers should be increased and they should 
be equipped to treat these patients. As the prevalence of diabetes is increasing and 
DKD remains the most common cause of CKD, optimal control of diabetes will be 
necessary to prevent CKD. 
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Chronic kidney disease is increasing worldwide (Arora, 2012). 
Glomerulosclerosis, resulting in reduced renal filtration and leading to renal failure is the 
common aetiology of a range of conditions leading to CKD – most notably diabetic 
nephropathy. Once triggered, glomerulosclerosis spreads throughout the kidney and the 
stress of reduced renal filtration causes death of podocyte cells, thus exacerbating the 
condition. It is known that the stress of reduced renal filtration induced by nephron 
underdosing, for example, as a result of poor maternal nutrition or preterm birth, is a key 
risk factor for susceptibility to glomerulosclerosis in adult (Bertram et al., 2011).  
The evaluation of kidney function is done through equations estimating the 
glomerular filtration rate (eGFR), replacing the traditional serum creatinine in 1999. Due 
to the more reliable evaluation system, more people have been identified and labelled 
as CKD. In a population of ageing people at 70 years old and over, about half would 
have eGFR of <60 mL/min/1.73 m2 (Ebert et al., 2017) which is actually the advocated 
threshold for diagnosing CKD (National Kidney Foundation 2002). The higher 
prevalence of detectable CKD with ageing also would increase the burden of manging 
CKD (KDIGO 2012).  
It is suggested that CKD shares a common pathway of progressive injury.  This is 
shown by the common appearance of glomerulosclerosis, vascular sclerosis and 
tubulointerstitial fibrosis (Olson and Heptinstall 1988) (basically a progressive scarring of 
renal tissues). The adaptation capabilities of the nephron are reduced as the changes 
occur with time and injury, eventually scarring occurs, and further reduces the 
capabilities of nephron and kidney as a whole, perpetuating a vicious circle, that ends up 
in end stage renal failure. The possible mechanisms underlying sclerosis may be 
different in relation to different kind of disease, but they may involve some factors such 
as; possible underlying predispositions for CKD, genetic factors and low nephron 
number, podocyte loss, hemodynamic factors, proteinuria, various cytokines and growth 
factors, renin–angiotensin–aldosterone system (RAAS) and specific mechanisms of 
tubulointerstitial fibrosis (Fogo 2007).  
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1.4.2 – Glomerulosclerosis  
Glomerular sclerosis also known as glomerulosclerosis is the condition where the 
glomerulus and its blood vessel in the kidney are scarred and hardened. Focal 
segmental glomerulosclerosis is where only some part of the glomeruli is damage or 
sclerosed. Both global and focal glomerulosclerosis have been shown to occur in 
various populations, age groups and kidney donors (Rule et al., 2010, Kubo et al., 2003, 
Hoy et al., 2003). In older people where there is reduction in podocyte number, a crucial 
functional cell in the glomerulus for filtration, this causes the glomerular tuft collapse and 
influences the development of glomerulosclerosis (Hodgin et al., 2015).  
 
Figure 1.4.2.1. Representative figure of H&E-stained kidney sections from wild 
type (wt) mice and mice revealing glomerular sclerosis (dense matrix of 
sclerosis), obliteration of the glomerular space and glomerular capillary. Image 
curtesy of Ahzad MSc (2010).  
 
Normal adults have some degree of a sclerosed glomerulus, but the upper 
reference (95th percentile) limit was determined from 1847 kidney donors for 
normotensive living kidney donors according to age (Kremers et al., 2015). For example, 
in a biopsy of a kidney showing 20 glomeruli, one of them is expected to be sclerosed in 
a 25-year-old, whereas 6 glomeruli are expected to be sclerosed in a 75-year-old. In 
patients with kidney diseases, risk estimation for CKD progression would be better with 
this age-specific glomerulosclerosis estimation (Srivastava et al., 2018, Hommos et al., 
WT Mutant 
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2018). FSGS, when seen in a biopsy of human kidney, is usually considered 
pathological. FSGS can be caused by a number of factors, one of those is the genetics. 
Genetic mutations that encode for protein functions in podocytes, slit diaphragm, 
glomerular basement membrane and fenestrated endothelial layer of the filtration barrier 
would contribute to FSGS formation. In children, FSGS usually follows an autosomal 
recessive pattern, in which the most common genes involved are nephrin (NPHS1), 
podocin (NPHS2), and phospholipase C epsilon 1 (PLCE1). For autosomal dominant 
FSGS, it usually manifested in older children, adolescents and adults.The most common 
genes involves are; inverted formin, FH2, and WH2 domain containing (INF2), actinin 
alpha 4 (ACTN4), TRPC6, WT1, and LMX1B (Barua et al., 2013, Hinkes et al., 2007, 
Santín et al., 2011). FSGS in these cases might presented as familial disease or 
sporadic, autosomal dominant or recessive, X-linked or matrilineal, in which case are 
thought to be related to mitochondria (An et al., 2018).  
 
1.5 – Denys Drash Syndrome (DDS) 
1.5.1 – Background 
Denys-Drash syndrome (DDS) is featured by a triad of male 
pseudohermaphroditism, Wilms tumour and progressive renal disease. In the kidneys of 
these patients, there will be diffuse mesangial sclerosis, scarring of the kidney that is 
seen from infancy, marked by proteinuria that later progress to nephrotic syndrome and 
renal failure. Pelletier et al. (1991) managed to identify a genetic mutation in the WT1 
gene in 10 of his DDS patients (out of 17 patients). Later on, Baird et al. (1992) showed 6 
out of 8 of his DDS patients had a similar genetic defect of heterozygous germline 
mutations. DDS patients were shown to have a germline point mutation in WT1 gene in 
the eighth or ninth exons, which resulted in the substitution of single amino acid, and 
almost all of these patients developed Wilms tumour in the kidney. By investigating 
these patients, Hastie (1992) demonstrated that the WT1 gene is important in 
development of the genitourinary system, with evidence of the WT1 mutation having a 
dominant negative effect in these cases. In the process of sexual differentiation, the 
WT1 gene interacts with SF1 (steroidogenic factor 1), and this is crucial for 
gonadogenesis in mammals. It acts via the regulation of MIS (Mullerian inhibiting 
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substance). In normal physiological development, Müllerian duct will form later female 
reproductive organs later on (these include oviducts, uterus, cervix, upper vagina), 
however in males, Müllerian duct regression (self-apoptosis) will occur, and WT1(-KTS) 
isoforms was shown before to be related to this switching of Müllerian duct continuous 
development or regression (Nachtigal et al., 1998). The WT1(-KTS) isoform was shown 
in vivo to be able to transactivate a gene that can determine sex in humans; the SRY 
gene, by promotor region binding and at least four mutations of WT1 were seen in DDS 
causing SRY gene failure for promotor activation (Hossain and Saunders 2001). In DDS 
glomerulopathies, it is thought that the loss of WT1 functions impairs the podocyte 
development and maintenance, and WT1 knockout mice showed podocyte 
differentiation defects, leading to kidney failure and early death (Dong et al., 2015). 
However, the exact molecular mechanism of how WT1 mutation cause the changes at 
cellular level is still undetermined.  
 
1.5.2 – Animal Model - Wt1tmT396/+ mice (a.k.a DDS/+) 
Heterozygous Wt1tmT396/+ a.k.a DDS/+ mouse in this thesis, were first produced 
in Patek laboratory at the Sir Alastair Currie Cancer Research UK Laboratories, 
University of Edinburgh.  Mice were then transported to Newcastle Medical School, 
Newcastle University in accord with our Home Office licence.  In both settings mice been 
given similar feed pellets with extra of sunflower seed given in Newcastle.  All animal 
sources used in the study listed were taken from Newcastle animal breeding centre. In 
the beginning, WtV1 gene targeting vector when introduced, inserting a Leu2/neo 
cassette in the middle of Wt1 exon 9 (Figure 1.5.2.1-a).  This brings about an amino acid 
substitution (S395R) which subsequently causes a premature termination within zinc 
finger 3 as a result of translational stop at codon 396 (Wt1tmT396) inclusions.  In general, 
it resulted in truncated protein of 7.3kDa with loss of the next 52 amino acids, together 
with the KTS insert (main isoform forming point) and the last zinc finger 4. The 
production and identification of these ES cells (DDS/+) by multiple analysis has been 
illustrated in detail in Patek et. al., 1999. Accurately targeted, 129/Ola-derived ES cells 
were then injected into host blastocysts of C57BL/6JLac. The product chimeric mice 
identified by their coat colour were then backcrossed to the original 129/Ola background 
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mice to get it close to the original wildtype as possible. Southern blot analysis identified 
the targeted ES cells (DDS/+) as distinct from the demonstrated bands of a wild-type 
(19kb) and mutant (13kb) (Patek et. al., 1999, Patek et. al., 2008), this was confirmed by 
PCR (Figure 1.5.2.1-c).  In order to advocate the line of pure 129/Ola genetic 
background, continuous breeding of heterozygous 129/Ola males with wild-type 129/Ola 
females as described by Patek et. al., 2008. This would maintain Wt1tmT396/+ mice as 
female DDS/+ mice are not fertile (Patek et. al., 2008) and unsuited for breeding. 
Heterozygous (DDS/+) mice were detected normally using PCR analysis of mice DNA 
utilising 3 primers in the same PCR reaction: Ex9F2 (5’-
AGACCTTCTCTGTCCGTTTAG-3’) positioned in exon 9, neo52 (5’-GATGCC 
TGCTTGCCGAATATCATGG-3’) positioned in the neo cassette, and Cre1R (5’-
TGTTCTGAATCTCCTGGACA-3’) positioned in intron 10. Amplification of the wild-type 
allele is by the primers Ex9F2 and Cre1R, producing a 345bp band product in wild-type 
and heterozygous mice (however not for Wt1tmT396 allele because of intervening 3.4kb 
Leu2/neo cassette). As for the primer pair neo52 and Cre1R, amplification of Wt1tmT396 
allele produce a 600bp band product in heterozygous and homozygous mice. For the 
rest of the thesis, this heterozygous Wt1tmT396 mice will be recorded as DDS/+ mice.      
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Figure 1.5.2.1: DDS/+ mouse strain production 
 (a) WtV1 inserts of the Leu2/neo cassette into Wt1 exon 9 (blue coloured).  This 
instigates an amino acid substitution (S395R) and premature termination within 
zinc finger 3 by inclusion of a translational stop at codon 396.  Figure 1.6 (b) 
Southern blot probing and generating bands of 19kb for the wild type allele and 
13kb for the Wt1tmT396 allele (heterozygous (het), homozygous mutants (hom) and 
wild type (WT)).  Figure 1(c) PCR bands of wild type (WT), DDS+/- (het, 
heterozygous) and Wt1tmT396+/+ (hom, homozygous) (wild type - 345 bp, 
Wt1tmT396 - 600bp). Image reproduced with permission from Patek et. al., 2008. 
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1.6 – Mitochondria  
  Mitochondria are important energy production organelles of eukaryotic cells. 
They have a double membrane and one of their major functions is to produce ATPs by 
oxidative phosphorylation (OXPHOS), as well as other cellular processes such as iron-
sulphur cluster biogenesis and calcium homeostasis (Duchen 2000, Stehling and Lill 
2013). In an individual cell, there will be numerous mitochondria, the number of which 
varies between cells and between individuals.   
 
Figure: 1.6.1: Figure depicting the cross-section and internal structure of mitochondria. 
Image, designua©123RF.com 
 
Mitochondria has its own DNA, mtDNA, that is circular, at 16.6kb that encodes 22 
mitochondrial tRNAs, 13 proteins of OXPHOS subunits and two mitochondrial ribosomal 
RNAs (mt-rRNAs) (Anderson et al., 1981). MtDNAl is exclusively inherited from the 
maternal ovum (Giles et al., 1980). For a mitochondrial to function properly, the mtDNA 
is not enough. There are about 1300 known nuclear-encoded mitochondrial proteins that 
will be transported into mitochondrial to support various functions and OXPHOS system 
(Calvo et al., 2016). So as the mitochondrial system depends on both mtDNA and 
- 29 - 
 
nuclear DNA, it is understandable that mitochondrial diseases would be caused by both 
nuclear and, mtDNA defects with their inheritance pattern, matrilineal (maternal) 
inheritance, or it can also be secondary from ageing associated somatic mutations 
(Greaves et al., 2014). 
Mitochondrial dysfunction would result in abnormalities in mitochondrial function, 
predominantly affecting tissues and organs which have high energy requirement. 
Clinically it can arise either in infancy or adulthood and can either affect various body 
systems or can also be isolated to certain organs only (Lightowlers et al., 2015). The 
recorded prevalence of mitochondrial diseases is around 4.7 for every 100000 children 
(Skladal et al., 2003) and about 12.5 for every adult population (Gorman et al., 2015). 
Mitochondrial diseases are very difficult to detect as correlation between the genotype 
and phenotype is somewhat lacking, which means diagnosis tends to be missed and 
complicated. 
With mtDNA having multiple copies of mitochondria within a single cell, this give rise to a 
unique aspect of mtDNA in which if all of mtDNA is of similar copies, this is called 
homoplasmy; there can also be a mixed population of mutant and wild type mtDNA, this 
is called heteroplasmy. mtDNA mutations are predominantly functionally recessive; a 
specific proportion of mutated mtDNA has to be present before a biochemical defect 
becomes apparent. (Stewart and Chinnery 2015).  When the threshold is exceeded, the 
most common biochemical defect is a reduction in the activity of the associated 
OXPHOS enzyme complex(s).. The most common mutational event for primary mtDNA 
disease is point mutations which are usually maternally inherited and also large-scale 
mtDNA deletions which usually occur de novo at the embryonic stage.  
Until to date, no study has proven any connection between the WT1 gene and 
mitochondrial genes and how they might relate each other.  
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1.7 – WT1, apoptosis and cell viability 
Apoptosis is a controlled active mode of cell death that is part of a normal 
physiological process which minimizes disruption to adjacent cells and structures (Taylor 
et al., 2008) and uses energy to proceed (Green and Kroemer, 2005).It plays an 
important role in tissue remodelling, regeneration and the establishment of tissue 
architecture in developmental processes (Meier et al., 2000). A dysfunction in apoptosis 
will contribute to an imbalance between mitosis and apoptosis, which manifests as 
developmental abnormalities, cancer or degenerative disease.  
During kidney development, the rate of apoptosis is highest during development 
(Koseki et al., 1992), and is involved in nephron number and pattern determination. A 
normally functioning kidney is critically dependent on intricate multicellular arrangement 
and nephron patterning. Loss of normal apoptosis regulation and balance can contribute 
to an exaggerated proliferative response. which can manifest as acute and chronic 
kidney diseases such as chronic tubular atrophy, podocytopenia and acute kidney injury 
(AKI) (Lorz et al., 2006, Olsen et al., 1985, Shankland SJ, 2006, Hughes and Savil, 
2005).  
At the cellular level, apoptotic cells show a distinct pattern of loss of specialised 
structures such as microvilli and also the loss of cell junctions, followed by cytoplasmic 
shrinkage, coalescent of nucleus in condensed mass, that later on breaks into 
fragments. The cells become convoluted after losing intracellular fluid and ions, and later 
breaks down into multiple membrane-enclosed apoptotic bodies that will be 
phagocytosed by mononuclear-phagocyte cells or sometimes the adjacent surrounding 
cells (Haanen and Vermes 1995) without activation of unnecessary inflammatory cells 
(Kroemer et al., 2005). 
Cell viability is maintained by an intricate interplay of various survival factors that 
actuate intracellular survival pathways and lethal factors that mediate the dormant lethal 
pathways to apoptosis system (Sanz et al., 2008) (Figure 1.7.1). Typically, cell death is 
an outcome of the cell microenvironment (Green and Kroemer, 2005, Riedl and 
Salvesan, 2007, Lorz et. al., 2006) in which surrounding the cells can be regulators of 
cell survival (e.g. soluble mediators, nutritional factors, and the extracellular matrix) or 
lethal factors (e.g. cytokines and cell stress). When triggered, cells may undergo 
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apoptosis through two main pathways: the intrinsic (intracellular homeostasis) and/or 
extrinsic pathways (ligation of plasma membrane death receptors).  
Extrinsic apoptotic pathway commenced when a death receptor is bound and 
ligated (Fas, tumor necrosis factor receptors) (reviewed in Tait and Green 2010) leading 
to the recruitment and assembly of multimolecular complexes (e.g. FADD (Fas 
associated death domain), caspase 8 and 10) (Ashkenazi and Dixit, 1999, Thorburn 
2004) which are then activated upon oligomerization and in turn activate downstream 
effector caspases (caspase 3 and 7). The intrinsic pathway implicates intracellular 
organelles complex interactions and the centre of it is mitochondria (Riedl and Salvesan, 
2007, Green and Kroemer, 2005, Ferri and Kroemer, 2001, Ravagnan et. al., 2002).  
 
 
 
 
Figure 1.7.1: 
Representative diagram 
of possibility that 
disrupted within the 
mutant kidney.  
- 32 - 
 
A complex interaction of proapoptotic and antiapoptotic members of Bcl2 family is 
integral for intrinsic pathways regulation. Among the most important, the proapoptotic 
Bak and/or Bax is triggered by the sentinel activator BH3-only proteins. (Tait and Green, 
2010), which will induce permeabilization of outer membrane of mitochondria, releasing 
more downstream proapoptotic factors, including cytochrome c, SMAC/DIABLO and AIF 
(apoptosis-inducing factor). These later then further promote apoptosis, either through 
caspase-dependent or caspase-independent pathways.  
 
 
1.8. - WT1 and disease 
1.8.1 - WT1 mutation, kidney development and disease 
Mammalian kidneys develop from the metanephric mesenchyme and ureteric 
epithelium interaction, consisting of three major stages. The intermediate mesoderm 
develops into the metanephric blastema, followed by ureteric bud outgrowth and 
branching, and subsequently the metanephric blastema condenses and forms renal 
epithelial cells (Kreidberg et al., 1993).  
In 1993, Kreidberg et al. developed a knockout mouse model for the WT1 gene. 
Mice lacking WT1 present with complete kidney agenesis and display the earliest renal 
deficiency of any knockout mouse (Sainio, et al. 1997, Ahzad Msc Project 2010). 
Knockout of the WT1 gene generated mice with multiple defects that died mid-gestation 
of abnormal heart development and completely lacked kidneys (Kreidberg et al., 1993, 
Patek et al., 2008). In adults, Wt1 is found to normally be expressed in podocyte cells of 
the kidney, gonad, spleen, the mesothelial lining of various organs, and granulosa and 
Sertoli cells (Lahiri et al., 2007). However, during kidney development, Wt1 is expressed 
in the metanephric mesenchyme at low levels and increases in the condensing 
mesenchyme of the developing nephron (known as comma- and s-shaped bodies) 
before becoming restricted to posterior part of the nephron and ultimately the podocyte 
cells of the mature glomerulus (Mundlos et. al., 1993). 
Wilms’ tumour suppressor gene (WT1) mutations in Denys Drash Syndrome 
(DDS) highlight the important developmental role of WT1 and link WT1 mutation with 
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glomerulosclerotic kidney disease (GS) (Pelletier et. al., 1991). However, recently WT1 
gene mutations have been implicated in non-syndromic kidney disease. 66% of cases of 
infant chronic renal disease carry mutations in either WT1, NPHS or LAMB2 genes 
(Hinkes et. al., 2007). Furthermore, WT1 mutations have been shown to contribute more 
widely to kidney disease, with mutations identified in numerous studies of nephritic 
syndrome (Ruf et. al., 2004, Gbadegesin et. al., 2007).  
 
 
1.8.2 - WT1 mutant mouse models of glomerulosclerosis – this subheading 
discusses mostly the previous data and findings of Caroline Wroe (PhD, 2009) and 
Colin Miles that lead to my work in this thesis.  
The failure to develop a full complement of nephrons is a significant risk factor for 
kidney disease later in life. However, the molecular mechanisms by which nephron 
number is determined are not fully known. The Miles laboratory has experimental 
evidence from mouse models carrying WT1 mutations (Patek et. al., 1999, 2003, 2007, 
Wroe PhD thesis] that both nephron underdosing and a failure to develop a full 
complement of podocyte cells contributes to the development of glomerulosclerosis in 
murine DDS. 
Miles Lab with the work of Caroline Wroe (PhD, 2009) has bred and 
characterized a genetically modified mouse strain that expresses a dominant negative 
mutant form of Wt1 (DDS/+ mice). The Wt1tmT396 mutation is analogous to a severe 
mutation causing aggressive form of Denys Drash Syndrome (Patek 199). DDS/+ mice 
show a 22% reduction in nephron number (Figure 1.8.2.1-A) and a failure to develop a 
full number of podocytes (Figure 1.8.2.1-B). 
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Figure 1.8.2.1: WT1 mutant DDS/+ (Wt1tmT396/+), Denys Drash Syndrome (DDS) 
mice present with a 22% reduction in nephron number (A) at 1 month of age 
(*p=0.034, n=6 per genotype). (B) Failure to develop a full complement of 
podocyte cells between 1 and 3 months of age. 25% fewer podocytes were 
observed in 3 months old DDS/+ glomeruli compared to wild type (*p=0.045, 
n=6). (Wroe, PhD thesis, 2009). 
 
In order to investigate the progression of GS, kidneys from DDS/+ mice were 
compared with those of wild type littermates before proteinuria and overt GS pathology 
sets in (Patek et. al., 2008).  An increase of 20% in mesangial volume fraction was seen 
using Transmission Electron microscopy (TEM) and stereology in 3-month-old DDS/+ 
kidneys consistent with the typical features of early glomerulosclerosis (Figure 1.8.2.2).  
 
 
 
 
Figure 1.8.2.2: Mesangial volume fraction of a 3 month 
old DDS/+ glomeruli showing increases by 20% 
(*p=0.023, n=6). (Wroe, PhD thesis, 2009). 
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In order to determine the consequences of reduced nephron number, the mean 
glomerular volume was measured in kidneys of one-month old mice. An increased mean 
glomerular volume with a strong negative correlation with nephron number (Figure 1.8.3) 
was observed in DDS/+ kidneys, indicative of compensatory hypertrophy. All other 
parameters were normal at this timepoint indicating that the first insult leading to GS is a 
reduction in nephron number sufficient to induce compensatory hypertrophy in the 
presence of normal numbers of podocytes (Figure 1.8.3 and Figure 1.8.2.1). Thus, the 
kidney is already responding to stress.  
 
 
  
Figure 1.8.3: 1 month of age DDS/+ mice 
showing negative correlation between nephron 
number and mean glomerular volume (MGV) 
compared to wild type. DDS/+ kidneys show 
reduced nephron number and compensatory 
hypertrophy prior to glomerular abnormalities. (r 
= -0.74, *p=0.006). (Wroe, PhD thesis, 2009). 
 
 
 
DDS/+ mice were also previously reported to show renin hyperplasia within the 
juxtaglomerular apparatus (JGA) of chimeric (DDS/+↔+/+) glomeruli (Patek et. al., 
2003). At the time this was suggested to be due to the reduction in filtration due to 
glomerulosclerosis, however, analysis of the JGA DDS/+ mice at 3 months of age 
showed that renin hypergranulation was also seen within the JGA of DDS/+ 
heterozygotes prior to extensive glomerulosclerosis (Figure 1.8.2.4).  
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Figure 1.8.2.4: Increased of Renin granulation in 
juxtaglomerular apparatus from 45% (+/-7%) in wild 
type to 66% (+/-11) in DDS/+, (*p=0.015, n=6). (Wroe, 
PhD thesis, 2009). 
 
 
 
 
Just before the onset of overt glomerulosclerosis, a normal glomerulus will 
attempt to compensate for renal stress by activation of the renin-angiotensin system 
(RAS). Some abnormalities within the podocyte were seen within DDS/+ glomeruli and 
also some localised abnormality of the glomerular basement membrane (GBM), though 
statistically not of significance. The most obvious change was the overall number of 
podocytes per glomerulus which was 25% lower in DDS/+ kidneys of 3-month-old mice 
when compared to wild type (Figure 1.8.2.1). Although the percentage was not 
substantial, this may reflect a role for Wt1 in the second wave of podocyte recruitment 
during adults that has been recently described (Appel et. al., 2009).  
In addition, newborn DDS/+ mice show evidence of increases in glomerular 
maturation. The maturing glomerulus shows open and well-defined capillary loops, 
fenestrated endothelial cells and well-defined podocytes and parietal epithelial cells. 
Under EM it was noted that DDS/+ glomeruli appeared to have more open capillary 
loops. The maturation of the glomerulus can be measured by measuring the fenestration 
of endothelial cells and this dramatic morphology can be quantified under EM by 
measuring the percentage of fenestration. The amount of fenestration was measured in 
newborn DDS/+ mice and shown to be double the percentage compared to wild type 
(Figure 1.8.2.5). 
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Figure 1.8.2.5: Percentage of endothelial cell 
fenestration in newborn DDS/+ showing 
doubling compared to wild type (p=0.027, t-
test, n=3 each group). (Wroe PhD thesis, 
2009) 
 
 
These data show that DDS/+ mice might have an accelerated development and 
maturation during the process of nephrogenesis. Fascinatingly, the mechanisms 
controlling the rate of maturation of nephrons and the signals triggering nephrogenesis 
to stop remain unknown. The disruption of these processes in the DDS/+ mice suggest 
they may provide a way to understand this process. We postulated that there exists the 
possibility of negative feedback loop expressed from these maturing glomeruli inhibiting 
further increase of nephron number in nephrogenesis. This also raised the questions of 
the molecular pathways and functions of the mutant Wt1 molecules within the kidney.   
DDS mutations, like DDS/+, typically produce an abnormal protein product and 
are considered dominant, whereas there is a related syndrome (WAGR syndrome) that 
is caused by haploinsufficiency for WT1 resulting in a condition with a reduced risk of 
developing Wilms’ tumour. In order to compare the effects of dominant DDS-like 
mutations with haploinsufficiency, a wholly inbred (129/Ola) haploinsufficient Wt1 mouse 
strain was created. The Wt1insGFP/+ strain have one copy of Wt1 inactivated by insertion 
of green fluorescent proteins (GFP).  Wt1insGFP/+ mice remain healthy beyond one year 
of age (Figure 1.8.2.6-A) with less than 10% presenting with proteinuria and GS 
detectable by light microscopy at 11 months of age, in contrast to DDS/+ mice. This 
finding is consistent with the more severe clinical presentation of DDS compared to 
WAGR syndrome. 
Comparison of nephron and podocyte numbers revealed that Wt1insGFP/+ mice 
show reduced nephron number without podocyte underdosing Figure 1.8.2.6-B, C).  
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Figure 1.8.2.6: (A) Survival graph of wild type, Wt1insGFP/+ and DDS/+ mice (B) 
Reduced nephron number in Wt1insGFP/+ mice at 1 month of age (**p=0.0071, 
n=5 per genotype). (C) Normal podocyte endowment Wt1insGFP/+ at 3 months 
of age (p=0.741, n=6 per genotype). [Miles unpublish data] 
 
 
Despite both strains showing a reduction in nephron number, the severity of 
glomerulosclerosis is associated with podocyte endowment, implying that the DDS/+ 
mutation affects the glomerular response to the stress of nephron underdosing, whereas 
haploinsufficiency does not. 
This project aims to exploit these refined genetic models of Wt1 mutation to 
investigate the mechanisms underlying both nephron and podocyte endowment.  
 
1.9 - Project strategy 
For the first part, we are going to compare gene expression profiles of isolated 
unilateral whole kidney from DDS/+ and wild type mice to identify the molecular 
pathways involved in changes leading to glomerulosclerosis and end stage renal failure. 
Such pathways will increase our understanding of this stage of glomerulosclerosis and 
may suggest potential therapeutic targets.  
Secondly, given the recent demonstration that podocytes can develop from 
parietal epithelial cells in adults and, the failure in adult podocyte generation in DDS/+ 
mice, podocytes and parietal epithelial cells will be analysed in this DDS model using 
immunohistochemistry and microarray analysis of purified glomeruli.  
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Subsequently we will develop ex vivo experimental systems with which to validate 
our findings in a physiologically relevant situation, using primary kidney cells freshly 
isolated from mice. 
 
1.10 - Experimental plan 
In order to highlight gene expression changes more likely to be causative, whole 
fetal kidney (e17.5) mRNA will be analysed by Affymetrix expression microarray. 
Previous histology results indicate that nephron number is normal at e17 but that 
nephrogenesis begins to cease prematurely in DDS/+ mice at the time of birth, as shown 
by the presence of mature glomeruli in newborn mutant kidneys. 
Whilst whole kidney analysis may “dilute” gene expression differences, ie, the 
cells affected may represent a small proportion of the whole kidney, we chose not to 
introduce potential sources of error by attempting to enrich subsets of cells for analysis 
but, instead, have designed the experiment such that small differences can be identified 
with confidence and, as far as possible, the samples will only differ with respect to 
genotype.  
The gene lists derived from this analysis will provide a unique insight into the 
molecular pathways controlling the cessation of nephrogenesis and nephron 
endowment. These experiments should create valuable, unique datasets that will shed 
light on two critical, yet poorly understood aspects of kidney development. Furthermore, 
an understanding of the processes of late nephrogenesis and post-natal podocyte 
production could potentially be exploited to increase podocyte/nephron numbers for 
therapeutic purposes.  
This DDS/+ mutation might have accelerated development and maturation during 
the process of nephrogenesis. Fascinatingly, the mechanisms controlling the rate of 
maturation of nephrons and the signals triggering nephrogenesis to stop remain 
unknown. The disruption of these processes in the DDS/+ mice suggest they may 
provide a way to understand this process. We postulated that there exists the possibility 
of feedback loop expressed from these maturing glomeruli inhibiting further increase of 
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nephron number in nephrogenesis. This also raised the questions of the molecular 
pathways and functions of the mutant Wt1 molecules within the kidney.   
However, the molecular mechanisms by which nephron number is determined are 
not fully known. The disruption of these processes in the DDS/+ mice suggest they may 
provide a way to understand this process. 
    
1.11 Overview of main objectives 
The overall aim is to investigate potential gene targets for future augmenting kidney 
function. 
Given the established causal link between nephron underdosing, podocyte loss 
and chronic kidney disease, this project will consist of fundamental research into the 
mechanisms underlying both of these aspects of kidney development. Using mouse 
models of WT1 that develop glomerulosclerosis with age, mimicking human CKD, the 
molecular pathways regulating final nephron number will be investigated by conducting 
microarray analysis to identify gene expression changes in late-gestation foetal kidneys. 
Similarly, the molecular pathways that are disrupted during podocyte development later 
in neonatal life will be identified by microarray analysis. The identification of 
factors/pathways regulating nephron and podocyte endowment will provide potential 
therapeutic targets. 
1.11.1. Project Aims 
Specific Objectives: 
1 To use WT1 mutant mice to understand the fundamental mechanisms 
regulating nephron and podocyte number. These basic aspects of 
development are currently poorly understood.  
2 To investigate the WT1 pathway or molecular involvement in the 
mouse models that would lead to glomerulosclerosis / diseased 
kidneys.  
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Wt1loxP/loxP mice (DDS20) 
Transgenic mouse model  
In view of the fact that the progress of the Nobel first gene knockout technique 
in mice in 1989 by Mario R. Capecchi, Martin Evans and Oliver Smithies, numerous 
study have been made to model human diseases in mice. Owing to the embryonic 
mortality of WT1 null mice, the function of WT1 in later phase of kidney growth, 
Wilms’ tumorigenesis and the function in mature podocyte are not known (Patek et 
al., 2008). Even though the likelihood of Wilms tumour develop in human DDS cases 
is 90%, merely a single case of tumour had been discovered in the mouse model 
(Patek et al., 1999). Examination of the mice discovered the tumour cell had an exon 
9 skip event in WT1 transcript. The Wt1tmT396 mutation model show truncated zinc 
finger (ZF) 3 at codon 396. Subsequently, to broaden the understanding of the effect 
of skipping exon 9 in WT1 gene and the function of ZF3, an inducible conditional 
WT1 gene knockout (Cre-LoxP system) mouse has been developed in the Miles 
laboratory. This mouse model carries WT1 alleles flanked by loxP sites before and 
after exon 9 (zinc finger 3) with the function to knockout exon 9 when Cre 
recombinase is expressed.  
The Cre-loxP technique is a system to overcome early embryonic lethality 
when compared to conventional knockout systems. It can be tissue-specific knockout 
of specific genes and can be time-specific when needed for more refined experiment. 
The method is very practical in elimination of a transgene or precise genetic 
sequence to imitate deletions, for example in a time course-dependant experiment. 
Cre is a 38 kDa recombinase protein derived from bacteriophage P1 that intercede 
site specific recombination between matching loxP sites. by means of fusing Cre to a 
mutated oestrogen receptor ligand-binding domain, the Cre recombinase is able to 
be expressed when introduced to synthetic oestrogen homologue, Tamoxifen (Indra 
et al., 1999).  
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Figure 2.1.1: Figure illustrate inducible knockout utilizing the CreERT2 system. 
CreERT2 transgene mice are crossbred to mice carrying the floxed gene. In the 
absence of tamoxifen, Cre is not active. When tamoxifen is administered, 
recombination of loxP sites (floxed) resulted in deletion of the intervening 
sequence.  
 
In order to facilitate temporal manipulation over Cre mediated 
recombination in experiments, the mice having the loxP modified WT1 alleles 
were crossed breed with ROSA-CreERT2 mice having ubiquitous expression of 
Cre recombinase that is fused to an oestrogen receptor, consequently placing it 
under control of Tamoxifen (Vooijs et al. 2001).  
  By means of conditional knock-out or knock-in technique, premature 
mortality of mouse model can be evaded. Utilizing this null WT1 gene conditional 
mouse knockout model cultivated in Miles Laboratory, the scope of experiment 
can be extended.  
 
Mice with 
inducible ‘Cre’  
Mice was 
mated to get 
heterozygous 
WT1 gene   
‘Cre’ mice were mated 
to get inducible ‘Cre’ 
genes into the 
heterozygous mice   
Mice with normal 
WT1 gene   
Mice with normal 
Lox-P site flanking 
exon 9 of WT1   
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Fp = forward primer, Rp = reverse primer 
 
 
 
 
Figure 2.1.2: Representative diagram of mutant Wt1 allele with loxP sites (blue) 
flanking exon 9 (Zn finger 3). FRT sites (red). 
 
 
 
 
 
 
Figure 2.1.3: Representative PCR genotyping using exon 8 primers of wild type 
type (wt) (¬320bp) and mutant (¬270bp), heterozygous (fl/+) and homozygous 
(fl/fl) mutant mice. 
 
2.2 Collection, preparation and analysis of Microarray data  
In order to expand our knowledge of stages involved in development of 
glomerulosclerosis and to find a potential therapeutic target, evaluating the gene 
expression profile of isolated unilateral whole kidney from DDS/+ and wild type mice 
would lead to discovering the altered molecular pathways involved that leads to 
glomerulosclerosis and end stage renal failure.  
In order to emphasize on gene expression that more likely to be contributory, 
whole foetal kidney (e17.5) mRNA was analysed by Affymetrix expression microarray. 
Prior histological study of this strain indicate that nephron number is normal at e17 and 
seems subjectively to have the nephrogenesis cease too early in DDS/+ mice, as shown 
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by the presence of more mature glomeruli in newborn mutant kidney compared to wild 
type at the time of birth (Wroe, 2009). 
Although whole kidney analysis may “dilute” gene expression discrepancy, i.e., 
the fraction of cells affected possibly will be represented by a small section from the 
whole kidney, I opted not to institute potential sources of inaccuracy by endeavouring to 
enrich any subsets of cells for analysis with artificial ex vivo set up, but as an alternative 
have deliberately design the experiment  so that such small variation can be identified 
with conviction and, as far achievable, the samples would only differ in revere to their 
genotype: 
1. Both mice was of the same strain and are wholly inbred, eradicating any 
potential strain-specific discrepancy. 
2. Embryos were sexed and sex-matched for analysis (only one sex group for 
expression microarray). 
3. Embryos were age-matched (e17.5) 
4. The foetal kidney were selected unilaterally (avoiding any unknown variables 
due to left-right asymmetry). 
5. Foetal kidneys were peeled of renal capsule. 
 
17 days pregnant mice were culled according to Home Office recommendation. 
Foetuses were decapitated, and kidneys were extracted and were instantly placed in 
liquid nitrogen and stored at -800C.  Foetal tails tips were cut and used for genotyping 
and sexed genotyped. RNA was isolated from whole kidney samples using the RNA 
extraction kit (Qiagen RNeasy micro kit (Cat No./ID   74004)).    
RNA pellet was resuspended in RNase free H20 according to kit protocol.  The 
quality and RNA concentration were verified by Nanodrop (UV spectrometry) and sent to 
Source Bioscience for quality control and microarray.  
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Microarray was performed using Affymetrix Mouse 1.0 ST V1 chips and analysed 
using the Genespring 12.5 computer program (Agilent technology).  Samples were 
normalized per chip to internal control and non-expressed intron control.  
In technical terms, before applying any of the statistical analysis methods, the 
data must be normalized. Normalization is used to reduce unwanted variation across 
chips and may use information from multiple chips. It would rectify for general chip 
brightness and other issues that may affect the numerical value of expression strength, 
facilitating the user to more confidently compare gene expression assessment between 
samples. For microarray, quantile normalization is routinely done to make the data 
distributions identical in statistical properties for further analysis. After performing 
normalization all gene expression values lower than 0% quantile were set to the value of 
this 0% quantile (5.74557625 for this experiment) to eliminate low level signals being too 
much scattered to be used in a reproducible analysis. 
Genes were quality controlled and check and recheck for expression with qRT-
PCR on multiple primers (full list of 238 primers were used). Pathway analysis was 
performed with Ingenuity Pathway Analysis (IPA), STRING and KEGG pathways. 
 
2.3. Mouse Embryonic Fibroblast (MEF) - preparation from Embryos, MEF cell 
culture and preservation 
Before proceeding to the embryos, D-PBS (Invitrogen cat number 14287-072), 
Trypsin/EDTA (cat number R-001-100) and MEF medium were prewarm at 37°C. MEF 
medium was prepared by combination of: 450ml DMEM (Dulbecco's Modified Eagle 
Medium) (high glucose without sodium pyruvate) 1x (Invitrogen cat number 41965-039), 
50ml FBS (Foetal Bovine Serum) (Invitrogen cat number 16000-036), 5ml NEAA (MEM 
Non-essential amino acids 100x) (Invitrogen cat number 11140-035), and 5ml 
Penicillin/Streptomycin containing 5000 units of penicillin and 5000ug of streptomycin in 
0.85% saline.  
 E13-14.5 embryos were used in this MEF culture. The abdomen of the pregnant 
mice was washed and swab clean with 70% ethanol. The uterus was removes in bulk 
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and washed with PBS. The individual sac and placenta were separated from rest, and 
then washed with warm sterile PBS 3x. The individual embryo is transferred to clean 
dish and separated from the placenta and wash clean with PBS. The individual embryo 
was transferred to 6 well culture plate and washed with warm PBS 3x using Pasteur 
pipette. Small part of the tail of each embryo were cut and transferred to 1.5ml tube for 
genotyping and labelled properly. The embryos were dissected and all the visceral, 
heart, liver (which looks reddish) were removed and discarded. The embryos then were 
clean and washed with warm PBS. The dissection was done under dissecting 
microscope for easy viewing.  
 Afterwards, the dissected embryos were transferred to tissue culture hood 
(clean/sterile). Individual dissected embryo was placed in petri dishes and 2ml 
trypsin/EDTA were added.  Embryo was minced with scissors and scalpels as finely as 
possible. This is repeated to all embryos using new/clean utensils. Additional 5ml of 
trypsin/EDTA was added to the minced tissue. The petri dishes were incubated for 15 
minutes at 37oC or until individual cells were visible under microscope. Next the content 
was transferred to a 50ml tube using sterile pipette. 13ml of prewarmed MEF medium 
was added to the tube and mix up and down. Letting the tube on a rack, after allowing 
the bigger pieces to settle down at the bottom of the tube, the top 12ml was transferred 
to one or two T25 culture flask. The remaining 8ml from the tube was transferred to 
another T25 flask. All flask was incubated at 37oC at fix CO2 and O2 for best result. and 
were observe for cell adherence. Cells were split when confluency was seen. Of note, 
MEF do not need feeding with new media every day. Only when the media turn 
yellowish in about 2-3 days and split to new flask if overgrown.  
 To split the cells, for best practice, a complete medium was prewarmed and feed 
to the cells for few hours prior to splitting. From the T25 flask, the medium was aspirated 
and discarded. The cells were washed first with prewarmed PBS (5ml for T25) and 
discarded after few gentle swirls. 1ml of prewarmed trypsin/EDTA was added to the cells 
and swirl to overall cell surface gently and then incubate at 37oC. for every 5 to 10 
minutes, the detachment of cells was monitored under microscope and the T25 was 
gently shaken. The last step was repeated until all cells were detached from the flask 
surface. After cells was seen to be detached, the trysin/EDTA was inactivated by adding 
prewarmed MEF medium (amounting to 10 volume totals, 10% FBS). The cell solution 
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was gently pipetted up and down using a 10ml pipette to homogenize the cells. To split 
to 3 T25 flask, additional MEF medium was added to total of 15ml, and then divided into 
3 (5ml each) into a new T25 flask. The cells were monitored for adherence and 
confluence as before, split when needed and used for intended experiments.  
 To preserve a cell line, cells were preserved and frozen at -80oC and in nitrogen 
cryogenic tank for long term. To freeze the cells from T25 flask, the medium was 
aspirated, and cells were washed with 5ml of prewarmed PBS. Cells were detached 
using trypsin/EDTA using similar technique as cell splitting. After the cells were seen to 
be detached under the microscope, the trysin/EDTA was inactivated by adding 
prewarmed MEF medium (amounting to 10 volume totals, 10% FBS). The medium 
containing the cells were transferred to 10ml tube and centrifuged at 1200rpm. Medium 
were aspirated and discarded. Cell palette was resuspended with 2ml Gibco™ 
Recovery™ Cell Culture Freezing Medium (cat number 12648010) and mix thoroughly. 
The media then were aliquot 1ml into each cryotube. The cryotube was then put into 
freezing container containing isopropanol and put into -80oC and in nitrogen cryogenic 
tank for long term.  
 
 
2.4 Tamoxifen preparation  
2.4.1. Tamoxifen on MEF (primary cell culture)  
Exon 9 of WT1 in MEF (with presence of Cre-ER) was deleted by addition 
of 1uM Tamoxifen (Sigma H7904-5MG, (Z)-4-Hydroxytamoxyfen, Lot 
#094M4049V). Tamoxifen was prepared in 1M stock (1000x) dissolved in cell 
culture grade dimethyl sulfoxide (DMSO) and stored at -20 C. Molecular weight: 
371.51 1 molar = 371.5 g/l 1 molar = 371.5 mg/ml 1mM = 371.5 ug/ml. 
Tamoxifen were prepared at 10mM stock in ethanol (EtoH). To add to cells 
(MEF), following protocol was followed:  
1) 5 ml medium (DMEM) + 5 ul of 10 mM stock (= 10 uM)  
2) Filter the solution through 0.2 um filter.  
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3) Add to culture medium at ratio of 1:10 (i.e. 0.5 ml + 4.5 ml full culture 
media) to get final concentration of 1 uM Tamoxifen. 
Cell at passage 1 (one) were allowed to grow in the Tamoxifen containing 
medium for 48 hours, then a small portion was genotype using PCR for deleted 
exon 9 at the end of 48 hours. If by any chance there are still not fully deleted, the 
cells were allowed to grow for another 24 hours in a new Tamoxifen containing 
medium. Usually all the cells would have exon 9 deleted after 72 hours when 
PCR were repeated.  
Cells were then allowed to continue growing in normal medium without 
Tamoxifen after above protocol and were passaged until passage 5 (five) to dilute 
any remaining Tamoxifen from the cells before being used for any experiments.  
 
2.4.2 Tamoxifen preparation for in vivo experiment 
The solution comprises of 20mg Tamoxifen (Sigma), dissolved in 200µl 
100% EtOH (42° C shaking) then later then mix this 200µl with 1800µl of peanut 
oil. Intraperitoneal injection of 2.5mg Tamoxifen was administered to pregnant 
female mice from a heterozygous (flox/+ CreERT2) X heterozygous (flox/+) mating 
to inactivate WT1 prior to birth. For newborn mice, Tamoxifen 2.5mg was 
administered subcutaneously to newborn mice from heterozygous (flox/+ CreERT2) 
X heterozygous (flox/+) mating. Mice of all possible genotypes were injected with 
Tamoxifen (prior to genotyping). 
 
2.5. Histology 
 2.5.1. Tissue preparation 
 
 2.5.1.1. Wax fixation and sectioning 
 Embryonic kidney of E12-14 of age were used. The kidneys were fixed in 
4% PFA at 4 degrees Celsius for 2 days. Afterwards the kidneys were processed 
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at room temperature for the following steps. They are washed in PBS two times 
for 15 minutes two times. Following that, the kidneys were immersed in 50% 
ethanol for 2 hours, followed by 70% ethanol for 2 hours times two, 95% ethanol 
for 2 hours, then 100% ethanol for minimum of two hour or overnight. Then the 
kidneys were immersed in histoclear solution for 30 minutes times two at room 
temperature. Following that, the kidneys were immersed in histoclear/wax mix at 
65 degrees Celsius once, followed by wax immersion at 65 degrees Celsius for 1-
hour times 6, then wax blocks were cooled to room temperature. The wax 
embedded tissues were sectioned by using a microtome at 5 to 10 micrometre 
thickness. Sections were then placed onto SuperFrost® Plus glass slides and left 
on a heating plate at 38° C overnight.  
  2.5.1.2. Cryofixation 
The kidneys of were first immersed in 4% PFA at 4 degrees Celsius for 2 
days. Then they are washed with PBS at room temperature for 15 minutes 2 
times. Then the kidneys were immersed in 30% sucrose in PBS at 4 degrees 
Celsius for 2 days. Following that, the kidneys were embed in OCT compound 
and then stored at -80 (minus 80) degrees Celsius until needed to be used.  
    The OCT embedded kidneys were sectioned by using the cryostat 
microtome machine cut between 5 to 10 µm thickness. The sectioned tissues 
were placed onto glass slides and stored at -20° C before being stained.  
         
2.5.2. Haematoxylin and Eosin (H&E) staining 
H&E staining and commercial DPX (Distyrene, plasticizer, and xylene 
mixture) chemical was used for slide mounted sectioned tissues using the method 
below at room temperature. 
The kidney sectioned from wax fixed procedure were used in this 
procedure. The sectioned kidneys were fixed first on glass slides. The slides were 
de-waxed by immersing in histoclear solution for 10 minutes. The sectioned were 
then hydrated through 100% ethanol for 2 minutes, then 80% ethanol for 2 
minutes, then 50% ethanol for 2 minutes, then ddH2O for 2 minutes. Following 
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that, sectioned were then immersed in Harris haematoxylin for 2 minutes, then 
rinsed with tap water until the running water becomes clear. Then slides were 
immersed in eosin solution for 3 minutes, then rinsed with running tap water until 
running water becomes clear.  The sectioned kidneys were then de-hydrated by 
immersion in 50% ethanol for 1 minute, then 70% ethanol for 1 minute, then 
100% for 1 minute. Then the slides were immersed in histoclear solution for 10 
minutes. Following that, the slides are covered with slide cover and DPX (Dibutyl 
Pthalate Xylene).  
 
2.6. Molecular Biology 
2.6.1. DNA preparation for genotyping: 
DNA preparation from the pieces of the mouse ear clips. For each PCR 
reaction, 5µl of the DNA solution was used. Ear clip DNA solution for mice 
genotype were prepared as follows. Each ear clip pieces (1-2 mm diameter) were 
isolated in a 1.5ml tubes, can be kept at -20 (minus 20) degrees Celsius or 
processed as soon as ear clip were obtained. 60µl of 25 mM NaOH/0.2 mM 
EDTA ph 12 were added to the tube containing ear clip and kept in shaking 
thermocycler at temperature 95 degrees Celsius for 20 minutes. The tube was 
cooled afterwards and 60µl of 40 mM Tris-HCL ph 5 (not Tris base) were added 
in the tube and mix well by vortexing. The tubes were then centrifuge at max G 
for 1 minute.  
 
2.6.2. PCR genotyping mix: 
PCR genotyping method below was used for ear clip genotyping. Each 
PCR reaction contains (prepared and added in the following order):    
AMOUNT MATERIAL 
5µL  DNA from ear clip 
30.7µL ddH2O 
10µL  x5 GOTAG flexi buffer 
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3µL MgCl 
1µL  dNTP mix (stock at 10mM each dNTP) 
0.1µL Oligonucleotide primers (stock at 
1µg/µl) 
0.2µL Taq polymerase enzyme 
 
Each PCR tube contains 50µl of reaction mix. For controls, positive and negative 
controls were used with addition of ddH2O control.  
Primers used: 
NO  TARGET SEQUENCE (5’- 3’) 
1 loxP For ex8 ATGGCTTTTTTTCCAAGTCAG 
2 loxP Rev ex8 CAGTGAGACACATAAGGCCGG 
3 Cre For TGCCACCAGCCAGCTATCAAC 
4 Cre Rev AGCCACCAGCTTGCATGATCT 
5 loxP For ex9 CTGCTGTGAACCTAAGTTTC 
6 loxP Rev ex9 CACTAGGAATGTCCTCAGTC 
7 DDS Ex9F2 AGACCTTCTCTGTCCGTTTAG 
8 DDS neo52 GATGCCTGCTTGCCGAATATCATGG 
9 DDS CRE1R TGTTCTGAATCTCCTGGACA 
 
 **For the remaining primers, please refer to the appendix. These primer 
sequences were used for qRT-PCR to measure the expression of genes found to 
be expressed in the array, and normal PCRs.  
Primers were designed using NCBI primer-BLAST (Available at 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome) 
2.6.2.1. PCR conditions: 
Below is the PCR conditions that being used for PCR in the PCR machine.  
2.7.2.1.1.  For PCR genotyping of Lox-P site and Cre site gene sequence, 
below is the PCR machine setup: 
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STAGE TEMPERATURE DURATION 
HEATED LID 110° C  
HOT START 95° C 00:05.00 
START CYCLE - 30x 
DENATURATION 95° C 00:00.05 
ANNEALING 58° C 00:00.30 
ELONGATION 72° C 00:00.30 
END CYCLE   
TEMPERATURE 72° C 00:05.00 
STORE  4.0° C Infinite  
 
 
2.6.2.1.2. For PCR genotyping of DDS/+ mice, below is the PCR machine 
setup for genotyping the exon 9 region of WT1,: 
 
 
 
 
 
 
 
 
 
2.6.3. DNA extraction using QIAGEN Tissue DNA Extraction Kit 
QIAGEN commercial extraction kit was used to obtained pure DNA 
extraction as protocol below.  25mg tissue was placed in 1.5ml microcentrifuge 
tube. 180µl Buffer ATL was added with 20µl proteinase K and then mix by 
STAGE TEMPERATURE DURATION 
HEATED LID 110° C  
HOT START 95° C 00:10.00 
START CYCLE - 32x 
DENATURATION 94° C 00:00.30 
ANNEALING 56° C 00:00.45 
ELONGATION 72° C 00:00.30 
END CYCLE   
TEMPERATURE 72° C 00:10.00 
STORE  4.0° C Infinite  
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vortexing. The microcentrifuge tube was incubated at 55° C overnight (or until 
tissues completely lysed). Afterwards, tubes were vortexed for 15 seconds and 
then incubated at 70° C for 10 minutes. 200µl 100% Ethanol was added and mix 
thoroughly by vortexing. Mixture was pipetted into DNeasy Minispin Column 
(QIAGEN) and placed in a 2ml collection tube, and then centrifuged at ≥6000g 
(8000rpm) for 1 minute. DNeasy Minispin Column was placed in a new 2ml 
collection tube and 500µl Buffer AW1 was added and centrifuged at ≥20000g 
(14000rpm) for 3 minutes, the flow-through was discarded. DNeasy Minispin 
Column was placed in a new 2ml collection tube, 500µl Buffer AW2 was added 
and then centrifuged at ≥20000g (14000rpm) for 3 minutes, the flow-through was 
discarded. DNeasy Minispin Column was placed in a new 1.5ml microcentrifuge 
tube, 200µl Buffer AE was pipetted directly onto the DNeasy Minispin Column 
membrane, incubate for 1 minute at room temperature, then centrifuged at 
≥6000g (8000rpm) for 1 minute. The last step was repeated in a new collection 
tube if needed. Finally, DNA concentration and quality were checked by 
Nanodrop (ND1000, LabTech) and stored at -80°c to avoid degradation of DNA in 
long term. 
 
2.6.4. RNA extraction 
  RNA extraction was done through general method of RNA 
extraction. Stored tissue for RNA extraction were stored at -80° C in 1ml of 
Invitrogen Trizol in 1.5ml microcentrifuge tube. Tubes with samples were allowed 
to thaw on ice, and then homogenized using homogenizer and left at room 
temperature for 5 minutes. Tubes were then centrifuge at 4° C at 12000rpm for 10 
minutes. 200µl chloroform were added and vigorously shake for 15 seconds and 
incubate at room temperature for 3 minutes. Tubes were then centrifuge at 4° C 
at 12000rpm for 15 minutes. The top aqueous layer was transferred to a new 
clean Eppendorf tube (RNase free). 500µl isopropanol were added for RNA 
precipitation and left at room temperature for 10 minutes. Tubes were then 
centrifuge at 4° C at 12000rpm for 10 minutes. Tubes were then centrifuge at 4° 
C at 12000rpm for 10 minutes. The supernatant was removed and discarded. The 
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pellet was washed with 1ml 70% ethanol (with diethylpyrocarbonate (DEPC) 
water). Tubes were then centrifuge at 4° C at 7500rpm for 5 minutes. Supernatant 
was removed, and the pellet was air dried for 30 minutes. 30µl RNase free water 
was added to resuspend the pallet (RNA) and then stored at -20° C or use for 
RNA experiment of choice.  
Alternatively, RNA was extracted using a RNeasy micro kit (Qiagen Cat 
No./ID   74004) following manufacturer protocol. Briefly, less than 1x107cells or 
30mg of tissues (Guan et al., 2006) were disrupted and homogenized in RLT 
buffer then ethanol was added for selected binding of RNA to the column. In the 
washing steps, all contaminants were washed efficiently. RNase-free DNase set 
(Qiagen) was applied to wash genomic DNA, in the case of using RNA samples 
for real time PCR.  
Finally, RNA concentration and quality were checked by Nanodrop (ND1000, 
LabTech) and stored at -80°c to avoid degradation of RNA in long term. 
 
2.6.5. Reverse Transcription – Polymerase Chain Reaction (RT-PCR) and 
Quantitative PCR (qPCR): 
By using spectrometer equipment and the optical density (OD) value of 
RNA obtained from it, 2µg of RNA was added to dd H2O to make a total volume 
of 11µl per sample. Then 1µl of 10mM dNTPs and 1µl of oligonucleotide dT 
primer were added. The mixture was then incubated at 65° C for 5 minutes. 
Afterward 4µl of Invitrogen 5x Buffer, 1µl of Dithiothreitol (DTT), 1µl of Invitrogen 
RNAse OUT and 1µl of Invitrogen Superscript III RNA polymerase were added. 
This mixture was then incubated at 50° C for 50 minutes and later at 70° C for 15 
minutes. The cDNA product was stored at -20° C to be used later.  
Alternatively, Promega (GoScript™ Reverse Transcription System, Cat A5001) kit 
were used for reverse transcription and method we followed as per kit 
instructions.  
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2.6.6. Quantitative PCR (qPCR): 
The qPCR was performed on the cDNA synthesised from the mouse 
kidneys RNA, MEFs, and extracted DNA. All cDNA and DNA were quantified and 
equalized between controls and mutants prior to run. The mouse kidneys used 
were the second kidneys from the mice whose kidneys were used in the nephron 
counts. The primers used in the qPCRs were designed using the NCBI primer 
BLAST software and primer3 software, the primers were checked to ensure that 
they spanned at least one exon-exon junction and that the product produced was 
between 70-250 base pairs long. For each sample the genes GAPDH, HPRT 
and/or Beta-Actin genes were used as control/reference genes. Each qPCR was 
performed using Quantstudio 7 Flex Real Time PCR System (Life Technologies). 
For each well 9µl of a master mix and 1µl of the cDNA was used. The master mix 
was made up from 5µl of SYBR Select Master Mix (x2), 0.5µl of the forward 
primer (10µM), 0.5µl of the reverse primer (10µM) and 3µl of RNase free water. 
Alternatively, Fast SYBR™ Green Master Mix (4385612) were used.  
 
2.6.7. Gel electrophoresis 
To prepare a 2% agarose gel, the materials needed were 4gram Agarose 
powder (Sigma), 20ml of TAE solution, and 180ml of ddH2O. The mixture is 
heated in microwave for 3 minutes. Then the gel was slightly cooled on running 
water. 20µl ethidium bromide was added and gel was then poured onto a running 
plate.  
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2.7. Immunostaining 
 2.7.1. Apoptosis/ TUNEL Staining for cryosectioned tissue samples 
Commercial Roche in Situ Fluorescein Cell Death Detection Kit was used 
for apoptosis antibody staining.  The previously cryosectioned kidney tissues 
were used. The methods used were from manual provided with the antibody. For 
one sample, 50µl of TUNEL mix was required. 50µl TUNEL mix equal to 5µl 
Enzyme solution plus 45µl Label solution. For one sample of negative control, 
50µl of Label solution only was used. To induce a positive control, a wild type 
tissue section was incubated with a mixture of DNase 1 recombinant (3 U/ml), 
50mM Tris-HCl ph 7.5 and BSA (1mg/ml) for 10 minutes. Tissue sections 
(cryosection) that was mounted on SuperFros® Plus glass slides were allowed 
for air dry for 1 hour.  The general step started with sectioned tissue fixation 
with 4% PFA for 20 minutes, then wash with PBS for 30 minutes. 
Permeabilization solution Triton-X 0.2% then used on the tissue section for 2 
minutes while the slides are on ice (cooled condition). Slide then rinsed with PBS 
2x and dap/dry lightly of remaining PBS. Following that, TUNEL mix was added to 
sample and positive control while adding Label solution only to negative control. 
The slides were incubated in wet chamber at 37°C in the dark for 1 hour. The 
slides were then rinse with PBS 3x. The slides were then mounted with 
Vectashield DAPI mounting medium and cover slip.  For evaluation by 
fluorescence microscopy use an excitation wavelength in the range of 450 – 500 
nm (e.g., 488 nm) and detection in the range of 515 – 565 nm (green). 
2.7.2. Apoptosis/ TUNEL Staining for paraffin/wax tissue samples 
 The routine for TUNEL staining protocol is as follows. Slides having wax 
sectioned kidneys of choice were taken, and then de-paraffinized and rehydrated 
in histoclear for 10 minutes, 100% ethanol for 5 minutes, then 70% ethanol for 3 
minutes, then 70% ethanol for 3 minutes, then 50% ethanol for 3 minutes, then 
water for 3 minutes. The slides were then immersed in 4% formaldehyde in PBS 
(Phosphate Buffered Saline) at room temperature for 15 minutes. Then the slides 
were washed in PBS for 5 minutes. The sections then were incubated at room 
temperature after adding 100µl of 20µg/ml Proteinase K solution onto each slide 
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for 8-10 minutes. Then slides were washed in PBS again for 5 minutes. Slides 
were then immersed in 4% formaldehyde in PBS for 5 minutes, then washed in 
PBS for 5 minutes. Then 100µl of equilibration buffer (Promega) was added to the 
slides and incubated for 5-10 minutes. Equilibration buffer was then removed and 
50µl of rtdt incubation buffer was added, using a plastic cover slip to ensure even 
distribution of the reagent. During this step the slides were kept out of light and 
incubated at 37°C for 60 minutes in a humidified chamber. Following this the 
slides were immersed in 2X SSC solution (Promega) to end the rtdt reaction for 
15 minutes. Then slides were washed 3x 5 minutes with PBS. Slides were then 
immersed in propidium iodide solution diluted to 1µg/ml in PBS (in dark area) for 
15 minutes. Then slides were washed in deionised water 3x 5 minutes. Then a 
drop of Anti-Fade solution was added to the treated cells and a coverslip was 
added. Then the edges of the coverslip were sealed using clear nail polish. For 
evaluation by fluorescence microscopy use an excitation wavelength in the range 
of 450 – 500 nm (e.g., 488 nm) and detection in the range of 515 – 565 nm 
(green). 
 
2.8 Cell Counts: 
There were two different cell counts performed; an apoptotic cell count and a 
nephron count. 
2.8.1 Apoptotic cell count: 
This was performed on TUNEL stained kidney sections where events and bright 
events were counted. Double blinded approach was used to make sure no bias in 
selecting and counting the florescence signal. Until all slides were counted, the 
slide numbers were then cross checked with the actual sample label. Both counts 
were checked for differences, analysed for discrepancies, and average was 
taken. Florescent signal counting was done using the image J software.  
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2.8.2 Nephron count: 
This was performed on PNA stained kidney (Peanut agglutinin (PNA)) 
sections where different stages of nephron development were counted, these 
were the glomeruli, S-shaped bodies and Comma shaped bodies, and they 
shaped were obvious under microscope when stained and easy to be identified 
especially PNA will stain the bodies different colour compared to the surrounding 
tissues. This was done using a light microscope with the nephrons being 
examined and counted using a 20x magnification, with each nephron stage being 
labelled, using a different colour, and counted. Five kidney sections were counted 
for each kidney, with each counted section being separated by roughly 15 
sections to avoid counting the same structures twice. The total number of 
nephrons, glomeruli, comma shaped bodies and S-Shaped bodies was then 
obtained and for each value the total number of bodies for that structure was 
obtained using a method outlined by Cullen-McEwen (2011), by using PNA 
staining and formula , where Nglom is the total 
number of PNA-positive nephrons, and SSF is the number of slide in between 
sectioned,  Q− is the actual number of PNA-positive structures appearing and 
disappearing in between slides. The counting was made by 2 people and double 
blinded. The slides sample numbers were covered and randomly labelled. They 
were shuffled, and nephrons were counted independently by the 2 persons. Both 
counts were checked for differences, analysed for discrepancies, and average 
was taken and accepted as the true count for the subsequent analysis. 
 
2.8.3 Analysis 
To examine the research question of relationship between genotype and 
nephron number, a linear regression was conducted to investigate whether or 
not independent variable (in this case genotype) predicts dependent variable (the 
nephron number).  A linear regression is an appropriate analysis when the goal of 
research is to assess the extent of a relationship between a dichotomous 
(genotype) predictor variable on an interval/ratio criterion variable.  In this case, 
the predictor variable is the independent variable and the criterion variable is 
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the dependent variable.  The following regression equation was used: y = b1*x + 
c; where y = estimated dependent variable, c = constant, b = regression 
coefficient and x = independent variable (as done through SPSS).  The F-test 
was used to assess whether the independent variable predicts the dependent 
variable.  R-squared reported and used to determine how much variance in the 
dependent variable can be accounted for by the independent variable.  The t-test 
was used to determine the significance of the predictor and beta coefficients will 
be used to determine the magnitude and direction of the relationship.  For 
statistically significant models, for every one-unit increase in the predictor, the 
dependent variable will increase or decrease by the number of unstandardized 
beta coefficients (positive or negative values).  The assumptions of a linear 
regression —linearity and homoscedasticity—will be assessed.  Linearity 
assumes a straight-line relationship between the predictor variables and the 
criterion variable and homoscedasticity assumes that scores are normally 
distributed about the regression line (as shown in appendix P-P plot of 
Regression Residual).   
 
2.9 PNA Staining: 
 Slides having wax sectioned kidneys of choice were taken, and then de-
paraffinized and rehydrated in histoclear for 10 minutes, 100% ethanol for 10 
minutes, then 70% ethanol for 10 minutes, then 70% ethanol for 10 minutes, then 
50% ethanol for 10 minutes, then water for 10 minutes. The slides then immersed 
in 2% methanol for 10 minutes. Following that, the slides were incubated with 
Neuraminidase (0.1 units/ml with 1% cacl2 in PBS) from Vibrio Cholerae (Sigma-
Aldrich, N7885-2UN) at 37oC for 30 minutes. Following that, the sections were 
immersed in 2% BSA, 0.3% Triton X-100 in PBS solution for 30 minutes. Then 
the slides were placed into a 20 µg/ml biotinylated PNA (Arachis Hypogaea, 
Sigma-Aldrich) diluted with 0.3% Triton X-100 in PBS, with 1mm 
cacl2/mncl2/mgcl2 solution and kept out of light for 2 hours. The slides were 
washed in PBS. Following that, the biotinylated PNA was visualised utilizing the 
Elite streptavidin/biotin amplification ABC Kit protocol (Vector Laboratories), the 
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reaction is then developed using Diaminobenzidine (DAB) and 0.01% H202 in 
PBS for 5-10 minutes. The slides were then washed again in PBS and 
counterstained using methyl green for 5-10 minutes. The slides were then 
washed and dehydrated for cover slip mounting with DPX solution.  
 
2.10 Western blot 
 Western blot experiments follow the standard protocol. Samples were 
homogenised either in Laemmli buffer or tissue lysis buffer using needles 
(19G,23G,26G). Samples were centrifuged at 4°C for 15 minutes at medium to 
maximum g. This will pellet cell debris at bottom. Supernatant were removed and 
place into fresh tube. Sonication were done to shear the DNA.  Samples were heated 
to 95°C for 5 mins. Samples were spin for 5 min at room temperature. Samples were 
loaded into wells of the polyacrylamide gel. The power-pac were set to run as 
follows; protein size 15 kDa (dye front) at voltage 115 for 1hr and protein size 40 at 
voltage 120 for 1hr 20 min.  
Once the gel has run, the transfer set assembled: Sheet is soaked of extra-thick 
blot paper in transfer buffer and place on the anode plate assembly, the gel was 
place on top of the membrane, one more sheet was added of extra-thick blot paper 
on top, re-soak the sandwich in transfer buffer. Voltage was set to 15V, current max 
to 0.5A and time to 45 minutes. If set up correctly, at 15V the current should be 
around 0.2A. After the run, the transfer cell was disassembled, membrane was 
rinsed with water, Ponceau S red was added and soak for 2 minutes to visualize 
transfer. Membrane were washed 2x for 10 minutes with TBST. The membrane was 
blocked in 10% milk in TBST for 1-hour at room temperature. The membrane was 
put into primary antibody over night at 4°C. The membrane was rinse once with 
TBST. Then wash 3x 15 minutes in TBST on roller. The membrane then was put into 
secondary antibody for 90 minutes, then rinsed once with TBST and washed 3x 15 
minutes in TBST on roller. The chemiluminescent substrate was mixed, and the West 
Dura is mixed 1:1. The membrane was placed inside a plastic pouch, added with 
substrate, and spread around. Second sheet of plastic was placed on top and 
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squeeze out excess with some blue roll. Membrane was placed into developing 
cassette and expose to film. 
For buffers, following are the standard buffers for western blot. The tissue 
extraction buffer (10ml) was prepared with combination of 2.4g Urea, 2.5ml 0.5M Tris 
pH6.8, 2ml 20% SDS, 500µl β-mercaptoethanol, 2ml 50% Glycerol, 3ml H2O, and 
then aliquoted into 0.5ml and freeze at -20°C. The 10X Running buffer (1L) was 
prepared with combination of 30.2g Tris, 188g Glycine and for each litre of 1X, 5ml 
20% SDS was added. The 10X Transfer buffer (1L) was prepared with combination 
of 29g Glycine, 58g Tris and for each litre of 1X, 1.85ml 20% SDS and 200ml MeOH 
(methanol) were added. The 10X TBS (1L) was prepared with combination of Tris 
and Sodium Chloride, at pH to 7.5 and prepared up to 1L by adding dH2O. For each 
L of 1X, 5ml 20% Tween was added. The Ponceau S Red (100ml) was prepared with 
combination of 0.1g Ponceau S red (0.1%), 5ml Acetic acid and then prepared to 
100ml by adding dH2O.  
 
2.11 Alamar Blue Assay 
This assay was designed to measure quantitatively proliferation animal 
cell. The indicator is H2O-soluble. It also can be used to establish relative toxicity 
of agents within various chemical classes. The system of reduction related to 
growth causes the REDOX (oxidation-reduction) indicator to change from 
oxidised form (non-fluorescent, blue) to reduced form (fluorescent, red). In order 
to prepare, 0.5 mM Resazurin sodium salt stock (R7017, Sigma-Aldrich) in PBS 
were obtained, 6.27925 mg of Resazurin sodium salt were put into 50 ml PBS 
and filtered, and then store at 4oC fridge until needed.  
In order to use the assay, medium from culture plates were removed, and 
additionally, cells were washed with sterile PBS to remove cell debris. To prepare 
medium with Alamar Blue, 10% of stock were added to the medium, and shake 
well. The Alamar Blue medium were added to the cell culture plate as needed 
(about 2-4ml) and incubated as usual. Regularly check for colour changes or as 
the experiment was designed (usually every 30 minutes to 2-3 hours). The 
medium then were pipetted out and triplicated into a 96-well plate to read under 
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plate reader. It is read it using Spectro fluorometer machine (excitation: 530-560 
nm; emission: 590 nm) or fluoroskan machine (excitation: 544 nm; emission 590 
nm). If required, the number of cells can be determined using standard curve 
(done separately). 
2.12 Cytochrome C Oxidase / Succinate Dehydrogenase (COX/SDH) Double-
labelling Histochemistry 
COX histochemistry 
Cryosectioned slides were allowed to dry (about 1 hour) and were pun in 
slide-staining chamber with wet filter paper. 1X DAB, 100 μM cytochrome c in 0.1 
M PBS pH=7.0 were prepared in chemical fumes hood and vortexed quickly. 2 μg 
bovine catalase (2 μg per ml) were added and vortexed to mix and break the 
catalase grains. 150- 200 μL of incubation medium were applied to each slide 
and spread evenly on the slide surface. It is let to incubate for 40 minutes at 37 
°C. Excess solution is removed. Slides were washed 4 times in 0.1 M PBS 
pH=7.0. 10 minutes each. Slide were returned back to slide-staining chamber.  
SDH histochemistry 
1.5 mM NBT, 130 mM sodium succinate, 0.2 mM PMS, and 1.0 mM 
sodium azide in 0.1 M PBS pH=7.0. were prepared in chemical fume hood, 
shielded from sunlight and quickly vortexed. 150- 200 μL of incubation medium 
were applied to each slide and spread evenly on the slide surface. It is let to 
incubate for 40 minutes at 37 °C. Excess solution is removed. Slides were 
washed 4 times in 0.1 M PBS pH=7.0. 10 minutes each. Each slide is dehydrated 
through 70%, 70%, 95%, 95%, 99.5% ethanol for 2 minutes each, plus additional 
10 minutes in 99.5% step. Slide is placed in xylene for 10 minutes, then mounted 
with coverslip. Slides were allowed to dry in ventilated area for 1-2 hours or 
overnight.  
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2.13 Copy number analysis 
The measurement of mtDNA copy number is done by measuring the relative 
different from qPCR of mutants’ controls/reference gene mtDNA (e.g. ND1, ND2, ND5) 
and the normal cell/mice controls/reference mtDNA copy number, and the differences of 
individual copy number relative to nuclear DNA copy number of control/reference genes. 
All mtDNAs were quantified using Nanodrop (ND1000, LabTech) and 
equalized/normalized between samples and controls prior to loading. Each qPCR was 
performed using Quantstudio 7 Flex Real Time PCR System (Life Technologies) and 
standard qPCR protocols were followed for protocols.  
2.14 Mitochondrial isolation  
Mitochondrial organelle was isolated using Thermo Scientific Mitochondrial 
Isolation Kit for Tissues (89801) and Mitochondrial Isolation Kit for Cultured Cells 
(89874).  
2.14.1 Isolation of Mitochondria using Reagent-based Method for Cultured Cells 
MEF cells were harvested from T25 flask and quantified. A pellet of 2 × 107 
cells was harvested by centrifuging cell suspension in microcentrifuge tube at 
about 850 g for 2 minutes. Supernatant was carefully removed and discarded. 
800 µL of Mitochondria Isolation Reagent A was added to the pallet and mixed 
with pallet by pipetting up and down. The tube was vortexed for 5 seconds at 
medium speed and then incubated on ice for exactly 2 minutes (do not exceed 2 
minutes). 10 µL of Mitochondria Isolation Reagent B was added to the solution 
and vortex for 5 seconds at maximum speed. The sample tube was incubated on 
ice for 5 minutes and intermittently vortexed every minute at maximum speed. 
800 µL of Mitochondria Isolation Reagent C was added to the sample tube and 
mix by inverting tube several times (but do not vortex). The tube was centrifuged 
at 700 g at 4°C.for 10 minutes Supernatant was transferred to a new 2ml tube 
and centrifuge at 12,000 g at 4°C for 15 minutes.  The supernatant (cytosol 
fraction) is transferred to a new tube. Pallet at the bottom of the tube is the 
mitochondrial fraction. 500 µL of Mitochondria Isolation Reagent C ws added to 
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the pallet, centrifuged at 12,000 for 5minutes. Supernatants was discarded. The 
pallet was kept on ice prior to further experiment, or frozen at -80°C until needed 
for experimentation.  
. 
2.14.2 Isolation of Mitochondria using Dounce Homogenization for Tissues  
50-200mg of tissue were washed 2x with 4ml of PBS, and PBS was 
discarded carefully. Tissues were cut into smaller pieces and 800µL of 
BSA/Reagent A Solution was added. Dounce homogenization was performed on 
ice. 800µL of Mitochondria Isolation Reagent C was added and mixed by inverted 
the tube few times. The tube was centrifuged at 700×g for 10 minutes at 4°C. The 
pallet was discarded. The supernatant was transferred a new 2mL tube, and 
centrifuged at 3,000×g for 15 minutes at 4°C. The supernatant (cytosols) were 
removed from the mitochondrial pellet and kept at 80°C until needed. 500µL of 
Wash Buffer was added to the pallet to perform a surface wash, then centrifuged 
for 5min at 12,000×g, and supernatant was discarded. The pallet was kept on ice 
prior to further experiment, or frozen at -80°C until needed for experimentation. 
2.15. Preparation of fresh MEF for FACS with MitoTracker® 
MEFs culture cells were made into single cell suspension using standard 
trypsin method and resuspended in DMEM only media. MEFs were transferred as 
the single cell suspension onto a 30-micron filter/cell strainer and let gravity filter it 
into a glass tube for FACS. Keep it on ice/dark until FACS, preferable as little lag 
time as possible to FACS. FACS LSRII (BD Biosciences) was applied to sort the 
cells based on MitoTracker(R) expression. The device was calibrated with the 
non-stained cells to set up the size gate, SSC and FSC of dot plots and baseline 
negative control for the fluorescent channels. LSRII (BD Biosciences) device was 
employed to detect the signals. Standard dead cell stain was used (e.g. 
Propidium iodide (PI) or DAPI) to detect dead cells. (DAPI – 1 microgram/ml is 
enough, detection at 355/450/50). Analysis was done with LSRII.  
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2.16 Seahorse mitochondrial analysis (XFe) - XF Cell Mito Stress Test 
Day1; XF96 well cartridge is hydrated with standard XF solution, wrap with 
cling film and left in non-CO2 incubator for 24 hours. The desired number of cell 
plate are prepared and seeded as per optimisation (15000 cells per well) and left 
overnight in normal incubator to settle down in XF96 well plate with 200ul normal 
MEF media per well (spin for 1 minute at 1000 rpm as required). 
Day 2; XF96 well plate containing the MEF was check for consistency and 
cells attached to the bottom of plate well under microscope. Media were replaced 
with XF Cell Mito Stress Test Media with final volume of 175ul per well and leave 
in non-CO2 incubator for 1 hour. Stock compounds/drugs were prepared as 
required concentration and 25ul of each are injected in the XF probe port A, B, C, 
or/and D as required.  
a. Port A-Oligomycin 1 uM 
b. Port B-FCCP 0.5 uM 
c. Port C-FCCP 1 uM 
d. Port D-Rotenon/Antimycin A (1uM each in combination) 
 
The template in XFe machine were created for the experiment. XF probe 
plate are inserted into the machine and calibrated. Culture plate were inserted 
replacing the bottom plate of XF probe. Experiment then run accordingly. When 
finished, XFplate containing the cells are emptied and lysed for protein 
concentration assay using standard Bradford assay and values were calibrated 
and used for normalisation of assay signals in the XFe software.   
 
2.17 Statistical analysis  
Unless specifically stated, the significant of differences between mutants 
and wild-type mice were tested with ANOVA or unpaired student t-test using the 
SPSS software.  Values are presented as mean +/- SE.  P values were deemed 
significant when ≤0.05.  Correlation coefficients were calculated using SPSS and 
stated as per in the result.  For all experiment samples were relabelled or slides 
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blinded prior to analysis and then genotypes and sexed for uniformity and 
confirmation.  
 
All experiments were approved by the animal ethics committee and were 
conducted in accordance with the UK code of practice for the care and use of 
animals and the Home Office Animals in Scientific Procedures act, 1985.   
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CHAPTER 3. DISRUPTED NEPHROGENESIS IN MURINE DENYS DRASH 
SYNDROME. 
3.1 Introduction 
In kidney development, the morphological stages of nephrogenesis are largely 
well documented. Studies on mutant and wild type mouse models, supported by 
analysis of human nephrogenesis have uncovered a deep insight into the contribution of 
some of the genes involves in the normal developmental processes. The nephron is the 
functional unit of a kidney, containing structures that filter blood within the glomerulus 
into solutes that at later segments are selectively reabsorbed and later excreted and 
concentrated as urine through the connected duct system, as required by the body. The 
Monash Series documents human nephron number analysis across 5 ethnic 
backgrounds, showing a 13-fold range from 210,000 to 2.7 million nephrons per kidney 
(Bertram et at., 2014) compared with between 11,000 and 19,000 nephrons per kidney 
in adult mice (Merlet-Bénichou et al., 1999).  There are no new nephrons are formed in 
human kidneys after approximately 36 weeks' gestation, thus the final number of 
nephrons is determined prior to birth, whereas in mice, nephrogenesis carries on for 
several days after birth. However, the process of nephrogenesis itself is most similar 
between these two species and involves almost the same genes (Cheval et al., 2012). In 
the adult mammalian kidney, the renal tubular network and multiple glomerular 
structures undergo constant cell renewal as a consequence of aging and injury but there 
is no evidence for the generation of new nephrons (Humphreys et al., 2008; Vogetseder 
et al., 2005). 
Although quite a number of studies shown a relationship between lower nephron 
number and various diseases, for example, hypertension and CKD (Luyckx et al., 2011), 
the underlying mechanism is not known. Variation of nephron numbers in adult are 
determined by the nephron number at the end of nephrogenesis and the rate of nephron 
loss during postnatal life and also other age-related loss of glomeruli due to 
glomerulosclerosis, disease affecting kidneys, hypertensive status and other attributes of 
health (Nyengaard and Bendsen 1992, Hoy et al., 2008, Bertram et al., 2011). 
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The total number of glomeruli (nephrons) in a kidney is an important 
microanatomical parameter for at least three reasons. First it provides an index of the 
success/extent of nephrogenesis. Second, low nephron number has been linked to an 
increased risk of cardiovascular and renal disease in adulthood and third, the knowledge 
of quantitative kidney microanatomy can illuminate our understanding of physiological 
mechanisms in health and disease (Bertram et al, 2013). Although low nephron number 
is implicated in hypertension and renal diseases, the mechanisms that determine 
nephron number are obscure. 
Numerous studies have indicated that Wt1 mutation, both dominant-negative and 
haploinsufficiency, cause glomerulosclerosis (GS) in mouse models but the underlying 
mechanisms remain to be identified (Patek et al., 1999). In the adult kidney, Wt1 
expression is strikingly restricted to the podocyte cells of the glomeruli and, given that 
mutation of podocyte genes, such as CD2AP, podocin, podocalyxin etc, also causes GS 
(Guo et al., 2002), it has been assumed that Wt1 mutation causes GS by disrupting 
downstream podocyte-specific gene expression. However, no such pathway has been 
identified to date and evidence, from studies of mouse chimaeras, indicates that Wt1 
mutation is neither necessary nor sufficient for GS to develop at the level of individual 
glomeruli (Patek et al., 2003). 
It has recently been shown that DDS/+ Wt1 mutant mice present with a 20% 
deficiency in nephron number at 4 weeks of age, prior to the onset of overt GS. 
Furthermore, this deficiency is physiologically relevant as mutant mice exhibit 
compensatory glomerular hypertrophy and increased activation of the renin-angiotensin 
pathway, thus it was suggested that Wt1 mutation causes abnormal nephrogenesis that 
results in a failure to develop a full complement of nephrons, leading to hypertensive 
changes that ultimately cause GS (Wroe et al., 2009). However, nephron loss is a 
common feature of GS, i.e., sclerotic glomeruli undergo atrophy and reabsorption (Denic 
at al., 2016), so a deficiency in nephron number at 4 weeks of age does not prove that a 
developmental abnormality affecting nephrogenesis underlies GS in murine DDS. 
Given the increasing evidence that Wt1 mutations are a significant factor 
contributing to GS in patients, it is important to determine whether Wt1-mediated 
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nephron underdosing is due to abnormal development or post-natal nephron loss. In 
order to address this question, kidneys from wholly inbred DDS/+ mice were examined 
at P0 (post-partum day 0, newborn) – a time at which nephrogenesis is ongoing in the 
mouse, therefore all key stages of nephron development can be assessed. 
3.2 Results 
The interdisciplinary field concerned with quantitative analysis of three-
dimensional (3-D) objects utilising two-dimensional (2-D) data aspects is called 
stereology and is widely employed in the analysis of nephrogenesis (Kelli et al., 2000).  
In order to precisely analyse nephrogenesis in Wt1 DDS/+ mice, kidneys were isolated 
from newborn (P0), sex-matched (female), wholly inbred (129/Ola) wild type and DDS/+ 
mice. Accurate measurements of kidney size (length and cross-sectional area) can 
provide an indication of abnormal development (Bridgette et al., 2010) but a more 
detailed approach is to use stereological techniques to count the absolute number of 
nephrons. In this current study, nephron number counts were extended to include 
different stages of nephrogenesis normally present in the newborn mouse kidney 
(glomeruli, comma- and s-shaped bodies).  
Kidney size measurements were taken under light microscopy to give length 
(pole-to-pole) and cross-sectional area, using AxioVision software, as illustrated in 
Figure 3.2.1 below. The kidneys were not weighed.  
 
Figure 3.2.1: 
Representative figure 
depicting the P0 (new 
born) mice kidney. 
Measurements taken 
were length (length 
pole-to-pole) (blue 
numbering) and cross-
sectional area of the 
kidneys.  
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In order to facilitate nephron counting, peanut agglutinin (PNA) staining was 
employed, with methyl green counterstaining of sections. In contrast to counting 
nephrons in an adult kidney, where glomeruli can be readily detected under 
conventional light microscopy, nephrons within the developing kidney are typically in one 
of three distinct states, immature glomeruli, comma-shaped body, and s-shaped body, 
that are more difficult to distinguish. Figure 3.2.2 and Figure 3.2.3 shows examples of 
developing nephrons following PNA/methyl green staining from the most immature 
comma-shaped body, through s-shaped body to the mature glomerulus.  
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Immature and mature nephrons were counted on 5 kidney sections, separated by 
15 sections, located towards the centre of the kidney (passing through the renal pelvis), 
for each kidney, under 40X magnification. Figure 3.2.2(C) shows representative images 
of PNA/methyl green stained kidney sections highlighting comma-shaped bodies, s-
shaped bodies and glomeruli. As can be seen, nephrogenesis occurs at the periphery of 
the kidney cortex, with more mature structures (glomeruli) being situated towards the 
inside of the cortex, with comma- and s- shaped bodies occupying the periphery, 
marking the “nephrogenic zone”.  
Figure 3.2.2: A. Representative section of P0 kidney stained with PNA/methyl 
green (5X magnification). B & C. Expanded view of boxed area from A under 
different contrasts to highlight a glomerulus (g), comma-shaped body (c) and s-
shaped body (s) within the cortical region (20X magnification).  
A B 
C 
(g) 
(c) 
(s) 
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The counting was made by 2 people and double blinded. The slides numbers 
were covered and randomly labelled. They were shuffled, and nephrons were counted 
independently by the 2 persons. The values were compared and calculated for the 
significance of the different between the counts. For all stages of nephron, the 
calculated p-value were significantly >0.05, indicating no difference between the 2 blind 
counts. The counted nephron numbers were averaged and were accepted as the true 
count for the subsequent analysis.  
 
 
Figure 3.2.3: Representative diagram of P0 kidney section stained with 
PNA/methyl green (40X magnification) under different contrasts, A & B. Highlight 
comma-shaped body. C & D. S-shaped body and glomeruli highlighted on P0 
kidney section stained with PNA/methyl green (40X magnification). Note S-
shaped body found peripheral to glomeruli, within the “nephrogenic zone”.  
A 
C 
B 
D 
(comma-shaped body) 
(s-shaped 
body) 
(mature 
glomeruli) 
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GENOTYPE 
 Wild type (n=7) DDS/+ (n=7) 
LENGTH POLE-TO-
POLE (LPP) 
 
3557.96 ± 107.07 
 
3501.29 ± 108.17 
LONGITUDINAL 
CROSS-SECTIONAL 
AREA (CSA) 
 
6780549.73 ± 
397093.94 
 
6286498.87 ± 
295393.36 
NNEPHRON 4268.57 ± 126.45 
 
3561.71 ± 171.00 
NGLOMERULI 
 
3068.57 ± 104.06 
 
2667.43 ± 135.12 
NS-SHAPED 
 
268.57 ± 20.27 
 
109.14 ± 13.26 
NCOMMA 
 
931.43 ± 35.13 
 
785.14 ± 51.18 
 
 
 
 
 
 
 
 
 
 
Table 3.2.1: Summary of measurements/counts carried out on P0 female kidneys. 
All values expressed as means ± standard error of the mean (SEM). Length pole-
to-pole /µm, Longitudinal cross-sectional area / µm2. 
- 74 - 
 
 
 
 
 
The data seems to provide evidence that nephron number is reduced in DDS/+ 
mice at birth, with all stages of nephrogenesis under-represented, particularly the s-
shaped body stage. However, the analysis of kidney stereology requires rigorous 
statistical analysis due to the influences of environmental factors that can confound such 
studies, even with the use of age- and sex- matched wholly inbred mice.  
In order to verify the distribution of data prior to statistical analysis, assessments 
of normality were carried out. Assessment of the normality of data is a prerequisite for 
many statistical tests because normal data is an underlying assumption in parametric 
testing.  
Figure 3.2.4: Summary of measurements/counts carried out on P0 female kidneys 
showing distribution of values of each genotype. Wild type (WT) = diamonds, 
DDS/+ = circles.  
WT    DDS/+ WT    DDS/+ WT    DDS/+ WT    DDS/+ 
WT    DDS/+ 
WT    DDS/+ 
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 The Shapiro-Wilk test is more appropriate for small sample sizes (<50 samples) 
and, under these conditions, a Sig. value below 0.05 indicates that the data deviates 
significantly from a normal distribution. The normality of the datasets can be presented 
graphically, by using the output of a normal Q-Q Plot. If the data are normally distributed, 
the data points will be close to the diagonal line. If the data points stray from the line in 
an obvious non-linear fashion, the data are not normally distributed. As we can be seen 
in Figure 3.2.5, the normal Q-Q plot below, the data is normally distributed. 
 
Tests of Normality 
 
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
LengthPoleToPole .119 14 .200* .939 14 .409 
LongCrossSection .130 14 .200* .953 14 .607 
TotalNephronNumber .090 14 .200* .974 14 .921 
GlomeruliNumber .110 14 .200* .984 14 .992 
CommaBodies .185 14 .200* .952 14 .595 
SshapedBodies .171 14 .200* .941 14 .429 
Genotypes .332 14 .000 .646 14 .000 
 
*. This is a lower bound of the true significance. 
a. Lilliefors Significance Correction 
 
Table 3.2.2 Results of the Kolmogorov-Smirnov Test and the Shapiro-Wilk Test of 
normality, indicating that all datasets follow a normal distribution (p-value >0.05).  
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 Having confirmed the datasets follow a normal distribution, further testing was 
carried out to investigate homogeneity of variance and means. This analysis adds 
further rigour and stringency and is designed to identify any “outlying” data points that 
fall within a normal distribution. These tests will inform whether parametric or non-
parametric analyses are most appropriate.  
The assumption of homogeneity of variance is an assumption of the ANOVA that 
assumes that all groups have the same or similar variance.  The ANOVA utilizes 
the F statistic, which is robust to the assumption, as long as group sizes are 
equal.  Equal group sizes may be defined by the ratio of the largest to smallest group 
being less than 1.5.  If group sizes are vastly unequal and homogeneity of variance is 
violated, then the F statistic is considered liberal when large sample variances are 
associated with small group sizes.  When this occurs, the alpha value is greater than the 
level of significance.  This indicates that the null hypothesis is being falsely rejected.   
The test statistic for Levene’s test is calculated by diverging the data for each 
group from the group mean, and then comparing the absolute values.  Levene’s test is 
Figure 3.2.5: Q-Q plots for data normalisation. Everything is within acceptable 
margin. 
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presented with the F statistic, as an ANOVA is conducted to compare the absolute 
values.  A p value less than .05 indicates a violation of the assumption.  If a violation 
occurs, it is likely that conducting the non-parametric equivalent of the analysis is more 
appropriate. 
 
Test of Homogeneity of Variances 
 
Levene 
Statistic df1 df2 
Sig.(P-
value) 
LengthPoleToPole .004 1 12 .949 
LongCrossSection .574 1 12 .463 
TotalNephronNumb
er 
.074 1 12 .790 
GlomeruliNumber .173 1 12 .685 
CommaBodies .951 1 12 .349 
SshapedBodies 2.162 1 12 .167 
 
Table 3.2.3 indicates that all parameters measured in this study show equal 
variance between groups (Levene Test is not significant, Sig.>0.05), thus ANOVA can 
be carried out with confidence without the need for non-parametric testing or log-
transformation of data. Analysis of variance (ANOVA) tests the hypothesis that the 
means of two or more populations are equal. ANOVAs assess the importance of one or 
more factors by comparing the response variable means at the different factor levels. 
The null hypothesis states that all population means (factor level means) are equal while 
the alternative hypothesis states that at least one is different. 
 
 
 
 
 
 
Table 3.2.3: Results of the 
Levene Test indicating the 
datasets show homogeneity 
of variance (Sig. value >0.05)  
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ANOVA  
 Sum of Squares df Mean Square F Sig. 
LengthPoleToPole Between 
Groups 
11240.211 1 11240.211 .139 
.716 
Within Groups 972877.378 12 81073.115   
Total 984117.589 13    
LongCrossSection Between 
Groups 
854301897755.11
4 
1 
85430189775
5.114 
.997 
.338 
Within Groups 10287515022089.
006 
12 
85729291850
7.417 
 
 
Total 11141816919844.
120 
13   
 
TotalNephronNumbe
r 
Between 
Groups 
1748764.571 1 1748764.571 11.046 
.006 
Within Groups 1899753.143 12 158312.762   
Total 3648517.714 13    
GlomeruliNumber Between 
Groups 
563204.571 1 563204.571 5.532 
.037 
Within Groups 1221595.429 12 101799.619   
Total 1784800.000 13    
CommaBodies Between 
Groups 
74898.286 1 74898.286 5.554 
.037 
Within Groups 161828.571 12 13485.714   
Total 236726.857 13    
SshapedBodies Between 
Groups 
88961.143 1 88961.143 43.317 
.000 
Within Groups 24644.571 12 2053.714   
Total 113605.714 13    
 
 
 
 
 
Table 3.2.4: Results of ANOVA and the P-value of each measurements are to the 
right side of the table.  
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Rigorous statistical analysis confirms that all stages of nephrogenesis are under-
represented in P0 DDS/+ female kidneys, whereas there are no differences in kidney 
size – either pole-to-pole length or cross-sectional area. The means of length pole-to-
pole and longitudinal cross-sections were equal and show no difference between groups 
(genotype). Whereas the other variables, total nephron number, glomerular number, s-
shaped and comma-shaped bodies have unequal means, indicating that they are 
different between genotypes. The data can now be visualised, as summarised, below. 
Figure 3.2.6: Box-whisker plots of data showing nephron number and nephron precursor 
number at P0 (newborn) age between wild type and DDS/+ mice. A- Difference between 
the total nephrons number in DDS/+ mice, *p<0.05.  B- Difference between the 
glomerular number in DDS/+, **p<0.05. C- Difference between the number of S-shaped 
bodies in DDS/+ mice, * P<0.05. D- Difference between the number of comma shaped 
bodies in DDS/+ mice, **p<0.05. Figure E and F p>0.05. In all cases n=7 both 
genotypes, female littermates, p value calculated by unpaired student t-test.  
WT    DDS/+ WT    DDS/+ WT    DDS/+ WT    DDS/+ 
WT    DDS/+ WT    DDS/+ 
[E] [F] 
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All data were then analysed using IBM SPSS version 23 for Windows. All data 
have been tested for normality using a Shapiro-Wilk test (and Kolmogorov-Smirnov test 
if ones preferred), and homogeneity of variance prior to analysis of variance ANOVA 
(Table 3.2.2). All data were found to be normally distributed. To compare stereology 
data at termination of treatment, a one-way analysis of variance (ANOVA) was 
performed with a post hoc analysis to determine differences between groups. A 
probability of 0.05 or less was considered statistically significant.  
 
Correlation Analysis and regression statistic  
 
Table 3.2.5: Pearson correlation (r) matrix of all factors calculated against each other. 
Significant p value was taken as p<0.05 1-tailed. Positive Pearson’s correlation value 
(top part of the table, in red box) indicate positive correlation (describes the relationship 
between X and Y perfectly, which Y increases as X increases), and negative values 
indicate negative correlation (which Y decreases as X increases). The Sig. value is the 
significance for each Pearson’s value. N is the total number of items in the calculation. 
The ranges of correlation coefficient is −1 to 1. No linear correlation between the 
variables indicated with value of 0. 
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The correlation table shows decomposition of each unique variables and each 
shows some level of unique predictive capacity towards respective variables from 
Pearson’s correlation calculations.  
Multiple regression is quite a sophisticated technique. Regression calculation was 
done on all predictive factors (not including genotype) towards glomerular number as 
dependant to see if any of these factors have the highest contributing predictive value 
with high level of accuracy towards nephron number using stepwise method in SPSS 
regression calculation. Stepwise method will choose the independent variable that has 
the largest Pearson’s correlation with the dependant variable, in this case glomerular 
number, and next will look at the next highest predictor from Pearson correlation matrix 
and continue the calculation and so on.  
 
Table 3.2.6: ANOVA of statistically significance of the model for prediction indicating 
potential predictors that can be used to assess nephron number.  
 
Table 3.2.7: Result of stepwise method for significant predictor for nephron number. 
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Stepwise method gave the S-shaped bodies as the most significant predictors for 
representation of final glomerular number in this case at this stage of renal development, 
F(1,12) = 43.317, p<0.005, R2 = 0.783. This points out that this stage gives a significant 
indication and contribution towards final glomerular number, adding to the technical 
aspect of it to be easily recognised when counting.  
To see whether the correlation between the two genotype groups is significantly 
correlated, regression calculation was done. The total number of nephron, and glomeruli 
number was set separately up as dependant variable and the genotype was the 
dichotomous independent variable in both calculations by default method (enter), result 
as shown below.  
Sum of Squares df Mean Square F Sig.
Regression 1748764.571 1 1748764.571 11.046 .006
b
Residual 1899753.143 12 158312.762
Total 3648517.714 13
ANOVA
a
Model
1
a. Dependent Variable: TotalNephronNumber
b. Predictors: (Constant), Genotypes
 
Sum of Squares df Mean Square F Sig.
Regression 563204.571 1 563204.571 5.532 .037
b
Residual 1221595.429 12 101799.619
Total 1784800.000 13
ANOVA
a
Model
1
a. Dependent Variable: GlomeruliNumber
b. Predictors: (Constant), Genotypes
 
Table 3.2.8: ANOVA of statistically significance of the model for prediction for both 
glomeruli and total nephron number.  
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3.3 Summary of key findings: 
I. Nephron number is decreased at birth in DDS/+ mice. Thus, it is abnormal 
development and not the disease state that leads to fewer nephrons in DDS/+ 
mice. 
II. DDS/+ kidneys do not differ in size from wild type at birth.  
III. There is a differential effect (can be recognized and identified) on different stages 
of nephrogenesis, with s-shaped body as the most significant.  
IV. Indication of factors contributing to the nephron number start before parturition 
(i.e. genotype or other factors) 
V. S-shaped body is both easy to be recognised technically and predictive of the 
nephron number.  
 
 
 
3.4 Discussion 
The exact pathways governing the end of nephron formation is not yet 
understood, although some genes have been implicated with specific spatial expression. 
Two possible mechanism initiating the ending of nephrogenesis have been proposed. 
First, the birthing or post birth processes trigger a system involving glycolytic pathways 
and the increase in oxygen tension, a theory based on differential gene expression 
changes (Brunskill et al, 2011). Second, the process of nephrogenesis gradually loses 
the progenitors’ stem cells capacity and exhausted itself, ultimately leads to 
differentiation into various specified cells types and loses progenitor attributes, thus 
ending the nephrogenic processes (Brunskill et al., 2011, Hendry et al., 2011).  
It has been documented that infants below 10th percentile of birth weight shown to 
have smaller kidneys plus fewer nephron number indicating possibility of relationship 
between body size, kidney weight, kidney size and nephron number (Hoy et al., 2003, 
Merlet-Benichou et al., 1999). In addition, correlation has been shown to exist between 
adult height and body surface area (Hoy et al., 2006), and between kidney weight, 
kidney volume and glomerular volume (Hughson et al., 2003). Mice with a lower birth 
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weights were documented to be are born with smaller kidney and kidney surface area 
(Murawski et al., 2010). 
It is well known that nephron number in humans can vary more than tenfold from 
200,000 to 1.8 million (Hughson et al., 2003) while in mice varies from 11,000 to 19,000 
per kidney (Merlet-Benichou et al., 1999). The end of nephrogenesis in human was 
documented to be at 36 weeks of gestation (Hinchliffe et al., 1991) and around one 
week (P6) after birth in mouse (Rumballe et al., 2011).  It is thought that this variation of 
nephron number, with lower counts having higher risk and highly associated with 
predisposition to renal disease (Brenner and Anderson, 1992; Luyckx and Brenner, 
2010.).  
Whilst the studies describe the association of nephron number and those factors, 
some have shown relationship of those to hypertension or chronic renal failure, and 
some have not (Hoy et al., 2003, Hughson et al., 2006, McNamara et al., 2008). This 
suggest the existence of other possible parameters that are independent, or maybe 
interdependent that obscure the relationship by means of multiple variations in gene 
expressions and environments.  
The wild type and DDS/+ mutant mice are of similar strain and background, with 
uniform exposure to surrounding environment making this model ideal for various 
comparison studies. Newborn mice (P0) were culled and the kidneys were isolated, 
measured for cross-sectional area (CSA) and pole-to-pole length (LPP) then prepared 
for nephron number counting. Kidney weight were previously shown to be correlated 
positively with kidney surface area suggesting that these measurements are 
interchangeable. (Murawski et al., 2010).  
Although it seems logical to assume if there was reduction of nephron number, 
the kidney should be smaller for the volume reduction. In this study, DDS/+ mice had 
slightly smaller kidneys than wild type mice measured as planar surface area and LPP, 
but insignificant statistically. This insignificant different might be as a result of 
supervening compensatory hypertrophy of the remaining nephron and glomeruli as adult 
DDS/+ mice have been shown to have significantly larger mean glomerular volume 
(MGV) compared to wild type (Wroe et al., 2009).  
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The study of the relationship between kidney size and nephron number came 
mostly from rat models. The relationship studies of naturally occurring low birth weight 
rat (Wistar rat) shows 20% reduction of nephron number and normal size kidneys with 
increase in glomerular volume (Schreuder 2007, Jones et al., 2001), while another strain 
of naturally occurring low birth weight rat (Sprague-Dawley rats) do not have a 
significant nephron number different and kidney weight or size (Jones et al., 2001). On 
the other hand, a study on mice kidney shows size correlates with birth weight, but 
nephron number does not correlate with birth weight or kidney size, and that the 
differences in nephron number cannot be predicted by a change in kidney size or body 
weight and that nephron number is an independent variable (Murawski et al., 2010). 
Unfortunately, the kidneys were not weighed prior to processing to correlate this 
previous finding. While other studies showed correlation between nephron number and 
kidney size with up to 5-fold correlated difference (Hoy et al., 2003, Nyengaard et al., 
1992, Hoy et al., 2006, McNamara et al., 2008), it is suspected that large comparative 
difference is needed of at least 2-fold to show any significant correlation between kidney 
size and nephron number (Murawski et al., 2010). Even though hypoplastic kidneys 
(small kidneys) were seen to be the results of multiple genetics and also environmental 
factors, it is not always reflected as kidney size abnormality for nephron number 
differences (Cain et al., 2010). These highlights the challenges and importance of 
understanding the underlying morphogenetic and molecular process of the kidney 
development.  
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Figure 3.4.1: Projection of nephron number (current counts at 15.9% and *Miles Lab 
unpublished data and 22% Wroe et al., 2009, Figure 1.8.2.1) at various stages of 
development between wild type and DDS/+ (Wt1tmT396/+) mice adapting the nephron 
number trend from Short et al., 2014. At e17 and e18, there were no gross different of 
total counts. At P0 there is observable reduction of 15.9% and at one month a 20% 
reduction on nephron number, p<0.05. 
 
The pattern of nephron formation, morphological segmentation and functions are 
guided partially by ureteric epithelium and the rest by the interstitial tissue and 
vasculature surrounding it (Costantini and Kopan, 2010 and Little and McMahon, 2012). 
Even the interaction is known, the complexity of alteration of one factor affecting another 
is still not predictable, let alone the relative changes they affect the stages of 
nephrogenesis are unknown. Contrary to logical impression of timely repeated 
synchronous growth, renal morphogenesis exhibits temporal discontinuity of its conserve 
branching growth, not to mention the branching and proliferation reduces over time 
(Short et al., 2013).  
It is known that cap mesenchymal (CM) cells may either aggregates and 
differentiate itself into nephrogenic epithelial cells or self-renew to support the growth of 
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ureteric tip (UT) while another UT contributes to the nearby duct formation. A 
morphometric analysis measuring the initial exit rate of the CM and UT of this branching 
processes was showing unbalance with CM niche show early depletion, displaying a 
heterogenous growth between the cell populations at the first half of nephrogenesis, 
though become balance in later half postnatally with exponential CM growth that 
resulting in final loss of the cell niche (Short et al., 2013).  
This confirms the previous finding of CM showing heterogenous growth (Mugford 
et al., 2009), with unequal depletion of fast rapid turn-over CM niche that thought to 
undergo differentiation, that later imparted the predominant possible observation of 
having more than 50% nephron originated from this rapid turn-over CM niche (Short et 
al., 2013). Nevertheless, lineage tracing indicates all CM would end up contribute to 
nephron formation (Boyle et al., 2008 and Kobayashi et al., 2008) which indicates that 
the remaining slow turn-over CM niche eventually contribute to nephron. This 
observation corroborates the hypothesis of decisive trigger prompted CM depletion by 
differentiation at parturition (Rumballe et al., 2011) implying possible CM sub-niche exist 
as progenitor in certain ration, decreasing by time denoting dissimilarity of early CM and 
later CM. This elucidate the study having disparate gene expression profiles of early CM 
and later CM after birth (Brunskill et al., 2011). 
S-shaped bodies show greater difference between wild type and DDS/+. This 
seems to indicate a dynamic difference in the process of nephrogenesis, in addition to 
fewer comma-shaped bodies developing. Could there be compensatory acceleration of 
nephrogenesis through the s-shaped body stage to counteract the reduction in nephrons 
being produced, i.e., spending less time at the s-shaped body stage is a possibility. This 
seems to affect the last wave of nephrogenesis post parturition.  
It is possible that pax-2 determines epithelial tubule specialization, whereas WT1 
determines glomerular visceral epithelial specialization in the developing nephron. WT1 
have also suggested suppression not only of transcription of early growth response 
gene (EGR-1), IGFII and platelet-derived growth factor-A (PDGF-A) (Drummond et al., 
1992) but also the transcriptional activation of WT1 itself (Wang et al., 1993). It does not 
appear to contribute to development of the other epithelial tubular cells of the nephron. 
However, in Wilms tumours, WT1 is over expressed in dysplastic tubular epithelium 
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(Yeger et al., 1992). WT1 serve as transcriptional repression of growth factor and 
receptor genes like IGFII, PDGF-A, CSF-1, TGF-13, IGF1R and transcription factors like 
RARct (Dey et al., 1994, Drummond et al., 1992). Under some circumstance 
transcriptional activation of these and other genes may also occur (Madden et al., 1991, 
Wang et al., 1993). 
Although nephrogenesis was seen to initiate early (12.5 dpc), the majority of 
nephrons (>50%) form once branching has ceased. Consequently, variability in final 
nephron number may not necessarily reflect variations in final branch generation 
number. Perhaps of greater interest is the clear sub sectioning of the CM into distinct 
populations based on cell-cycle length, with the slower cycling population representing 
those portions of the CM containing the highest level of Six2 protein. (Short et al., 2013), 
which Six2 together with WT1 are involve in early nephron formation. There are more 
questions than answers at this stage, perhaps there are other contributing factors to it 
such as effect of programmed cell death, or maybe abnormal differentiation or 
proliferation in affect?  
From Figure 3.4.1, it is postulated that the most likely time point suitable for 
investigation of gene expression would be between e17.5 to e18.5. This would give a list 
of genes that would give an idea towards the role of WT1 gene and its downstream 
affecting the formation of new nephron. Next chapter would explore more on this in 
interesting time point of what genes change when WT1 was disrupted that would lead to 
phenotype of low nephron in DDS/+.  
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CHAPTER 4. ALTERED GENE EXPRESSION PATTERNS DURING KIDNEY 
DEVELOPMENT IN MURINE DENYS DRASH SYNDROME 
 
Introduction 
The role of multiple systemic disease processes in the pathogenesis of chronic 
kidney disease (CKD) has been recognised, for example in ageing DDS/+ mice (Patek 
et al., 2008), and the concept of a ‘first hit’ in renal disease is becoming widely accepted 
(Hershkovitz et. al., 2007). This concept has developed such that kidney diseases are 
now thought to often be associated with low nephron number (LNN), in particular as a 
mechanism involved in CKD development and progression. Multiple observations on 
intrauterine growth restricted (IUGR) babies initially led to this conceptual formulation 
(Hershkovitz et. al., 2007). Consistent with these observations, many studies in rats 
induced to have LNN by protein restriction diet resulted in animals with impaired renal 
function (Woods et. al., 2004, Bauer et. al., 2002). This positive correlation has also 
been documented from studies involving mortality of stillborn and infants within the first 
year of life (Manalich et. al., 2000). Thus, an individual with the ‘first hit’ LNN kidney then 
later becomes vulnerable to various forms of renal injury, the ‘second hits’, thus 
enhancing the development toward CKD.  
As been shown in previous chapter, DDS/+ mutant mice have lower nephron 
compared to wild type. In order to investigate the gene expression changes directly 
related to this abnormal kidney development, kidneys were taken for analysis at e17.5, 
prior to any gross differences being apparent, such as reduction in nephron number that 
has been discussed in previous chapter. The e17.5 to e18.5 timing is taken because it is 
just before birth of the mice (Figure 3.7), and this is the timing assumed to be a crucial 
turning point for nephron development. Instead of using RNA-seq, I have opted for 
microarray for several reasons, namely it is a test with proven clinical utility, cost 
efficient, and is a direct measurement of annotated genes.  
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4.1 Microarray data and analysis of DDS/+ mice e17.5 kidneys versus wild type  
Foetal kidneys from DDS/+ mice were compared with age- and sex-matched wild 
type littermates was carried out in order to identify molecular pathways disrupted by Wt1 
mutation.  
The overall quality of the analysis was determined by Source Bioscience for RNA 
integrity and array signal optimisation and normalization. As can be seen below, only 
minimal normalisation was necessary across the 8 hybridisations: 
  
 
Figure 4.1.1: A chip-to-chip comparison before and after normalization. The plots on the 
diagonal show the names of the chips compared. The plots above the diagonal show the 
comparison of the data of two chips. After normalization, the red line should be close to 
zero (the blue line). The plots below the diagonal show the variance of the ratios. The 
variance equals zero, if the compared chips are identical. 
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Figure 4.1.2: Boxplots of log2 transformed expression values before and after 
normalization. 
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Unbiased Principal Component Analysis revealed the global differences in gene 
expression between wild type and mutant samples (wild type red triangles, mutant blue 
crosses) and the hierarchical clustering of the top 50 differentially expressed genes is 
depicted by the heat map below: 
 
Figure 4.1.3: PCA of expression values for normalized and filtered genes for the arrays. 
First four principal components (PCs) are plotted against each other. The numbers in the 
diagonal show the proportion each PC contributes to the overall differences between the 
arrays. 
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Figure 4.1.4: The heatmap shows a two-dimensional clustering of the top 50 genes. 
Expression intensities are normalised row wise by the Z-score: Row Mean - Value / 
Row-Standard Deviation. Those Z-score values are represented by red and blue, for 
high and low intensities, respectively. White indicates medium intensities. 
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The top 120 differentially expressed genes, ranked by fold change are listed below (with 
transcripts lacking annotation removed for clarity): 
 
 
 
Lfc (negative-down 
regulated, positive-up 
regulated) 
p-value Genes 
1 10598075 -2.22903 0.00083 tRNA-Ala 
2 10598081 -2.12106 0.025774 tRNA-Tyr 
3 10598077 -1.85398 0.031739 tRNA-Asn 
4 10598062 -1.53878 0.003805 tRNA-His 
5 10598064 -1.51768 0.012982 tRNA 
6 10598057 -1.18111 0.022606 tRNA-Arg 
7 10598018 -1.08121 0.027798 tRNA-Phe 
8 10357488 -0.91549 0.019895 Cd55  
9 10536401 0.841199 0.010346 Nxph1 
10 10419559 -0.78621 0.005714 Rnase12  
11 10578413 0.765265 0.018589 Gm5346 
12 10492300 -0.7533 0.042471 Aadac 
13 10386093 -0.75041 0.017522 Snord1c 
14 10382844 -0.74899 0.017813 Snord1c 
15 10344897 -0.7368 0.009932 Sulf1 
16 10385770 -0.73139 0.040264 Olfr1372-ps1 
17 10472235 -0.7077 0.032637 Dapl1  
18 10528207 -0.70188 0.043533 Cd36  
19 10601598 -0.68867 0.048529 3110007F17Rik  
20 10478383 -0.68431 0.018082 R3hdml  
21 10372139 -0.68268 0.036528 Nts 
22 10344981 -0.67303 0.043962 Pi15 
23 10472400 -0.67012 0.010298 Scn2a1 
24 10511631 -0.66949 0.01448 Slc26a7  
25 10371740 -0.64001 0.015135 Ano4 
26 10554547 -0.62115 0.033853 Mir1839  
27 10366640 -0.61023 0.041946 Llph  
28 10389759 -0.59724 0.004574 Ankfn1 
29 10528015 -0.59716 0.038962 Steap1 
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30 10390080 0.596323 0.007788 Tmem92-ps 
31 10601867 0.593682 0.029672 Kir3dl1  
32 10536216 -0.58981 0.036545 Gng11 
33 10351039 -0.5882 0.041848 Gas5 
34 10447885 -0.57518 0.040072 Acat3 
35 10603746 -0.57487 0.014565 Maob 
36 10417408 -0.5672 0.042637 D830030K20Rik 
37 10414545 -0.56683 0.007217 Eddm3b 
38 10536405 0.566299 0.007919 Nxph1 
39 10450363 -0.55038 0.049447 Snord52  
40 10559179 -0.53265 0.024009 E330027M22Rik  
41 10462922 -0.51966 0.039754 Plce1 
42 10522788 -0.51921 0.016472 Stap1 
43 10429128 -0.51376 0.009071 Sla 
44 10547664 0.511662 0.018797 Clec4e  
45 10472531 -0.51108 0.005387 G6pc2 
46 10368970 -0.50362 0.028189 Prdm1 
47 10587988 -0.50303 0.044305 Gk5 
48 10346164 -0.49389 0.034008 Sdpr 
49 10579958 -0.49364 0.044267 Il15  
50 10458122 -0.49156 0.034577 Nme5 
51 10455123 -0.48945 0.038048 Pcdhb19 
52 10494821 -0.48898 0.040524 Tspan2 
53 10368907 0.483124 0.012591 Nr2e1 
54 10478461 0.481125 0.04532 Svs3a 
55 10504664 -0.48021 0.01283 E230008N13Rik 
56 10354563 -0.47177 0.03986 Dnahc7b  
57 10510191 -0.46746 0.040806 Zfp600 
58 10401068 0.465756 0.033258 Spnb1 
59 10514313 0.465296 0.022729 Gm13280 
60 10458725 0.464576 0.035711 Spink11  
61 10462818 -0.46375 0.009839 Hhex 
62 10494281 0.459147 0.038373 Hormad1 
63 10538802 -0.45823 0.039896 A930038C07Rik 
64 10407707 -0.45796 0.031596 Gm10336 
65 10574598 0.457852 0.040883 Ces3a 
66 10493896 0.456502 0.010185 Lce3b  
67 10351873 0.45483 0.016871 Pyhin1 
68 10506213 -0.45475 0.044067 Ube2u  
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69 10572097 -0.45371 0.022646 Sh2d4a  
70 10346321 -0.45346 0.039115 Gm10561 
71 10473557 0.453405 0.008877 Olfr1131 
72 10472366 -0.45205 0.025266 Scn2a1 
73 10466932 -0.45186 0.01664 Insl6  
74 10408629 -0.45106 0.026002 1300014I06Rik  
75 10471912 -0.44212 0.037525 Kynu 
76 10496457 -0.44209 0.041203 Adh6b 
77 10399027 0.440232 0.047945 Adam6a 
78 10434845 -0.43881 0.038171 Il1rap  
79 10530536 -0.43858 0.040619 Tec 
80 10555894 0.436814 0.005808 Dub1  
81 10439651 -0.43644 0.047642 Cd200  
82 10442779 0.435282 0.012199 Prss29 
83 10507152 -0.43451 0.011948 Cyp4a12b  
84 10458875 -0.43399 0.011031 Dtwd2 
85 10427461 -0.43391 0.029826 Ptger4 
86 10347033 -0.43302 0.04243 Crygf  
87 10401968 -0.43197 0.03626 Galc 
88 10352497 -0.4315 0.011979 Snora36b  
89 10554745 0.431012 0.026423 Vmn2r78 
90 10542414 -0.43009 0.020478 Ptpro 
91 10461820 0.429948 0.031995 Olfr1489 
92 10432278 -0.42948 0.007339 Ddn 
93 10493114 -0.42787 0.006861 Nes 
94 10591749 0.427276 0.005877 1810064F22Rik  
95 10536697 -0.42686 0.035286 Asb15 
96 10445909 -0.42603 0.040321 Kat2b 
97 10361265 0.425487 0.001135 Mir205 
98 10400510 -0.4246 0.027049 Clec14a  
99 10371578 0.424148 0.013115 Ascl1 
100 10356457 -0.42269 0.034074 Dnajb3  
101 10491106 -0.4207 0.020578 Pld1 
102 10602896 -0.41864 0.022076 Gpr64 
103 10497197 0.416634 0.01406 5330432E05Rik  
104 10492281 0.416094 0.007682 4930449A18Rik  
105 10489545 0.412805 0.046791 Tnnc2 
106 10431585 -0.41191 0.049342 Chkb 
107 10515828 0.41188 0.039201 Olfr1335 
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The microarray has provided us with an interesting list of novel genes that 
change between mutant and the wild type that are strong candidates that play 
important role in kidney development, in particular in terms of regulating nephron 
endowment that may give clues towards the initiation of the renal stress leading 
to CKD.  When compared, the expression profiles of the mutant and wild type 
sample RNA showed that many genes would have been identified as genes up- 
or downregulated and need to be validated. 626 genes have been found 
upregulated and 511 downregulated. For some an example, genes such as Sulf1 
has been shown previously to be regulated by WT1 (Ratelade et al., 2010). 
Nonetheless, many other genes have yet to be identified for association with WT1 
regulation in renal development. 
 
 
108 10603807 0.410597 0.031278 Mir222 
109 10374777 -0.40916 0.02635 Efemp1 
110 10554778 0.408558 0.028678 Grm5 
111 10427918 -0.40345 0.034643 Fam105a 
112 10420362 -0.40302 0.049286 Gjb2 
113 10396402 -0.402 0.04288 Prkch 
114 10471945 -0.39995 0.027294 Gm13476 
115 10395733 -0.39883 0.00993 Npas3 
116 10523451 -0.3987 0.040458 Anxa3 
117 10407126 -0.39684 0.04899 Plk2 
118 10502042 -0.39427 0.021116 Alpk1 
119 10368918 0.393518 0.000809 Sobp 
120 10574098 0.393368 0.04925 Nlrc5 
1040 10474295 0.339383 0.027389 Wt1 
Table 4.1.1: List of significant differentially expressed genes (p < 0.05) with 
highest fold ratio from microarray analysis of DDS/+ (Wt1tmT396/+) foetal 
kidneys. The negative values in Lfc column are downregulated gene 
expression, the positive values in Lfc column are upregulated genes 
expression.  
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4.2 Reduction in tRNA expression levels, but not ND5, confirmed in independent 
DDS/+ (Wt1tmT396/+) mutant kidney samples. 
 
 
 
 
 
 
Given the striking representation of mitochondrially encoded tRNAs in the 
differentially expressed gene lists, qRT-PCR was employed to verify these findings. 
Of the mitochondrial tRNAs, PCR primers were able to be designed for 4 and the 
specificity of the PCR reactions confirmed by conventional PCR and gel 
electrophoresis. 
 
 
 
Figure 4.2.1: Whisker-Box plot of qRT-PCR analysis of independent samples 
showing mitochondrial tRNA expression levels being reduced in DDS/+ foetal 
kidneys compared with wild type. ND5 is a mitochondrially encoded gene, suggesting 
the downregulation is specific for tRNAs. N=3 wild type vs 3 mutants, with technical 
triplicate each. 
- 99 - 
 
 
  
 
 
Figure 4.2.2: Representative gel electrophoresis of qRT-PCR analysis of each 
primer pairs for mitochondrial genes.  
  
qRT-PCR confirmed down regulation of all 4 mitochondrial tRNA genes (Figure 
4.2.1). 
 
 
 
 
 
 
Table 4.2.3:  Table: Show the non-normalized data obtained from qRT-PCR 
analysis of 5 genes in the mitochondria. ND5 sample group is not different to control 
group. tRNA-arg, tRNA-phe, tRNA-ala and tRNA-his are DOWN-regulated in sample 
group (in comparison to control group).  
 
As there was no significant different between the controls and the samples for the 
gene ND5 (which is a gene that is conserved and almost constant in mitochondria, 
given no mutation in those gene), ND5 may be used as a reference (housekeeping 
gene in the mitochondrial genome). To evaluate indirectly mitochondrial copy number 
(based on ND5 expression) between the two groups, the ND5 was analysed in 
reference to the nuclear housekeeping genes, GAPDH and B-actin. 
Gene P-value Result 
ND5 0.079 No change 
tRNA-arg 0.001 DOWN 
tRNA-phe 0.003 DOWN 
tRNA-ala 0.004 DOWN 
tRNA-his 0.009 DOWN 
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Table 4.2.4: ND5 sample group is not different to control group.  
 
As there are no significant different of expression of ND5 gene seen between the 
two groups, this may reflect that there was no significant change with regard to 
mitochondrial copy number. We then chose to use ND5 can act as the reference for 
the expression of the other mitochondrial genes of interest. 
Given the small, circular nature of the mitochondrial genome and the extremely 
high copy number of the mitochondrial genome compared with the nuclear genome, 
we conducted a further control to ensure that the mitochondrial tRNA signals were 
derived from RNA and not contaminating mitochondrial DNA. As tRNAs have no 
introns, we carried out qRT-PCR on cDNA and compared this with qRT-PCR carried 
out on an equivalent amount of RNA without reverse transcription (cDNA). This 
confirmed that the signals detected by the microarray and our qRT-PCR were 
derived from RNA (Figure 4.2.5). 
 
 
 
 
Gene P-
value 
Result 
GAPDH 
  
B-actin 
  
ND5 0.088 No 
change 
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Figure 4.2.5: Gel electrophoresis of qRT-PCR products from cDNA (lanes 1-4) 
and from equivalent amounts of pure RNA stock, without reverse transcription 
(lanes 5-8). This indicates that the tRNA signals do not arise as a result of 
mitochondrial DNA contamination of the original RNA preparation.  
 
The most statistically significant fold changes are seen in member of the tRNAs 
that are involved in mitochondrial functions. In human, mitochondrial mRNAs are 
translated by the mitochondrial protein synthesis mechanism that utilize the 22 
species of mitochondrial tRNAs (mt tRNAs) encoded by mtDNA (Taanman, 1999). 
The structural features of mt tRNAs is unique in comparison to cytoplasmic tRNAs 
bearing the canonical cloverleaf structure. mt tRNAs genes are prone to point 
mutations and are linked with a wide range of pathologies related to mitochondrial 
disease. Various nuclear factors implicated in the biogenesis and function of mt 
tRNAs have been recognized. These include tRNA-modifying enzymes and 
processing endonucleases indicating the nuclear-mitochondrial interaction and the 
importance of mt tRNAs for mitochondrial activity (Suzuki et al. 2011). Given that mt 
tRNA genes change in the microarrays suggest it is possible that WT1 has some 
regulatory influence on those genes in particular that may play a role during kidney 
development and contribute to the reduced nephron number endowment that 
subsequently predisposes to a higher risk of renal disease. 
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4.3 Nuclear genes with the largest fold-change were also confirmed in 
independent Wt1tmT396/+ mutant kidneys. qRT-PCR for 4 out of the top 5 nuclear 
genes ranked by fold-change are shown below – confirming reduced expression 
of Aadac (red), CD55 (blue) and Rnase12 (white), and increased expression of 
Nxph1 (green). 
 
           It is of interest that amongst the most differentially expressed genes, the four 
nuclear genes that showed significant differences have not previously been linked with 
Wt1 in any way. AADAC gene is arylacetamide deacetylase that goes up against the 
action of cytosolic arylamine N-acetyltransferase, which involve in heterocyclic amine 
carcinogens pathways. It also has been proposed to be involved in triglyceride catabolic 
process and the protein product are localize in various of cells (Nourbakhsh et al. 2013). 
Rnase12 is ribonuclease RNase A family 12. Not much known of its function in mice. In 
human, it is annotated as RNA phosphodiester bond hydrolysis, has endonucleolytic 
endoribonuclease activity, and related to extracellular region nucleic acid binding 
(Carbon et al. 2009). Nxph1 is Neurexophilin 1, is a highly conserved secreted protein 
that forms a very tight complex with alpha neurexins, which may resemble 
neuropeptides signalling molecules (Kinzfogl et al. 2011). 
 
Figure 4.3.1: 
Whisker-Box plot 
of qRT-PCR 
showing nuclear 
genes 
expression level. 
N=3 wild type vs 
3 mutants, with 
technical 
triplicate each. 
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4.4 Selected genes within the top 150 ranked by fold change were verified by qRT-
PCR. 
 
 
 
 
 
 
 
The total number of significant differentially expressed genes with p<0.05 is 1137. 
Although the largest difference was seen in mitochondrial tRNA genes, we tested a 
selection of genes down the list randomly to verify the overall accuracy of the microarray 
analysis. Even the gene ranked #132 has been shown to be changed by qRT-PCR 
analysis of gene expression in independent samples. Thus, the microarray data appears 
robust and appropriate for further, detailed analysis. 
  
 
 
 
 
 
 
 
 
 
 
Gene 
 
P value Result 
HPRT 
   
NES 
 
0.03 DOWN 
GAPDH 
   
EFEMP1 
 
0 DOWN 
ANKFN1 
 
0 DOWN 
SULF1 
 
0 DOWN 
Table 4.4.1: qRT-PCR of selected 
genes in the microarray list for 
verification. Sulf1 – rank #16, 
Ankfn1 – rank #32, Nes – rank 
#113, Efemp1 – rank #132 could 
all be verified. N=3 wild type vs 3 
mutants, with technical triplicate 
each. 
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Figure 4.4.2: A) A selection of reference genes used in qRT-PCR, GAPDH and HPRT 
for nuclear genes and ND1, ND4 and ND5 for mitochondrial reference genes comparing 
between wild type kidney and DDS/+ e17.5 kidneys, show no different of expressions. 
B) ND5 expression level between wild type and DDS/+ e17.5 kidneys. C) ND5 gene 
copy number reading between wild type and DDS/+ e17.5 kidneys. All show no 
significant different, (p>0.05). N=3 wild type vs 3 mutants, with technical triplicate each. 
 
 
Wild type         DDS/+ Wild type         DDS/+ 
 
A) 
B) C) 
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4.5 Ingenuity Pathway Analysis (IPA) 
Given the robust nature of the microarray data, assembly of genes networks and 
Ingenuity pathway analysis (IPA) was conducted on the differentially expressed gene 
list. Their corresponding diagrams of the calculated networks connections are shown in 
Figure 4.5.1. IPA can generate a network of interactors based on the recognized 
relations among target genes. It will not just show discovered pathways, but also give 
ideas towards new experiments through the utilization of the established network.  
Multiple WT1 signalling pathway target genes were suggested in the overlay of 
connectivity networks. There were multiple genes dysregulated in the heterozygous 
(DDS/+) kidneys. Overlaying our WT1 regulated signalling pathways on to the 
connectivity networks of differentially expressed genes demonstrated that directional 
changes in gene expression patterns (up or down) in multiple networks of adjacent gene 
nodes (Figure 4.5.1) could be a result of WT1 signalling. 
To show how WT1 affected the gene network, we over-laid gene expression in 
the IPA network system (Figure 4.5.1). Various shapes of gene nodes are displayed 
representing the class of the gene product. Two main colours are shown in our original 
gene list, green represent down regulation of gene expression and red signifies up 
regulation of gene in which the colour intensity shows their significance in the network. 
The interactions shown in Figure 4.5.1 also consist of other colours that represent 
inconsistency and unpredicted from the IPA knowledgebase. This might give more 
insight towards WT1 up and downstream genes and it proposed potential interactions.  
Utilising the Ingenuity Pathway Analysis software to analyse our gene list, we 
identified multiple molecular networks of genes differentially expressed in relation to our 
microarray of e17.5 kidneys. These inter-connections between genes are developed 
from literature that was assimilated into the system, describing the physical or functional 
interactions of the molecules. The gene networks with the most significant are shown in 
Figure 4.5.1, depending on their cellular functions and imputed interaction of the 
molecules.  
Functional analysis using the Ingenuity Pathway Analysis system were also 
performed together. These data demonstrated functional clustering of differentially 
- 106 - 
 
expressed genes within known canonical pathways, and highlighted tRNA splicing and 
renal related responses as mechanisms for disease (Figures 4, 5).  
 
 
  Figure 4.5.1: Ingenuity Pathway Analysis showing networks of interacting molecules, 
overlapping our array data and IPA databases of genes from publication. The upper 
half of the picture (molecules/genes in shades of green or red) are genes from our 
microarray data, meanwhile the lower half (molecule/genes with white or brown) are 
from IPA databases, and unchanged in our data. 
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The IPA in figure 4.5.2 were the genes from array with p value < 0.05 were put 
into IPA analysis. There are 1137 genes to be included for network generation with log 
fold changes ranging from -2.2 log fold change (lfc) down-regulation to 0.8 lfc up-
regulation. IPA suggested that our gene list is associated with the canonical pathways 
listed in Figure 4.5.2-A. The tox list in Figure 4.5.2-B, is an analysis that convey a 
focused toxicity and safety assessment of targeted compounds uncovering the biological 
mechanisms that are associated to toxicity on particular molecules. Interestingly this 
analysis show mutation in WT1 gene has negative impact of renal glomerulus. When the 
genes with p value < 0.005 that constitute of 51 genes included for network generation 
with log fold changes ranging from -2.2 log fold change (lfc) down-regulation to 0.4 lfc 
up-regulations. Among the top canonical pathways, the most intriguing are genes are 
related to tRNA splicing, in which we seen at the top of our microarray gene list.   
 Figure 4.5.2: Table show IPA analysis of genes list from our microarray with p < 
0.05 values. 
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These results suggest that WT1 may play a noteworthy coordinated regulation in 
the pathways. Further evaluation of these genes is necessary to clarify their role in 
kidney nephron endowment. 
Focussing on differentially expressed genes with a stringent p-value <0.05, IPA 
revealed some significant pathways linked to renal glomerulus panel (Figure 4.5.2). 
Figure 4.5.2-D confirms the previous findings of the microarray analysis (note CD55, 
Aadac and Sulf1 amongst the top downregulated genes) and indicates that the settings 
applied to the IPA suite are appropriate and that the outcomes are likely to be 
biologically relevant.  
 
4.6 Comparative Database Analysis 
As described before, multiple differentially expressed genes and molecular 
pathways were identified that differ between DDS/+ and wild type mice using whole 
kidney microarray expression profiling analysis of e17.5 kidneys. Some have been 
described and associated with IPA, revealing functional clustering of these genes. The 
microarray data was shown to be of high quality and shown to be robust. 
However, despite the identification of known Wt1 target genes, such as Sulf1, and 
IPA clusters consistent with Wt1 mutation and a target of such functions, such as 
hematopoietic stem cell differentiation, the data did not highlight known genes critical to 
normal nephrogenesis. For example, the following genes are not differentially 
expressed: Wnt4, Wnt11, Six2, Cited1, Gdnf, Pax2, Pax8, and c-Ret.  
The array provided a global view of gene expression within a developing kidney. 
This has given me some insights into genes regulated by WT1 in nephron development. 
To get a deeper understanding of these genes listed in the microarray, I have 
compartmentalized the list of genes from the expression microarray. I compared E17.5 
differentially expressed gene list (p<0.05) to few other arrays from isolated glomerulus, 
podocytes and isolated cells from kidneys from public databases. This comparison 
provided me with genes list that suggested being glomerular specific WT1 regulated 
genes (Figure 4.6.1). 
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Figure 4.6.1: A Venn diagram showing overlap of comparison database of 3 microarrays 
(p<0.05). [A] is E17.5 whole kidney microarray, [O] is DDS/+ heterozygous adult isolated 
podocyte glomerulus kidney microarray from Ratelade et al., 2010, and [P] is WT1 
heterozygous mutant adult isolated glomerulus kidney microarray from Schumacher et 
al., 2011, and [B] genes in Brunskill et al., 2011 listing genes involve in patterning and 
development of podocytes to become part of nephron. Adjacent tables showing the 
respective overlap list of differentially expressed genes in mutant mice together with 
regulation status and listed indication for presence of WT1 transcriptional binding. These 
datasets reveal several within my array that suggested specific to glomerulus  
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I then compare the 1136 hits (comparison in Venn diagram differ in number due 
to the redundant names for some genes) from my array to a dataset from Kann et al., 
2015. This dataset was derived from ChIP-seq of WT1 bound genes in podocytes of 
adult kidneys. They validated the WT1 binding domains to two other ChIP-seq of WT1 
targets sequence derived from embryonic kidneys (Hartwig et al., 2010, Motamedi et al., 
2014). Their data show specific role of WT1 in regulating transcriptome through the 
target genes promoter and enhancers region. The domain of WT1 targets were found in 
promoter region of target genes (21%), 5’ UTRs region (7%), genic sites; Intron, Exons, 
3’ UTRs (29%) and mostly in intergenic sites (43%). This highlighted the role of WT1 in 
regulating genes at non-promoter sites.  
There are 216 genes from my array list that contains WT1 binding domain. These 
genes are involved in various parts of the kidney, including apoptosis and mitochondrial 
related genes.   
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The referred dataset was taken from Brunskill et al 2014. They describe 
experiment conducted on precursor cells of nephron (metanephric mesenchyme, and to 
some extend cap mesenchyme) from age e11.5 to e15.5 delineating comparison of 
groups of individual precursor cells that were expressing (induced) genes that known to 
develop more differentiated cells. These include cells that will differentiate into renal 
vesicles, renal epithelial cells, stroma and podocytes. Induced are cells that express 
genes like Six2, Foxd1, or/and Cited1. Uninduced are the cells of similar origin without 
the expression of those genes (Figure 4.6.3).  
216 WT1 Target domain 
828 Not WT1 Target domain 
93 NR (No record) 
Figure 4.6.2: Comparison 
of WT1 ChIPseq datasets 
in embryonic kidneys and 
podocytes (Kann et al., 
2015) to my array list of 
significant genes. A) 
Venn diagrams showing 
overlap of the two 
datasets. Within a single 
diagram, circles are 
drawn disproportionally. B 
and C) the fraction and 
number of genes contain 
WT1 binding domains 
and tables of their 
respective numbers. 
Appendix Table A-4.6.2 
show the list of 216 gene 
having WT1 target 
domain.  
 
[A] 
[B] 
[C] 
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The dataset from Brunskill et al 2014 gave sets of genes list that were differently 
expressed that was hypothesized to be the genes that responsible for the differentiation 
of precursor cells into specific type of cells within the nephron structures, defining the 
changing pattern of gene expression propelling nephrogenesis. As such, we found 
several tissues specific WT1 regulated genes from my array involved in this mechanism 
(Figure 4.6.4) 
Comparing with dataset from Brunskill et al 2014, there are several genes listed 
from my array that involved in the metanephric mesenchyme differentiation into renal 
epithelial cell/ nephron, genes involved in differentiation of cap mesenchyme into renal 
vesicles, genes involve in differentiation into stroma and genes involved in proximal 
tubule formation.  
The list of genes in overlapping area are those of glomerular specific. When 
compared to metanephric mesenchyme induced cells, Pgm2 gene is listed. Sulf1 was 
listed from cap mesenchyme induced cells genes list. Sulf1 contain WT1 target 
sequence is a well-known WT1 target and nephron related genes.  
Given that I am able to compartmentalize some of the differentially expressed 
genes from my array into more specific part of kidneys, and 19% of the listed genes (of p 
< 0.05) in my array have WT1 target sequence, it is undoubtedly containing genes 
responsible to parts of renal development. Isolating the genes involved in nephron 
number endowment would not be easy. It will take time to get more structured 
connection of the genes toward better understanding of nephron number genes.  
- 113 - 
 
 
 
Figure 4.6.3: A model representation of nephrogenic area of developing kidney.  A) to C) 
are diagrammatic representation of cellular development nearby nephron niche. D) 
depicting the cellular components of the tubule and the nephron niche with main gene 
expression that differentiate the cells, Stroma/Interstitium (Foxd1), stem cell progenitor 
(uninduced progenitor cells, expressing both Six2 and Cited1), induced progenitor cells 
(Six2 expressing cells) that will proliferate and differentiates to be a component of 
pretubular aggregates (PTA) later becomes the nephron.  
 
 
A) B) C) 
D) 
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Figure 4.6.4: Comparison database Venn diagrams showing overlap of the two datasets 
of different constituents. [A] Represent overlaps of genes listed E17.5 array (listing gene 
names are redundant for alternative gene names, p<0.05) and [J] Represent overlaps of 
genes listed in Brunskill et al 2014 from differential expression of genes in cap 
mesenchyme (Six2 versus Six2+Cited1 cells, giving the genes involve in CM induction 
to become nephron, p,0.05). Overlapping are listing 14 genes that are identical in both, 
giving a list of genes from E17.5 array that are involve in CM induction and differentially 
expressed in mutant mice (table) with listed indication if those genes contain sequences 
for WT1 transcriptional binding.  
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Figure 4.6.5: A Venn diagram showing overlap of comparison database of 3 microarrays 
(p<0.05). [A] is E17.5 whole kidney microarray, [O] is DDS/+ heterozygous adult isolated 
podocyte glomerulus kidney microarray from Ratelade et al., 2010, and [P] is WT1 
heterozygous mutant adult isolated glomerulus kidney microarray from Schumacher et 
al., 2011, [M] (pink) MitoCarta2.0 that listing genes that directly related to the 
mitochondrial and [J] (light blue) genes listed in Brunskill et al 2014 listing genes involve 
in CM induction to become nephron. Adjacent tables showing the respective overlap list 
of differentially expressed genes in mutant mice together with regulation status and 
listed indication for presence of WT1 transcriptional binding. 
 
- 116 - 
 
 
Figure 4.6.6: (Continuation as not enough space to list all) A Venn diagram showing 
overlap of comparison database of 3 microarrays (p<0.05). [A] is E17.5 whole kidney 
microarray, [O] is DDS/+ heterozygous adult isolated podocyte glomerulus kidney 
microarray from Ratelade et al., 2010, and [P] is WT1 heterozygous mutant adult 
isolated glomerulus kidney microarray from Schumacher et al., 2011, [M] MitoCarta2.0 
that listing genes that directly related to the mitochondrial and [L] genes listed in 
Brunskill et al 2014 listing genes involve in patterning and polarizing renal vesicle 
development to become nephron. Adjacent tables showing the respective overlap list of 
differentially expressed genes in mutant mice together with regulation status and listed 
indication for presence of WT1 transcriptional binding. 
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Figure 4.6.7: (Continuation as not enough space to list all) A Venn diagram showing 
overlap of comparison database of 3 microarrays (p<0.05). [A] is E17.5 whole kidney 
microarray, [O] is DDS/+ heterozygous adult isolated podocyte glomerulus kidney 
microarray from Ratelade et al., 2010, and [P] is WT1 heterozygous mutant adult 
isolated glomerulus kidney microarray from Schumacher et al., 2011, [M] MitoCarta2.0 
that listing genes that directly related to the mitochondrial and [B] genes in Brunskill et 
al., 2011 listing genes involve in patterning and development of podocytes to become 
part of nephron. Adjacent tables showing the respective overlap list of differentially 
expressed genes in mutant mice together with regulation status and listed indication for 
presence of WT1 transcriptional binding. 
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Figure 4.6.8: IPA functional analysis in relation to nephron and glomerular development. 
The array list of p<0.05 were put into IPA system, and selected for renal related 
functional analysis. A) and B) are those involved in mesenchymal cells, C) in 
development of early kidney and D) genes involved in glomerular development. All of 
these genes have sequences in the gene region for WT1 binding while Sp7 and Gdf5 
have the sequence adjacent to their gene sequences.  
 
 
 
 
 
- 119 - 
 
 
F
ig
u
re
 4
.6
.9
: 
A
d
a
p
ta
ti
o
n
 o
f 
K
E
G
G
 p
a
th
w
a
y
 (
c
o
m
b
in
a
ti
o
n
 o
f 
m
u
lt
ip
le
 K
E
G
G
 p
a
th
w
a
y
 i
n
 r
e
la
ti
o
n
 t
o
 
W
T
1
 g
e
n
e
) 
a
n
a
ly
s
is
 r
e
fl
e
c
ti
n
g
 t
h
e
 g
e
n
e
s
 c
h
a
n
g
e
s
 i
n
 E
1
7
.5
 a
rr
a
y
 w
it
h
 t
h
e
 g
e
n
e
s
 i
n
v
o
lv
e
d
 d
o
c
u
m
e
n
te
d
 
to
g
e
th
e
r 
w
it
h
 r
e
s
p
e
c
ti
v
e
 u
p
 o
r 
d
o
w
n
 r
e
g
u
la
ti
o
n
 a
n
d
 w
it
h
 i
n
d
ic
a
ti
o
n
 o
f 
p
re
s
e
n
c
e
 o
r 
a
b
s
e
n
c
e
 o
f 
g
e
n
e
 
s
e
q
u
e
n
c
e
 f
o
r 
W
T
1
 b
in
d
in
g
 (
+
 f
o
r 
p
re
s
e
n
c
e
, 
- 
fo
r 
a
b
s
e
n
c
e
).
 
- 120 - 
 
 
 
Figure 4.6.10: IPA functional analysis for genes associated with post-translational 
modification via tyrosine phosphorylation (of phosphate). This type of post-translational 
modification has been shown previously to be associated with mesenchymal-epithelial 
modification which play an important role in ‘budding’ of nephron progenitors in kidney 
development.  
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Figure 4.6.11: STRING diagram showing olfactory related genes differentially expressed 
in E17.5 kidney array. Reduction of WT1 +KTS isoforms has been link to disruption of 
olfactory products. Gnal (down, ++). This related back to the basic of WT1 mutation in 
DDS/+mice, which resulting in imbalance on +KTS and -KTS isoforms of WT1 protein. 
Disruption in exon 9 region of WT1 contribute to less +KTS isoform with the loss of 
fourth zinc finger region. This is to show that the array gene list does portray the 
outcome of WT1 mutation.  
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4.7: Summary of key findings 
I. Microarray data were analysed and validated. 
II. Gene expression profile of e17.5 DDS/+ kidney and wild type revealed novel 
genes underlying development and biochemical interaction in foetal kidney 
development in relating to WT1 gene. 
III. Changes seen in mitochondrial tRNA and its alteration give clues towards more 
complex interaction between nuclear genes, mitochondria and WT1. 
IV. Comparative databases analysis shows confirmation of some genes that were 
found to be involved in nephron formation.  
V. Ingenuity Pathway Analysis (IPA) showing networks of interacting molecules and 
biological functions related to WT1 
 
4.8: Discussion 
Our hypothesis is that the dominant negative mutation in the Wilms’ tumour 
suppressor 1 regulatory gene carried by DDS/+ mice will alter the expression of 
downstream genes in the developing kidney. As there is no comprehensive list of Wt1 
target genes, we chose to carry out a microarray experiment to identify these genes. In 
order to identify genes involved in the earliest known kidney phenotype (reduced 
nephron number) of the DDS/+ (Wt1tmT396/+) mice, we elected to analyse foetal (e17.5) 
kidneys from 4 DDS/+ mice and 4 wild type controls. At this stage, mutant and wild type 
kidneys are indistinguishable under light microscopy, so we do not assume that any 
gene expression changes will be large, nevertheless any changes between mutants and 
wild types are more likely to be directly causative, as opposed to secondary.  
Prior to our array, both RNA and raw frozen e17.5 kidneys were sent to Source 
Bioscience for RNA extraction. In both cases, RNAs were analysed for RNA integrity 
prior to running through the array, and the best of those were used. In our setting, 
initially cDNA was prepared using Invitrogen RNAse OUT and 1µl of Invitrogen 
Superscript III, but the result seems to be not as consistent when run for qRT-PCR. 
Changing to a complete kit setup improved the result obtained. The complete kit setup 
may influence the quality of cDNA and crucial for getting a confidence result.  
- 123 - 
 
Recent advancements have shown that the mitochondrial system is an important 
cellular component that is essential for maintaining normal health. Additionally, a large 
proportion of mitochondrial disease mutations have been found in mt-tRNAs (Moreno-
Loshuertos et al. 2011). However, the situation is complicated by the fact that even 
similar homoplasmic tRNA mutations cause variable phenotypes and variable 
penetrance, likely through compensatory expression of metabolic pathways or by 
upregulating mitochondrial biogenesis (Fernández-Ayala et al. 2010) or may also 
increase the expression of tRNA-interacting genome loci (Perli et al. 2012). In fact, it has 
been shown previously that expression of nuclear-encoded genes is known to modify 
mitochondria related disease (Francisci et al. 2011). Thus, the combined mitochondrial-
nuclear interaction at tRNAs and their target may have much more pronounced effects 
than previously known.  
Analysis of the microarray data showed that these tRNAs were expressed less in 
the mutant. Validation of these findings was carried out by qRT-PCR for the four tRNAs 
that could be successfully amplified and ND5 as a mitochondrial encoded gene not 
appearing on our differentially expressed lists. ND5 is part of an enzyme complex for 
transducing energy in the respiratory chain in mitochondria. Its function is the transfer of 
electrons and protons from NADH to ubiquinone across the membrane. (Walker, 1992, 
Yagi & Matsuno-Yagi, 2003, Brandt, 2006, Zickermann et al., 2009). In mice, mtDNA 
ND5 is tightly controlled and its regulation can compensate for its needs in harsh 
expression variation NADH dehydrogenase-dependent respiration rate (Bai et. al., 
2000). 
Given the unexpected nature of this result, we sought to interrogate the finding 
thoroughly. Some tRNAs are known to have nuclear analogues, pseudogenes (Mishmar 
et al., 2004). We sought to investigate if the tRNA species identified by the microarray 
and verified by qRT-PCR were nuclear pseudogenes or true mitochondrially encoded 
tRNAs. A series of BLAST searches were conducted spanning the entire tRNA 
sequence covered on the array and by qRT-PCR which revealed that two of the four 
validated tRNAs have no nuclear pseudogene (whereas 2 clearly have nuclear 
pseudogenes with 100% sequence similarity on Chr 1 and Chr 2). See figures 4.8.1 
below. 
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Figure 4.8.1: TBLASTN output from ENSEMBL for (A), tRNA-his Affymetrix probe 
showing 100% identity to chromosome 2, (B) tRNA-phe Affymetrix probes minimal 
nuclear chromosomal identity. 
A - tRNA-his 
B- tRNA-phe
B- tRNA-phe
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There has been little previous research into mitochondria and tRNAs in the 
developing kidney, however, nephrogenesis is likely to be a very high-energy requiring 
process with rapid cell divisions and differentiation. Hence the reduced amount of 
mitochondrial tRNAs may reflect a general reduction in mitochondria or a specific 
reduction in those tRNAs. The expression data suggests that the mitochondrial copy 
number is not reduced based upon ND5 expression data. Further confirmation needed 
to be done.   
In terms of what is known of Wt1 biology, it is plausible that reduced levels and/or 
the presence of the DDS mutation could affect RNA. As we know, Wt1 can interact with 
splicing factors (Davies et al., 2004), can localise within a cell with splicing factors 
(Larsson et al., 1995), and also involved in regulating other alternative splicing such as 
Vegf (Cunningham et al., 2013), though Vegf did not significantly change in the array. In 
addition, it is noteworthy that two independent probe sets for a small nucleolar RNA 
species are differentially expressed (2 probe sets maybe self-validating) along with 
RNase12 and several other RNAs, in which increase our confidence in these data.  
In our gene expression analyses, mitochondrial tRNA genes show significant 
differential expression in foetal kidneys from DDS/+ mice compared with wild type 
littermates. This finding raises the question as to the involvement of these tRNAs in the 
physiopathology of renal disease development, in particular nephron endowment. Our 
data suggest that there might be some interruption of mitochondrial tRNA gene 
expression. A much more in-depth analysis needed to be done to confirm these finding. 
No published data that we know of shows any correlation between WT1 and 
mitochondrial genes. These unexpected findings raise two questions: what is the role of 
mitochondrial tRNA genes in nephrogenesis, and by what mechanism does Wt1 
mutation affect mitochondrial tRNA levels? In terms of a role for tRNAs in 
nephrogenesis, it is intriguing to note that mitochondrial tRNAs do show differential 
spatial levels of expression in different components of the developing kidney (Figure 
4.8.2).  
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Figure 4.8.2: A diagram of expression analysis from GenitoUrinary Development 
Molecular Anatomy Project (GUDMAP) website showing tRNA-tyr expression in 
developing kidney, a representative example of mitochondria tRNA displaying strong 
tissue-type specificity of expression. Red area indicates positively expressed. 
 
It has previously been documented that mitochondrial abnormalities may instigate 
abnormalities in various organs. Mitochondrial respiratory chain deregulation has been 
correlated with chronic kidney disease (CKD) and in those patients going to 
haemodialysis (HD) via analysis of their peripheral blood mononuclear cells (Granata et. 
at., 2009). Although other publications shown various mutations in the mtDNA that 
relates to end-stage renal disease, our microarray of DDS/++ mutant mice imply that 
deregulation in the nuclear genome, in this case the Wilms Tumor 1 gene, may actually 
involve in mtDNA expression in kidney development that may lead to nephron number 
endowments and subsequent higher risk to renal disease.  
Decay-accelerating factor (DAF) also known as CD55 is a Glypiated (GPI)-linked 
membrane complement regulator. It has a protective role to the plasma membrane of 
cell and associated with classical and alternative complement activation pathways and 
also expressed widely in mammals, including the kidney. In adult human, it was found in 
glomeruli and in glomerular visceral epithelial cells (GEC) culture. In adult rats, it was 
exclusively seen on the apical surfaces of GEC via antibody staining (Bao et al., 2002). 
Recent research suggests that CD55 expression has a protective effect on kidney, 
reducing the intensity of insults on the glomerulus (Sogabe et al., 2001, Bao et al., 2009) 
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and show increase survival in transplanted kidney (Brodsky et al., 2009). There is very 
little research so far investigating the role of CD55 in mice embryonic kidney. However, 
there are data of specificity of CD55 when the expression pattern in developing kidney is 
examined (via GUDMAP). It can be seen that high levels of CD55 are found in 
developing podocytes and renal corpuscle (Figure 4.8.3). In our array, CD55 
(downregulated) is at the top of the list of significantly change gene from the nuclear 
genes group.  
 
Figure 4.8.3: A diagram of expression analysis from GenitoUrinary Development 
Molecular Anatomy Project (GUDMAP) website showing CD55 expression in developing 
kidney, a representative example A displaying strong tissue-type specificity of 
expression. Red area indicates positively expressed, notably within the renal corpuscle 
(the condensing nephron mesenchyme, coincident with Wt1). 
 
Two other genes that of particular prospects are FGF9 (upregulated from the 
array) and FGF20 (upregulated) which are profound prosurvival genes, show such 
increases in my array list. These genes are especially important and critical for 
maintaining nephron progenitor survival in transgenic mouse models, and mutation in 
FGF20 is implicated in severe renal dysplasia (Barak et al., 2012). To what extend these 
two genes exerts its function to progenitor nephron survival is yet unknown. 
The pathway analysis such as Database for Annotation, Visualization and 
Integrated Discovery (DAVID), Ingenuity Pathway Analysis (IPA) or KEGG (Kyoto 
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Encyclopaedia of Genes and Genomes) were considered and used because of ease of 
access and robust database, having Causal Network Analysis comprehensively 
identifies upstream molecules that control the expression of the genes helps to build and 
better identify the  pathway. IPA has contributed to the possible interaction on WT1 gene 
and the genes from the array. Even though this array dataset is of kidney origin, it is 
noteworthy (Figure 4.5.2-A) that IPA has highlighted pathways that are consistent with 
known functions of WT1, such as Haematopoiesis from multipotent stem cells (see 
Cunningham et al., 2013). Given the Wt1 expressing cells within e17.5 kidneys are 
differentiating mesenchymal stem cells, the similarities with hematopoietic stem cells 
may reflect similar underlying mechanisms in both sets of differentiating stem cell. Whilst 
the Tox List (Figure 4.5.2-B) is not a direct measurement of biological function, the 
identification of renal, cardiac and hepatic systems can be seen as consistent with the 
known roles of Wt1 in development (Carmona et. al., 2010).  
Given the insight that the main mechanism on nephron formation and 
mesenchymal-epithelial transformation was disrupted, it is of interest to see whether the 
mechanism of controlled cell death during the kidney is disrupted, as this is also a 
possible mechanism in which the early nephron niche was lost during this 
developmental stage which might contributes to the lack of nephron number. Comparing 
known apoptosis related genes to the array list, quite a number of genes were listed and 
can be group in two, apoptotic gene upregulated, anti-apoptotic genes downregulated.  I 
further analysed the overview of apoptosis event in foetal kidneys.  
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CHAPTER 5. APOPTOSIS IN DEVELOPING KIDNEYS OF MURINE DENYS DRASH 
SYNDROME MICE AND DISRUPTION OF MOUSE EMBRYONIC FIBROBLAST 
CELLULAR METABOLISM 
 
Introduction 
The first nephrons are seen at embryonic stage e12.5 in the mouse, then 
branching continues, increasing nephron number until e15.5 where nephrogenesis 
slows almost to a plateau but that later there is a rapid acceleration of nephrogenesis 
between P0 to P4 (after birth) (Short et al. 2013). This emphasizes the rapid two-stage 
nature of nephrogenesis during embryonic stages and then postnatally in mice. The 
mechanism which regulates both of these two rapid phases will determine the final 
nephron number. We know DDS/+ mutants have 20% less nephrons in the adult. If we 
know the number of nephrons at the plateau phase (between the rapid phases), that 
might give us a clue as to which part of prenatal or postnatal development that WT1 is 
significantly involved in nephron number regulation and thus nephron endowment. 
Previously it has been shown that nephron endowment is a potent modulator of the risk 
of developing renal disease (Walker et al. 2012). 
Mutations of p53 and Pax2 in embryos from mouse models shows lower 
expression of these genes in nephron progenitors and an increase in apoptotic activity 
(Saifudeen et al. 2012). In other studies, mutation in genes Bmp2 and Smad4 mice, 
demonstrated reduced mesenchymal proliferation, also in Bmp7 mice demonstrating 
metanephric mesenchyme cell apoptosis (Dudley and Robertson, 1997; Hartwig et al., 
2005). There are other examples of gene mutations associated with apoptosis in 
developing kidneys at various stages of development; these include Wnt9b (Karner et al. 
2011), Mdm2 (Saifudeen et al. 2002) and MMP9 (Arnould et al. 2009). There are also a 
few genes that show no evidence of apoptosis pertaining to nephron development. 
These includes examples like gene mutations in Alk3 (Giovanni et al. 2011), Cv2 (Ikeya 
et al. 2010), and Ptc1 (Cain et al. 2009). Some of these were associated with delayed 
maturation of the nephron (e.g. MMP9). These highlight the possible pathways relating 
to the development of nephrons from nephron progenitors to mature glomerulus.  
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Short et al. 2013 highlight the lack of evidence for cell death within the cap 
mesenchyme in early normal physiological renal development. This suggests that 
apoptosis might not be part of normal renal development and the lack there-off in normal 
nephron growth afterwards. As in our data, few known pro-apoptotic genes were 
upregulated, and anti-apoptotic genes were shown to be both down regulated and 
upregulated. As to question how these are related is not yet known and very interesting 
to be uncovered.   
 
Results  
5.1 Apoptosis gene list 
Of the 1136 genes hit list from the array, there are a number of genes that were 
listed to have roles in apoptosis. Various known potential genes related to apoptosis 
were listed and compared to our array genes list and shortlisted as in table below.  
 
Mechanism in Apoptosis 
System 
Genes 
WT1 
target 
Domain 
Array Log fold change 
Induction of Apoptosis by 
Extracellular Signals 
Adora1 yes up 
0.174696015 
Induction of Apoptosis by 
Extracellular Signals 
Cd5 yes up 
0.26880245 
Induction of Apoptosis by 
DNA Damage 
Trp73 no up 
0.204253675 
Other Genes Involved in 
Induction of Apoptosis 
Map3k10 no up 
0.103516552 
Other Genes Involved in 
Anti-apoptosis 
Map3k10  no down 
-0.491563283 
Other Genes Involved in 
Anti-apoptosis 
Polb no down 
-0.215526653 
Other Genes Involved in 
Anti-apoptosis 
Tgfb1 no down 
-0.158113741 
Other Genes Involved in 
Anti-apoptosis 
Xiap no down 
-0.175726026 
Positive Regulation of Anti-
apoptosis 
Opa1 no down 
-0.155242003 
Caspase Inhibitors Xiap no down -0.175726026 
TRAF Domain Proteins Traf7 no down -0.11277985 
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Inhibitor of apoptosis Sirt1 no down -0.169357687 
Inhibitor of apoptosis 
protein (array) 
Naip2 no down 
-0.33938724 
 
 
 
 
This list indicates that there is a role for apoptosis in the development of nephron. 
It is logical to assume that organ development requires a huge number of cells to divide 
and at some points, some have to be programmed to die. What is most surprising is that 
WT1 has transcriptional target domains on two of the genes. What and how exactly WT1 
regulates the apoptotic mechanism are yet unknown.  
 
5.2 Apoptosis staining 
To further validate the possibility of dysregulation of apoptosis mechanism 
deregulated in these developing kidneys, I performed TUNEL (Terminal 
deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling) apoptosis screening test 
to observe any different between the wild type and DDS/+. 
 
5.2.1 Localizing apoptotic segment of developing nephron of P0 kidney 
On general notes, there were quite a number of fluorescence signal seen within 
sections of both wild types and DDS/+. In most circumstances, these signals were 
seemed to be generalised within the kidneys, mainly the tubular structures. This is 
understandable given the role of the renal tubules’ roles in urine production. Working 
with kidney sections allow one to be able to discern with eyes the structure of nephron 
on kidney sections, especially the identifiable arrangement/appearance of mature 
glomerulus, s-shaped bodies and comma shaped bodies. What I am interested is the 
area where the renal glomerulus develops, the cortex and nephrogenic zone. This area 
shows quite a number of TUNEL signals. On higher magnification, specifically on the 
Table 5.1.1: Listed are the genes related to apoptosis that were 
significantly changed in my array, with respective column indicating the 
presence of direct WT1 binding sites and array changes.  
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developing structures of glomerulus, these TUNEL signals were seen mainly at the 
elongated tail region of the comma-shaped bodies. These were seen in both wild types 
and DDS/+.  
 
 
 
 
 
 
 
 
DAPI 
x20 
TUNEL 
x20 
DAPI + TUNEL 
x20 
Figure 5.2.1: Representative figure wild type kidney showing the 
Immunofluorescence of TUNEL staining (Life Technologies) to detect the presence 
of DNA fragments cause by programmed cell death. The Sections are viewed at 
20x magnification showing a ‘comma shaped’ body of a developing nephron 
indicated by blue arrow. TUNEL signal were seen at the tail of the comma shaped 
body, indicated by yellow arrow. N=3 P0 kidneys of wild type and N=3 of DDS/+ 
were examined.  
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5.2.2 Quantifying the TUNEL signals on cortex region of P0 kidney section 
In general overview of the kidney sections, there were no significant different of 
the placement of the TUNEL signal. I then counted the signal to investigate further if 
there is any increment or decrease of signals seen between wild types and DDS/+.  
Counting was done (by double blinded counting by two persons) in the cortex region 
delineated by the line drawn at 200um from the edge of the kidney section (as this was 
determined by the subjective observation of the developing glomerulus. This will be 
repeated after the exact delineation can be obtained from PNA staining of the same 
stage of kidney development later on). Longitudinal kidney section region can be divided 
into 3 (three) region in general, the cortex which is the outermost region, medulla which 
is the middle region and the renal pelvis which is the urine outflow from the kidney. 
Kidney cortex region is where the nephrogenic zone is located, where nephron is 
developing, is where the interest of this study lies.  
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The counting was done using ImageJ software, and repeated by another person 
by double blinded counting, the two groups of count were assessed for significant 
difference with t-test, and the difference were of no significant (p>0.05) for each section, 
and the average was taken as the final count. As for the counts, they are divided into all 
signals, high intensity signals alone and low intensity signals alone from individual 
perspective. These counting were then calculated for their significance. In all those 
circumstances, there were no significant difference of TUNEL signals (P > 0.05) 
between the wild type and DDS/+ (Figure 5.2.5). Caspase 3 staining on the kidneys 
previously (Wroe 2009) support my finding, which uses the same DDS/+ strain mice at 
similar time frame of development.  
 
Wild type (left) and DDS/+ (right)  
Figure 5.2.4: Representative figures of TUNEL staining of P0 kidneys. All 
TUNEL staining were done with DAPI co-staining (not shown). Images show 
multiple green dots of overall pattern of program cell death in the kidneys. 
(These above images were slightly edited to enhance the colour due to pixel 
lost when resized) 
Cortex 
 
Medulla 
 
Medulla 
 
Cortex 
 
Renal pelvis 
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Figure 5.2.5: Counts (normalized by log10) of TUNEL signals (events) from sections of 
newborn kidney (p0) od wild type mice versus DDS/+ (N=6 wild type vs N=6 mutant 
kidneys). NZ = nephrogenic zone.  
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ANOVA 
 
Sum of 
Squares df 
Mean 
Square F Sig. 
All_Cortex Between 
Groups 
.043 1 .043 .660 .434 
Within Groups .709 11 .064   
Total .752 12    
All_NZ Between 
Groups 
.053 1 .053 .676 .429 
Within Groups .856 11 .078   
Total .909 12    
BE_Cortex Between 
Groups 
.006 1 .006 .051 .825 
Within Groups 1.306 11 .119   
Total 1.312 12    
BE_NZ Between 
Groups 
.006 1 .006 .036 .852 
Within Groups 1.830 11 .166   
Total 1.836 12    
 
Table 5.2: SPSS calculation using one-way ANOVA of the TUNEL signal counts 
normalized to log10. The differences between wild type and DDS/+ is insignificant 
(p>0.05).   
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5.3 Mouse Embryonic Fibroblast impairment of cellular metabolism 
In order to investigate the effect of WT1 mutation on cellular viability, I opted to 
use the Alamar Blue assay. This assay has been shown able to elicit deficit of cell 
viability in mitochondrial related conditions, albeit not specifically (Rampersad 2012). 
The active ingredient of alamarBlue® (resazurin) is a nontoxic, cell permeable 
compound that is blue in colour and virtually nonfluorescent.  Upon entering cells, 
resazurin is reduced to resorufin, which produces very bright red fluorescence. Viable 
cells continuously convert resazurin to resorufin, thereby generating a quantitative 
measure of viability and cytotoxicity over time. In order to see the effect of WT1 mutation 
on live cells, given the fact that the DDS/+ mice are difficult to breed and the introduction 
of  a bias in cell growth due to the inherent mutation, I choose to use mouse embryonic 
fibroblasts (MEF) derived from DDS20 (Chapter 2.1), utilising the cells inducible Cre-
loxP system. The Cre-loxP system is a method to overcome early embryonic lethality in 
mice in conventional knockout systems. Cre is a 38 kDa recombinase protein from 
bacteriophage P1 that mediates site specific recombination between compatible loxP 
sites. In addition, by fusing Cre to a mutated oestrogen receptor ligand-binding domain, 
the Cre recombinase is able to be expressed with exposure to the synthetic oestrogen 
homologue, Tamoxifen (Indra et al., 1999). In order cultivate the cells free of influence of 
mutation, I opted for this DDS20 strain rather than DDS/+ strain mice. This would 
prevent the WT1 mutation influencing the growth of the cells prior to experiment. This 
DDS20 mice was shown to have similar characteristics of DDS/+, in which it causes 
chronic kidney disease (CKD) in mice (Ahzad MSc 2010).  
5.3.1 Tamoxifen-induced MEF versus normal MEF 
MEF were cultured and divided into two, one was given Tamoxifen while the other 
were kept as control. The number of cells were kept at 500000 per well of a 6 well plate. 
6 cell lines were used, 3 for MEF control (MEF (no Tamoxifen)) while other 3 was given 
Tamoxifen (MEF (Tamoxifen)) 48hour prior to experiment and the cells were taken for 
PCR assessment of Cre-loxP recombination event of 100% (all cells were induced for 
loxP exonal deletion). The media were measured for absorbance in triplicate per well of 
cell culture plate after the intended exposure to Alamar Blue containing medium.  
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Figure 5.3.1: Bar chart depicting the absorbance value of Alamar Blue according to time 
of MEF culture after addition of Alamar Blue. Four different medium preparation were 
done. P-value were calculated using T-test, *p-value were >0.05 which is insignificant. 
N=3 MEF (no Tamoxifen) vs N=3 MEF (Tamoxifen).  
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The bar charts (Figure 5.3.1) show the absorbance values changes at different 
time points, immediate (within 15 minutes after introducing media), at 90 minutes and at 
480 minutes in four different medium preparation. The control is the MEF without giving 
any Tamoxifen induction. From the data, there was no significant different seen in 
normal culture condition at 37°C.  
 
5.3.2 Oxygen deprived MEF (Tamoxifen)  
Given there was no significant different seen in normal culture of MEF (no 
Tamoxifen) versus MEF (Tamoxifen), MEF were exposed to oxygen deprivation to 
induce stress conditions. In order to simulate a stressful situation to the cells in which 
oxygen is deprived, subsequent cull culture was overlaid with a superficial layer of 
mineral oil on the surface of the medium after adding Alamar Blue containing medium.  
 
Figure 5.3.2: Box-plot chart depicting the absorbance value of Alamar Blue according to 
time of MEF culture after addition of Alamar Blue. Four different medium preparation 
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were done. P-value were calculated using T-test and MEF with normal media were used 
as referenced, *p-value were >0.05 which is insignificant. **p-value <0.05, which is 
significant. All MEF were given Tamoxifen, N=9 technical replicates times four different 
media. Each well was read with triplicates.  
The box plot chart (Figure 5.3.2) show the absorbance values changes at 
different time points, immediate (within 15 minutes after introducing media), at 90 
minutes and at 480 minutes in four different medium preparation, namely normal media, 
media without substrate (0% media), media with only galactose as substrates, and 
media with galactose and glucose as substrates. All the MEF used were exposed 
Tamoxifen prior experiment and were checked for 100% recombination.  
From the data, there are some significant differences in absorbance at all time 
points. For the immediate time point (0), the different might be attributed to the delay 
due to preparation of culture plates. But the changes seen at 90 minutes and 480 
minutes (8 hours) are significant, as this MEF experiment were repeated 3 times on 3 
different MEF with 9 technical replicates each and seen similar pattern at 90 and 480 
minutes. There was a higher absorbance value seen in galactose plus glucose media 
compared to normal media (contain glucose only), galactose only media and no 
substrate media (0% media) as time went by. This shows when deprived of oxygen, 
there is disruption of cellular physiology of MEF (Tamoxifen) when deprived of certain 
substrate, presumably for energy production.  
 
5.4 Summary of key findings: 
I. There are genes related to apoptosis dysregulated from microarray data.   
II. No different of pattern of apoptosis seen between wild type immature 
nephron and DDS/+ P0 kidney. 
III. No evidence of disruption of apoptosis seen in cortex region of renal 
sections in both wild type and DDS/+ P0 kidneys. 
IV. There is disruption of normal cellular physiology in MEF (Tamoxifen) when 
in an unfavourable environment (different substrates and oxygen 
deprived).   
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5.5 Chapter Discussion 
Given the number of studies showing the role of apoptosis in the kidney 
development, it was hypothesised that the apoptosis might be playing a significant role 
in nephron number endowment. In this case, there were no increase in TUNEL positive 
cells in association with the finding of lower nephron number in DDS/+ kidneys at this 
stage of development. This opens the possibility of another mechanism that determined 
their number, or the possibility that the nephron number that were determined via 
apoptosis, if true, were at a slightly earlier stage of kidney development then what I see 
here, at P0. It is unfortunate that e17 to e18 mice kidneys were not able to be assessed 
for apoptosis as they are too small for successful sectioning. Although the technique of 
counting the TUNEL positive signal is from slide section was performed, I would be more 
convinced if a volumetric assessment could have been done for the kidney. This would 
give a much more comprehensive data for the whole kidney. Hopefully there will be a 
better quantification technique that can be applied for apoptosis detection in the small 
kidneys in the future.  
However, given the list of genes involved in apoptosis mechanism are 
significantly different in the e17.5 kidneys, there might be another possibility. A recent 
study suggested that in some specific conditions, there is the possibility of incomplete 
activation of apoptosis (mitochondrial) pathway, in which the incomplete apoptosis 
activation was shown to be a part of survival mechanism of the cells (Yee et al., 2014). 
They provided some interesting insights into a unique pattern of gene expression 
triggered when there is mitochondrial dysfunction, ultimately providing a protective 
mechanism against stress. The genes from the Table 5.1.1 are possibly involved in this 
postulated mechanism. The pro-apoptotic genes Adora1, Cd5, Trp73 and Map3k10 that 
was all upregulated might be balanced out by the antiapoptotic genes Nme5, Polb, 
Tgfb1, Xiap, Opa1, Xiap, Traf7, Sirt1 and Naip2 as a protective measure. Seeing the list 
of pro-apoptotic generally upregulated and anti-apoptotic generally down regulated, it 
really is plausible that somehow in mutated form of WT1 caused this imbalance, and 
somehow a nephron precursor would die prematurely before it can develop further. 
Hopefully this can be the aim of another experiment in the future. In a normally 
developing kidneys, these two mechanisms are always in balance in order for cells to 
have normal spatial expansion and tissue growth in timely manner. As this array 
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suggested changes to these genes, this really does imply that imbalances occur within 
the system. Although no evidence of apoptosis was seen, the implication of involvement 
of proliferation related factors might be very important in this context of renal 
nephrogenesis. It might be a circumstantial indication of reduce survivality or survival 
factors and the balance between it and apoptosis. In depth experiments are needed to 
further elucidate their involvement in renal nephrogenesis and nephron number. 
This disruption of balance might affect the cellular viability. In order to assess this, 
Alamar Blue assay was used, primarily as it can also give indication of involvement of 
mitochondrial and non-toxic. The resazurin dye in Alamar Blue assay would go to the 
electron transport chain and perform as an intermediate electron acceptor without 
interference of the normal function (Page et la., 1993). There are several reasons why 
multiple substrate options were used. It has been shown that galactose enhances 
mitochondrial metabolism and is a good substrate to use to study mitochondrial 
dysfunction in cultured cells (Aguer et al., 2011). Usually through production of pyruvate 
from glycolytic metabolism, 2 net ATP is yielded. However, if galactose were used, no 
net ATP produced, and thus for cells to get ATPs, the cells would need to rely on 
oxidative phosphorylation (OXPHOS) from mitochondria (Marroquin et al., 2007, 
Bustamante and Pedersen 1977). Thus, for the cells, there would be increase of oxygen 
consumption for increment of aerobic state and would have to rely on the capacity of 
OXPHOS (Rossignol et al., 2004). If the cell mitochondrial do not function normally, it 
would not survive for long in galactose medium (Robinson et al., 1992).  
Fluorometric absorbance value between normal MEF and MEF (Tamoxifen) show 
no significant different in normal culture environment, thus suggesting that in normal 
condition without stress, the cell could function close to normal without obvious 
observable abnormality (Figure 5.3.1). But when stressful situations were introduced, 
these cells would be unable to cope. From result of Figure 5.3.2, normal media, media 
without substrate (0% media), media with only galactose as substrates, and media with 
galactose and glucose were used. The use of galactose was to redirect the reliance of 
cells to OXPHOS within mitochondria. The MEF in galactose and glucose medium 
provide higher absorbance value compared to MEF in normal medium (have glucose 
only) was to be expected, as galactose enhance the process of producing ATP from the 
readily available glucose, thus reflected in the faster increment of absorbance value. 
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Where as in galactose only medium, although the MEF were enhance with presence of 
galactose to produce more ATP, as there was no glucose available, the cellular function 
was reduced, the change of absorbance value is lower, close to the value of MEF 
without any substrate (0% medium) and the process of producing ATP is disrupted. This 
clearly shows that MEF (Tamoxifen) that was induced for WT1 exon 9 deletion would 
decrease the capacity of cell to cope with stress, specifically in this experiment oxygen 
and substrate changes.  
Given this insight that WT1 mutation does affect normal functions in mitochondria, 
to clarify further how WT1 relates to mitochondria and it effect in DDS/+ and DDS20 
MEF, various experiments were done in subsequent chapter.  
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CHAPTER 6. A MITOCHONDRIAL ROLE FOR WT1 
 
Introduction 
In our gene expression analyses, mitochondrial tRNA genes show significant 
differential expression in foetal kidneys from DDS/+ mice compared with wild type 
littermates. This finding raises the question as to the involvement of these tRNAs in the 
physiopathology of renal disease development, in particular nephron endowment. My 
data suggest that there might be some interruption of mitochondrial tRNA gene 
expression. A much more in-depth analysis needed to be done to confirm these finding. 
No available data that I know of shows any direct correlation between WT1 and 
mitochondrial genes.  
In terms of what is known of Wt1 biology, it is plausible that reduced levels and/or 
the presence of the heterozygous WT1 mutation could affect RNA expression. As was 
previously published, Wt1 can interact with splicing factors (Davies et al., 2004), can 
localise within a cell with splicing factors (Larsson et al., 1995), and also involved in 
regulating other alternative splicing such as VEGF (Cunningham et al., 2013).  
There has been very little research into mitochondria roles in the developing 
kidney. However, it is presumed that nephrogenesis is likely to be a very high-energy 
requiring process with rapid cell divisions and differentiation. Hence the reduced amount 
of mitochondrial tRNAs may reflect a general reduction in mitochondria or a specific 
reduction in those tRNAs. Measurement of mitochondrial DNA copy number (qPCR) 
analysis data suggests that the mitochondrial copy number is not reduced based upon 
ND5 DNA measurement. 
These unexpected findings raise two questions: what is the role of mitochondrial 
tRNA genes and other mitochondrial genes in nephrogenesis, and by what mechanism 
does Wt1 and Wt1 mutation affect mitochondrial gene expression levels? In terms of a 
role for tRNAs in nephrogenesis, it is intriguing to note that mitochondrial tRNAs do 
show differential spatial levels of expression in different components of the developing 
kidney (GUDMAP data).  
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It has previously been documented that mitochondrial abnormalities may instigate 
abnormalities in various organs (Stepien et. al., 2017). Mitochondrial respiratory system 
deregulation has been correlated with chronic kidney disease (CKD) and in those 
patients going to haemodialysis (HD) via analysis of their peripheral blood mononuclear 
cells (Granata et. at., 2009). Although other publications shown various mutations in the 
mtDNA that relates to end-stage renal disease, our microarray of DDS/+ mutant mice 
imply that deregulation in the nuclear genome, in this case the Wilms Tumor 1 gene, 
may actually involve in mtDNA expression in kidney development that may lead to 
nephron number endowments and subsequent higher risk to renal disease. 
In cells, 99% of the mitochondrial proteins are imported from cytosol, where they 
are synthesized. The preproteins that were synthesized interact with chaperone and 
carried towards mitochondria, where they interact with various mitochondrial outer 
membrane translocase (Tom) complex, as the main entry gate into mitochondria (Fan et 
al., 2006), then later involve the translocase of the inner membrane (Tim) complex to 
transport preproteins across the inner membrane and mitochondrial intermembrane 
space import and assembly (Mia) complex. Different complexes will direct the 
preproteins to their respective destination and compartment in mitochondria. The 
proteins interplay is crucial to the import machinery of mitochondrial proteins which are 
encoded by nuclear gene. 
Among the differentially expressed genes from my array, some of them are 
among the nuclear genes encoding mitochondrial proteins, and at least five of them 
have the sequence for direct targeting of WT1 genes (Table 6.1.2.1). This further 
strengthens the hypothesis that WT1 may have a more direct function in mitochondria 
system than previously thought.   
 In order to determine the role of WT1 gene in mitochondria system, further 
analysis was performed.  
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6.1 Mitochondrial related functional analysis, Public and Published Cross-
Databases Analysis 
6.1.1 ToppGene® 
Ingenuity Pathway Analysis (IPA) is no doubt among the main choice for 
functional analysis for selections of interest genes, however, to increase confidence in 
the findings of this analysis, the microarray data was further analysed using the 
ToppGene Suite (http://toppgene.cchmc.org). Among the main uses of ToppGene® are 
to list out the functional enrichment for the selected genes, network analysis or 
functional annotation of candidate genes, and novel candidate gene identification for 
related diseases.  The system uses several algorithms to compute any similarity 
between genes, then statistically combining individual scores and random sampling of 
whole genome to give p-values.  
 
 
Figure 6.1.1.1: Cellular component and disease list categories annotated from e17.5 
kidney array list processed through ToppGene website, showing the significant genes 
related to the individual components, listing the p-values, and the genes from input and 
annotated.  
 
The two highest and the only significant (p-value < 0.05 with post hoc Bonferroni 
correction) disease list in this algorithmic analysis is of the mitochondrial disease. 10 out 
of 21 annotated genes accounts for this list, including all tRNAs that changed in the 
array list and complex 1 subunit. This further implicates mitochondrial function as one of 
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the most important mechanisms in the mutant model. The highest listed significant (p-
value < 0.05 with post hoc Bonferroni correction) changes are the component of plasma 
membranes, either integral, intrinsic and the sides. Most of these have to do with 
transportation of molecules between the two sides of membranes. This can be 
considered logical as kidney function is to filter in and out selected molecules, and 
changes of these genes might implicate some abnormality in regard to its ability to 
maintain normal function that might later on predispose to secondary and progressive 
damage by stress throughout life.  
 
6.1.2 MitoCarta 2.0 
To directly assess the potential mitochondrial involvement of differentially 
expressed genes in DDS/+ foetal kidneys, the e17.5 array list (converted to ENSM gene 
ID) was cross-referenced to the MitoCarta 2.0 Mouse gene list that was updated 
recently. The MitoCarta 2.0 database represents a comprehensive, highly curated, 
representation of seven proteomic analyses of mitochondrial sub-compartments.  
Figure 6.1.2.1: Venn diagram of E17.5 array gene list and mitochondria MitoCarta 2.0 
Mouse gene list (latest update and last accessed September 2016).  
The e17.5 array genes total to 1396 when converted from 
Affy_Mogene_1_0_St_V1 gene ID to Ensembl Gene ID (ENSMUST) and MitoCarta 2.0 
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Mouse consist of 1151 genes as September 2016. The common genes of the two 
databases are listed on table below, together with any presence of WT1 bindings 
sequence and the array expressions of each genes, together with the full names.  
E17.5 vs 
MitoCarta2
.0 
WT1 
interacting 
sequence 
(developing 
kidney 
ChIP) 
WT1 
interactin
g 
sequence 
(podocyte 
ChIP) 
Lfc 
Array 
express
ion 
 
LYRM4 yes No -0.1795036 down 
Mus musculus LYR motif 
containing 4 
SLC25A40 yes No -0.3736200 down 
Mus musculus solute carrier 
family 25, member 40 
(Slc25a40), nuclear gene 
encoding mitochondrial protein 
SLC25A14 yes Yes -0.2687070 down 
Mus musculus solute carrier 
family 25 (mitochondrial carrier, 
brain), member 14 (Slc25a14), 
nuclear gene encoding 
mitochondrial protein 
CLPB / 
Rpl31 
yes No -0.3278431 down 
Mus musculus ribosomal protein 
L31, mRNA 
TXNRD2 yes Yes -0.0973281 down 
Mus musculus thioredoxin 
reductase 2 (Txnrd2), nuclear 
gene encoding mitochondrial 
protein 
OXR1 yes No -0.1604140 down 
Mus musculus oxidation 
resistance 1 (Oxr1) 
STOM yes Yes -0.3308239 down Mus musculus stomatin (Stom) 
tRNA-His no No -1.5387803 down 
NC_005089 ::: 
gi|34538597|ref|NC_005089.1|:1
1546-11612 
tRNA-Arg no no -1.1811108 down 
NC_005089 ::: 
gi|34538597|ref|NC_005089.1|:9
808-9875 
MTERF4 / 
Mterfd2 
no No -0.2057496 down 
Mus musculus MTERF domain 
containing 2 (Mterfd2) 
FOXRED1 no No -0.1813044 down 
Mus musculus FAD-dependent 
oxidoreductase domain 
containing 1 (Foxred1) 
RNMTL1 no No -0.1580168 down 
Mus musculus RNA 
methyltransferase like 1 (Rnmtl1) 
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PCK2 no Yes 0.1363217 up 
Mus musculus 
phosphoenolpyruvate 
carboxykinase 2 (mitochondrial) 
(Pck2), nuclear gene encoding 
mitochondrial protein 
COX17 no No -0.3244111 down 
Mus musculus cytochrome c 
oxidase, subunit XVII assembly 
protein homolog (yeast) (Cox17) 
PDHA2 no No 0.1667518 up 
Mus musculus pyruvate 
dehydrogenase E1 alpha 2 
(Pdha2) 
TUFM no No -0.1765575 down 
Mus musculus Tu translation 
elongation factor, mitochondrial 
(Tufm), nuclear gene encoding 
mitochondrial protein 
UQCRC1 no no -0.1394423 down 
Mus musculus ubiquinol-
cytochrome c reductase core 
protein 1 (Uqcrc1) 
LETMD1 no Yes -0.1472563 down 
Mus musculus LETM1 domain 
containing 1 (Letmd1) 
TMEM11 no Yes 0.1277565 up 
Mus musculus transmembrane 
protein 11 (Tmem11) 
SLC25A18 no Yes 0.3162048 up 
Mus musculus solute carrier 
family 25 (mitochondrial carrier), 
member 18 (Slc25a18), nuclear 
gene encoding mitochondrial 
protein 
CPS1 no No 0.0853237 up 
Mus musculus carbamoyl-
phosphate synthetase 1 (Cps1), 
nuclear gene encoding 
mitochondrial protein 
OPA1 Yes* No* -0.1552420 down 
Mus musculus optic atrophy 1 
homolog (human) (Opa1), 
nuclear gene encoding 
mitochondrial protein 
MAOB no No -0.57487 down 
Mus musculus monoamine 
oxidase B (Maob), nuclear gene 
encoding mitochondrial protein 
Table 6.1.2.1: List of genes with description of nuclear gene encoding mitochondrial 
protein, mRNA. Listed also the presence of direct WT1 target sequences and changes 
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of their respective expression in DDS/+ kidneys. Developing kidney Wt1 ChIP 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58179 ), Podocyte Wt1 ChIP 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64063 ). *Note: Opa1 has 3 
Wt1 binding sites in both developing kidneys and podocytes identified by ChIP that are 
between 50-80Kb downstream of the gene.  
 
 
 
Figure 6.1.2.2: ChIP data visualised using UCSC Genome Browser: Downstream 
elements associated with Opa1 are shown, plus the more typical pattern of Wt1 binding 
sites at transcription start site, shown for Slc25A14 (developing kidney upper panel, 
black bar, podocyte lower panel, grey bar). 
 
Thus, several nuclear genes encoding mitochondrial proteins that are potentially 
regulated by Wt1 are differentially expressed in DDS/+ kidneys. However, none of these 
have previously been identified as bona fide Wt1 target genes prior to this, but the 
positive findings from ChIP-seq represents strong evidence (Table 6.1.1.1).  
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6.1.3 STRING database 
Given that none of the identified genes has previously been studied in the context 
of Wt1, further in silico analysis was carried out to further investigate the relationship, if 
any, between these genes using the STRING online website. STRING (Search Tool for 
the Retrieval of Interacting Genes/Proteins) is a web resources for biological database 
used for predicting protein–protein interactions and network interactions (Lehmann et 
al., 2000). The STRING database contain experimental data, computational algorithmic 
prediction and public data collections.  The system also highlights functional 
enrichments of user listed genes and proteins, incorporating other functional 
classification systems including GO, Pfam and KEGG.  
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Figure 6.1.3.1: STRING analysis of mitochondrial related genes. 26 cross-database 
listed genes plus additional system genes (up to 10 interactor gene setting) to fill in the 
gap of network. See appendix for each gene annotated functions. WT1 is highlighted in 
the red box, showing its permutated downstream interactions with mitochondrial genes 
Mitochondrial  
WT1 
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at the bottom right of the figure. The meaning of each coloured connection is in the 
legend at the top of the figure. Please refer to appendix Table A-6.1.3.1 for gene 
annotation for STRING analysis.  
In the figure 6.1.3.1 showing STRING analysis, there are strong nodes of 
interaction featuring Map3k7 and mt-ND3, for example, however, the genes that contain 
Wt1 binding sites within their promoters are randomly distributed across the network, 
either not clustering or in many cases showing no interactions (individual node not 
connected to other node). It should be noted that Wt1 links to the major nodes via 
TGFß1 or a single link between Ciao1 and Nfs1 (both are not significantly changed in 
the array, but both have WT1 binding region from developing kidney ChiP). Association 
analysis like this were hoped give meaning and show specificity, such as those that 
share common function, however those does not necessarily bind close to each other. 
STRING database include a lot of sources, including public text, experimental data, and 
those predicted by computational algorithm. It is a tool and resource for further 
experiment and analysis. 
Whilst this analysis indicates the evidence for Wt1 involvement in known gene 
networks is weak, this most likely reflects the novelty of the findings and, without 
experimental verification, these results must be treated with caution.  
 
6.2 Mitochondrial function: Succinic dehydrogenase (SDH) and Cytochrome 
oxidase (COX) staining 
In order to observe mitochondrial activity within the developing kidney, COX-SDH 
staining was performed on cryostat sections from e18 of DDS/+ and wild type kidneys. 
This staining is done in conjunction with the Mitochondrial Group at Institute of Genetic 
Medicine. This specific staining method of mitochondrial activity has previously been 
optimized for muscle fibres. Complex IV, or cytochrome c oxidase (COX) reflects 
indirectly the mtDNA integrity, as the catalytic subunits of COX are encoded by mtDNA 
and are essential for assembly of the complex. Thus, proper synthesis and function are 
largely based on mtDNA integrity by observing the activity of the respiratory complex. 
Complex II, or succinate dehydrogenase (SDH), is entirely encoded by nuclear DNA. 
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And its activity is usually not associated directly to mtDNA dysfunction, however 
abnormalities in SDH may reflect abnormalities in mitochondria biogenesis (Tanji and 
Bonilla, 2001). 
 
Figure 6.2.1: Representative figures of Succinic dehydrogenase (SDH) and Cytochrome 
oxidase (COX) staining of e18 male mice kidneys of [A] wild type and [B] mutant. COX 
staining will show brown colouration and SDH staining show bluish staining if positive as 
in [C] muscle staining of myopathy. [D] Whole section of wild type, [E] whole section of 
mutant. Note there is no gross difference of the staining between the two glomeruli. 
Thank you to Jensflorian for positive control of Image [C]. N=3 wild types vs N=3 
mutants. 
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Figure 6.2.2: Representative figures of COX-SDH staining of foetal kidney for every 
stage of nephron development from pre-tubular aggregates (PTA), comma shaped 
body, S-shaped body and glomerulus, Wild type [A] to [D], mutants [E] to [H].  [A] and [E] 
Pre-tubular aggregates, [B] and [F] comma-shaped bodies, [C] and [G] S-shaped 
bodies, [D] and [H] mature glomerulus. N=3 wild types vs N=3 mutants.  
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Mutant   and wild type    glomeruli of similar developmental stage (blue arrows) 
show no differences in COX/SDH staining (Figure 6.2.1 and 6.2.2). Examining the 
overall patterns of COX/SDH staining of whole kidney cross sections and specific stages 
of nephron development (Figure 6.2.2), there were no dramatic alterations of those 
enzymatic staining in any kidney compartment comparing mutant to wild type. However, 
there is higher concentration of COX brownish staining, suggesting evidence of high 
mitochondrial activity within the developing nephron (comma- and S- shaped bodies) 
and in condensing mesenchyme at the ureteric bud tips, suggesting these stages of 
nephrogenesis may be sensitive to mitochondrial abnormalities. As for doing it during 
the e18 instead of e17.5, there should not be much of a different in physiology of the 
kidneys as it is still in the fast pace of nephron development, and any changes would be 
obviously reflected in these stages of nephron growth. In overall, there is no difference 
between wild type and mutant kidney, however, as this technique has not previously 
been applied to kidney, alternative analyses may be needed to draw a definite 
conclusion. 
 
 
6.3 ex-vivo system for WT1 
To create an ex-vivo system for WT1 dysfunction in cultured cells, mouse 
embryonic fibroblasts (MEFs) were isolated from homozygous “floxed” Wt1 embryos that 
carried a tamoxifen inducible, constitutively active, Cre recombinase transgene (R26-
Cre-ERT2). Deletion of exon 9 of Wt1 resulting in truncation of zinc finger 3, 
transforming into a null allele in these mice. Whilst this is not the exact situation in 
DDS/+ mice, we reasoned that a complete loss of function may prove informative in 
terms of a potential role for Wt1 in mitochondria. 
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6.3.1: DDS20 is a null allele. 
In order to determine if the DDS20 Wt1 “floxed” mice were comparable with 
DDS/+ mice, homozygous DDS20 containing the inducible Cre-loxP system were bred. 
When the female mouse pregnant at e19, a dose of tamoxifen was given 
subcutaneously to induce deletion of exon 9 in the littermates. Kidneys of littermates 
were taken, genotyped, and qRT-PCR was used to measure expression of several of 
the differentially expressed genes previously identified by microarray analysis of DDS/+ 
kidneys in newborn kidneys of DDS20 mice treated with tamoxifen. The most 
significantly downregulated genes in DDS/+mice were all similarly downregulated in 
newborn DDS20 mice. The comparison is between mice given tamoxifen and mice not 
given tamoxifen.  
 
Figure 6.3.1.1: qRT-PCR of day one newborn mice kidney after injection of 
Tamoxifen at e19 of pregnant mice. Nuclear genes Sulf1, CD55, Nxph1, and 
Rnase12 show significant downregulation with p-value<0.05 (normalised to 
GAPDH, B-actin, HPRT) and mitochondrial genes tRNA-Ala and tRNA-phe show 
upregulation (p<0.05) (normalised to ND5).  
 
Sulf1, CD55, Nxph1, and Rnase12 genes were chosen as target for this qRT-
PCR because Sulf1, CD55 and Rnase12 are at the top of the list in micro array and 
Nxph1 is at the bottom region and gene changes in the array (p>0.05). Sulf1 is a direct 
target of WT1 binding and inhibits signalling by heparin-dependent growth factors, 
diminishes proliferation, and facilitates apoptosis in response to exogenous stimulation. 
CD55 is a WT1 target from developing kidney ChiP dataset and involved in the 
- 160 - 
 
regulation of the complement cascade. Nxph1 is a WT1 target from developing kidney 
ChiP dataset and part of a group of proteins that promote adhesion between dendrites 
and axons. Rnase12 has no known WT1 target site and involve in nucleic acid binding 
and ribonuclease activity. The reason e19 was chosen as a time because by 
experience, injection at earlier time points contribute to early sudden death of pregnant 
mouse and littermates.  
 
6.3.2 DDS20 Mouse Embryonic Fibroblast 
However, analysis of Wt1 conditional-null mouse embryonic fibroblasts isolated 
from DDS20 mice and treated with tamoxifen revealed dramatic differences in the 
response to Wt1 mutation in kidneys compared with MEFs. Most notably, those 
downregulated genes were, in fact, upregulated upon Wt1 inactivation and mitochondrial 
tRNA genes also showed some discrepancies. Although discrepancies were seen, these 
discrepancies still involve the genes that were dysregulated from the array list. MEF was 
chosen because it was intended to be a replacement system to investigate changes 
downstream to WT1 genes, as a result from WT1 mutation. The reason replacement is 
needed because DDS/+ strain mice have a very serious problem of breeding difficulties. 
Although DDS20 strain used for MEF do breed slowly, it is still acceptable in order to be 
used as replacement.  
Figure 6.3.2.1: qRT-PCR of mouse embryonic fibroblast (MEF) after cultured, and 
introduction of Tamoxifen for 48 hours for exonal deletion and confirmed for of 
exon 9 deletion by PCR genotyping. Nuclear genes Sulf1, CD55, Nxph1, and 
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Rnase12 show significant downregulation with p-value<0.05 (normalised to 
GAPDH, B-actin, HPRT), except for ND5 which was unchanged (used for 
normalisation of mitochondrial genes). 
 
The dramatic cell-type specific differences most likely reflect the mode of action of 
Wt1 itself – recently it has been shown that Wt1 protein can occupy the same genomic 
location (bind the same sequence of a specific gene) but contribute to either gene 
activation or repression depending upon cell type.  
Furthermore, examination of gene expression profiles of MEF cells available via 
GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15325) reveals that 
both Sulf1 and CD55 are, in fact, upregulated in Wt1 mutant MEFs, consistent with the 
findings on DDS20 MEFs. 
 
Table 6.3.2.1: Gene expression profiles of Sulf1 and CD55 from MEF cells available via 
GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15325) showing the 
changes of expression in MEF with WT1 mutation.  
 
ID P.Value logFC Gene.symbol Gene.title 
     
1436319_at 1.10E-04 0.5591 Sulf1 sulfatase 1 
     
1418762_at 0.008024 2.529887 Cd55 CD55 molecule, decay 
accelerating factor for 
complement 
1443906_at 0.012715 2.412084 Cd55 CD55 molecule, decay 
accelerating factor for 
complement 
1460242_at 0.009413 2.31916 Cd55 CD55 molecule, decay 
accelerating factor for 
complement 
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Whilst it appears that tRNA-Ala and tRNA-Phe behave in different ways, it should 
be noted that tRNA-Ala P<0.009, whereas tRNA-Phe is far less significant P<0.046. This 
may reflect the fact that tRNA-Ala is encoded by the mitochondrial Light strand, whereas 
tRNA-Phe is encoded by the Heavy strand.  
Despite differences between MEF cells and developing kidney, DDS20 MEFs will 
provide a cell-culture based system with which to investigate the consequences of Wt1 
loss of function on mitochondria using various methods.  
As the MEF cells were different from DDS/+ mutant mouse foetal kidney, we 
analysed the expression pattern of selected genes in MEF and compare it to our e17.5 
foetal kidney. Expression of tRNA-Ala (the gene with the highest fold change in kidneys) 
was reduced in MEFs lacking Wt1. This MEF system was initially intended for us to use 
to represent the finding seen in our e17.5 DDS/+ kidney. Regardless of the dissimilarity 
of in-vivo and in-vitro system, the finding relating to the mitochondrial cannot be 
disregard.  
MEF system in this case was not intended to look upon similarity to the actual 
kidney microarray data, but to look into the feasible separate ex vivo system can show 
changes when WT1 is knock-out. In this case, yes, this MEF system provide another 
tool to investigate the upstream and downstream genes regulation of WT1 gene. We 
have the intention of proceeding with another microarray or gene sequencing specifically 
for MEF in this case to look deeper into WT1 gene regulation, specific to MEF knockout.  
 
6.3.3: MitoTracker® staining  
In order to investigate the role of WT1 in mitochondrial biology in mouse 
embryonic fibroblast (MEF) in more detail, mitochondrial network analysis was 
undertaken using MitoTracker® in order to visualise mitochondrial networks following 
fluorescent staining. This technique is typically used to study monolayer cells growing in 
culture as it involves staining live cells. The mitochondrial probe MitoTracker® does not 
florescent in aqueous solution. Upon uptake and accumulation in the mitochondria, it will 
give a red fluoresce signal, without any effect from mitochondrial membrane potential. 
MitoTracker® allows observation of the mitochondrial morphology in these cells in the 
- 163 - 
 
presence/absence of functional Wt1. Wild type MEF (no Tamoxifen) acted as the 
control, showing normal appearance of MitoTracker® within cells and MEF flox-Cre 
(Tamoxifen), Cre induced floxed exon 9 deletion of WT1 genes would be the subject of 
interest.  
The mitochondrial staining shows clustering and fragmentation of MitoTracker® in 
mutant that differentiates it from the wild type. It is interesting to see that mutation of 
WT1 and disruption of its function leads to aggregation of mitochondria in the MEF. 
MitoTracker® staining of MEF cells with and without Cre activation revealed multiple 
clustering of mitotracker signals seen in the cytoplasm of MEF Flox-Cre, ie, those 
lacking Wt1 (Figure 6.3.3.1).   
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Figure 6.3.3.1: Immunofluorescence of mouse embryonic fibroblasts (MEFs) 
showing mitotracker staining in wild type MEF (no Tamoxifen) and MEFflox-
Cre (Tamoxifen), Cre induced floxed exon 9 of WT1 genes, showing the 
appearance of fragmentation. x20 magnification. N=4 wild type (as control) 
vs N=4 mutant MEF, repeated on 3 different batched of MEFs.  
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Figure 6.3.3.2: Representative figure showing disruption of mitochondrial network / 
Double immunostaining. X63 magnification. N=4 wild type (as control) vs N=4 mutant 
MEF, repeated on 3 different batched of MEFs.   
 
In normal wild type, when stained for mitochondria using MitoTracker®, the 
mitochondrial network would show continuous trail of ‘connecting’ beads, this is what is 
referred to mitochondrial networks. In MEF (Tamoxifen), this network shows 
discontinuity, and seems to cluster in small groups. This is the most likely reason why it 
seems to be fragmented/clustered when seen at lower magnification. These finding 
correlates with the downregulation of Opa1, as mutation in Opa1 has been shown to 
cause fragmentation (Wai et al., 2015).  
MEF flox-Cre 
(Tamoxifen) 
Wild type MEF 
(no Tamoxifen) 
DAPI X63 
WT1(6H-F2) FITC X63 MITOTRACKER X63 
DAPI+MITOTRACKER+WT1(6H-F2) FITC X63 
DAPI X63 
WT1(6H-F2) FITC X63 MITOTRACKER X63 
DAPI+MITOTRACKER+WT1(6H-F2) FITC X63 
Mitochondrial 
network 
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6.3.4: Flow cytometry analysis 
In order to quantify and confirm the aggregation of MitoTracker® signal that was 
evident in under fluorescence microscopy in MEF cultured cells, flow cytometry was 
used. From visual observation of MEFs under the microscope, the mutant MEF 
(Tamoxifen) is easier to recognised and identified as it shows more florescence signal 
compared to wild type MEF (no Tamoxifen) at similar exposure setting. 
Two batches of MEF cells (wild type and “floxed Wt1”) were treated with 
Tamoxifen for 48 hours and then further diluted and passaged until passage five to 
eliminate any residual Tamoxifen. The disruption of Wt1 by Cre-loxP mediated 
recombination was confirmed and the cells were stained with MitoTracker® and then 
analysed.  
Figure 6.11: Figure showing MFI (Mean florescence intensity) of flow cytometry analysis 
of wild type + TAM (dark red) and WT1ex9-/- cre + TAM (blue) MEF cells labelled with 
Mitotracker® Deep Red. Fluorescence intensity is displayed on the x-axis (logarithmic), 
with the number of cells containing that fluorescence level plotted on the y-axis). N=4 
wild type vs N=4 mutant MEF. This experiment was repeated two times with N=7 
different MEF on the second run, with similar finding seen.  
 
- 167 - 
 
From the figure, there is a clear different between the two groups of cells. The 
wild type cells show an average fluorescence intensity of ~800 (red graph), whereas the 
mutant cells show an average fluorescence intensity of ~2500 (blue). The MitoTracker® 
seems to be retained more and aggregate inside the mutant cells, consistent with the 
fluorescence microscopy. Given the mechanism of MitoTracker® which permeates 
through the mitochondrial membrane, to see more signals in the mutant indicates some 
level of abnormal function of the membrane system or changes towards the membrane 
potential or may also indicates increment of mitochondrial mass.   
 
 
6.4 – WT1 localisation within mitochondria 
6.4.1 – WT1 localisation in e17.5 kidney fraction 
Although there is a lack of very strong evidence that Wt1 regulates expression of 
nuclear-encoded mitochondrial proteins, multiple mitochondrial tRNA species were 
within the top differentially expressed genes in DDS/+ kidney when ranked in terms of 
fold-change or p-value. As Wt1 is known to encode a multifunctional protein that has 
been linked to transcription, RNA processing and translation, and has been shown to 
shuttle between nucleus and cytoplasm, it is possible that Wt1 exerts a direct effect on 
tRNA expression within mitochondria. In order to test whether WT1 protein is present 
and, thus has the potential to directly interact with mitochondrial protein inside 
mitochondria, western blotting was carried out on fractionated mouse fetal kidneys. 
Mitochondria were isolated using a commercially available mitochondrial isolation kit 
(Thermo Fisher) to provide isolated mitochondrial, nuclear and cytoplasmic protein 
fraction.  
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Fetal kidney 
mitochondria 
fraction 
50kDa -  WT1 6F-H2 
(49kDa) 
Fetal kidney 
(whole kidney 
protein) 
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Fetal kidney 
mitochondria 
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COX IV 
(15kDa) 
(mitochondrial 
protein) 
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nuclei 
50kDa -  
(B-ii) 
Figure 6.4.1.1: Western blots of wild type e17.5 foetal kidneys, 
isolated foetal kidney nuclei, and isolated mitochondrial. Three 
antibodies were used, A) WT1 6F-H2, B-i) WT1 H290, B-ii) COXIV 
(mitochondrial) antibody were used to confirm the presence of 
mitochondrial protein. Figure A is overexposed.  
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Figure 6.4.1.2: Western blots of wild type e17.5 foetal kidneys, isolated foetal kidney 
cytosolic fraction. Three antibodies were used, WT1 6F-H2, WT1 H290, COXIV 
(mitochondrial) antibody was used to confirm the presence of WT1 protein inside 
mitochondrial fraction. No COXIV band seen in cytosolic fraction. The blot been cut 
separately for ease of staining of primary and secondary antibody.  
 
 
 
Figure 6.4.1.3: Western blots of wild type e17.5 foetal kidneys, isolated foetal 
kidney cytosolic fraction, nuclear fraction and mitochondrial fraction of PCNA antibody, 
intended as control for nuclear fraction.  
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The western blots show two different WT1 antibodies that were used to identify 
WT1 proteins from the mitochondrial isolates. 6F-H2 antibodies bind to N-terminal region 
of protein whereas H290 bind to middle part of WT1 protein. COXIV antibodies were 
used to confirm the presence of mitochondrial proteins. Although Figure 6.4.1.1-A is 
overexposed, it is suggestive of similar weight of protein seen. Figure 6.4.1.2 shows 
similar antibodies in cytosolic fraction and mitochondrial fraction. Only anti-H290 band 
was seen in cytosolic fraction, and this most likely due to its binding in the middle site of 
WT1protein compared to 6F-H2 which bind to N-terminal side, or maybe WT1 protein 
too diluted in cytosol to be detected with 6F-H2 antibody. Figure 6.4.3 show PCNA 
antibody staining, initially intended for nuclear control as it was the only nuclear antibody 
I have at the time of experiment. However, PCNA antibody may stained minimally in 
cytoplasm and in mitochondria (Naryzhny and Lee 2010). Given the option in the future, 
other nuclear antibody can be look into and tested on fractions as not all nuclear specific 
antibodies commercially available stained specifically only to nuclear fraction.  
For these western blots, only wild type mice foetal kidneys were used, due to the 
difficulties in obtaining more DSS/+ mice within the timeframe of the project. This was 
because the DDS/+ strain of mice are very difficult to breed as they have the inherent 
problem of sexual organ development.  When we need e17.5 kidneys, each pregnant 
female mouse must be killed too plus littermate count are usually varied from 1 to 5, 
disregarding the genotype that one-third of the time are wild types. In addition, the size 
of e17.5 kidneys are very small, about 2mm in length, therefore a number of e17.5 
kidneys are required in order to get enough biological samples for a number of different 
experiments.  This is a real challenge, due to the physiological nature of this mice.  Due 
to this inherent difficulty, experiments with e17.5 kidneys are difficult to repeat.   
 The localization of WT1 protein in mitochondria (Figure 6.4.1.1 and 6.4.1.2) 
suggests a direct function for WT1 in mitochondria and interactions with mitochondrial 
proteins and processes, but more evidence is needed to support this hypothesis. In 
doing this western blot, although the centrifugation technique used to separate the 
nuclei, cytoplasm and mitochondrial components is reliable, there is still a possibility of 
minimal contamination of different fraction extracts. With limited number of foetal kidneys 
available due to slow breeding and few adult mice available, extra repeats of the 
experiment were not plausible.  
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6.4.2 – Mouse Embryonic Fibroblast fraction comparison 
Given that western blotting of cytoplasmic, nuclear and mitochondrial extracts 
derived from foetal kidneys had previously suggestive of Wt1 protein to be present within 
mitochondria, MEF cells were similarly fractionated into nucleus, cytoplasm and 
mitochondria. In order to see the differences in protein expression between the mutant 
and wild type condition, Western blot were done on MEF (no Tamoxifen) and MEF 
(Tamoxifen). Loading of protein fraction were calculated based on protein concentration 
measured on Nanodrop protein reader.  
 
Figure 6.4.2.1: Western-blot (with florescence secondary antibody) of MEF (no 
Tamoxifen) and MEF (Tamoxifen) cell isolate of cytosols, nucleus and mitochondria. B-
actin, Gapdh, H290 (WT1), and CoxIV were used. Protein were first quantified via 
nanodrop, and similar concentration were loaded for Western blotting for each fraction. 
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Note: To get an appropriate concentration of mitochondrial proteins for each run, similar 
fractions of each genotype were pooled together and quantified.  
  
When western blotting is done comparing MEF (no Tamoxifen) and MEF 
(Tamoxifen), there are some differences that can be seen. The WT1 protein seems 
smaller in the nucleus as this can be attributed to the truncated mutant proteins with less 
pronounce band of normal WT1 protein allele. In mitochondrial, there seems to be less 
WT1 protein as compared to wild type mitochondrial isolates. COXIV protein expression 
also seems to be less in mutant compared to wild types when compared with ß-actin. To 
get an appropriate concentration of mitochondrial proteins, fractions were pooled of at 
least 8 tubes per run. This exhausted the fresh MEF fraction significantly, and difficult to 
control cross contamination of fraction. To get absolute isolated fraction at higher 
concentration is very difficult, but side-to-side comparison would give a better general 
idea of the differences between control and mutant.    
 It is also reasonable that fractionation procedure may introduced contamination of 
each fraction to one another. This is also an issue to keep in mind. To overcome this, 
the most appropriate way I think plausible is to increase the protein concentration of 
each fraction and introduced fewer primary antibodies. But in my case, it is almost not 
plausible to test this method given the limited amount of protein fractioned per each very 
small kidneys, the breeding difficulty, and also limited number and lifespan of primary 
MEF cultured (to remind, MEF is cultured from body of e14 mice, taken from culling 
pregnant mice, thus downsizing the breeding pool of the mice, not to mention only small 
number of MEF carried heterozygous Cre and loxP sequence).  
 With many of the mitochondrial gene expression to be lowered compared to the 
wild type, it is not surprising to see lowered protein expression in mutant mitochondrial. 
However, to see a lowered content of WT1 might attributes to the normal dysregulated 
of its normal role within mitochondrial system. This might be due to lowered normal WT1 
protein inside mitochondrial, or it can also be attributed to the possibility of malfunction 
mutant protein (dominant negative effect), it is uncertain at this moment. More evidence 
is needed to make a conclusive summary.  
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Given that Wt1 “conditional knockout” MEFs display evidence of mitochondrial 
abnormality, these cells could be subjected to a more rigorous examination of 
mitochondrial function.  
 
6.5 Comprehensive mitochondrial analysis using metabolic profiling 
Previously, in other studies, in order to assess mitochondrial function in cultured 
cells, methods utilising probes to detect oxygen consumption were carried out on intact 
mitochondrial organelles and enzyme activities were measured in lysates. However, 
those methods required extensive manipulations such as cell lysis that risk disturbing 
the biological function that one intends to measure. The ability to measure actual live 
intact cells provides insight into the actual physiological function of the mitochondria (Will 
et al., 2006, Brand et al., 2011). Currently the standard protocol to measure changes of 
oxygen consumption of cultured cells use an electrode called Clark electrodes (Clark et 
al.,1953). Recent advancement has miniaturised and adapted oxygen consumption 
probes into improved fluorimetric systems for adherent cells in culture (Wu et al., 2007, 
Ferrick et al., 2008, Gerencser et al., 2009). 
The Seahorse XFe96 Analyzer from Seahorse Bioscience Agilent Technologies 
allows for measurement of Oxygen Consumption Rate (OCR) which reflects oxidative 
phosphorylation and Extracellular Acidification Rate (ECAR) which reflects glycolysis 
with measurement of O2 and protons (pH) in cell culture of live intact cells in a 96-well 
plate and accurately quantify mitochondrial function in intact cells (Dranka et al., 2010, 
Hill et al., 2009, Hill et al., 2010, Perez et al., 2010). These indicators are the main 
indicators of mitochondrial respiration and glycolysis, and comparable to data acquired 
using the Clark-type electrode. These readings will supply a systems-level view of 
cellular metabolic function of ex vivo live cells mitochondrial physiological functions.  
The system provides invaluable data on normal physiological and pathological of 
mitochondrial function in cellular setting toward various stressors, including changes of 
cellular bioenergetics by various oxidative stress (Ferrick et al., 2008, Wu et al., 2007). 
The Seahorse XFe96 Analyzer capable of measuring 96 wells total (92 samples 
and 4 blank controls) at one time with four injection ports per well probe. These four 
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ports allow for sequential injections of selected inhibitor or compound of interest in order 
to elucidate the defect and differences between cells of interest.  
In order to elucidate physiological mitochondrial changes in WT1 mutant MEF as 
compared to wild type, cells were incubated in non-buffered Seahorse media with 
glucose and pyruvate substrates, and four inhibitors were introduced sequentially into 
the wells, allowing the Seahorse XFe96 Analyzer to measure 1) basal OCR, 2) ATP-
linked OCR, 3) proton leak OCR, 4) maximal OCR, 5) reserve capacity OCR, and 6) 
non-mitochondrial OCR. These parameters are shown below.  
 
Figure 6.5.1: XF Cell Mito Stress Test time points and compartments for 
experimental representation (figure from Seahorse Bioscience website). This 
figure will be a reference in order to understand the meaningful data from Figure 
6.5.2. 
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The inhibitors that were used are oligomycin (ATP synthase inhibitor), carbonyl 
cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) (uncoupling of mitochondrial 
inner membrane allowing for maximum electron flux through the electron transport chain 
(ETC) / protonophoric uncoupler), rotenone (complex I inhibitor) and antimycin A 
(complex III inhibitor) (Seahorse Bioscience website).  
Three groups of MEFs were analysed to provide adequate controls: 
1. Wt1loxP/loxP (FF no TAM) – wild type for WT1, no tamoxifen. 
• This is wild type MEF control 
• Coloured purple in the XF Cell Mito Stress Test graph in Figure 6.5.2 
2. Wt1loxP/loxP +Tamoxifen (FF plus TAM)  
• this is wild type control for WT1, with addition of tamoxifen control as 
control measures to make sure tamoxifen does not affect normal cell 
physiology. 
• Coloured green in the XF Cell Mito Stress Test graph in Figure 6.5.2 
 
3. Wt1loxP/loxP: RosaCreERT2 +TAMOXIFEN (FFC plus TAM)  
• MEF of interest with deletion of exon 9 of WT1 gene.  
• Coloured blue in the XF Cell Mito Stress Test graph in Figure 6.5.2 
 
Total sample well N=92 for wild type MEF (FF noTAM) – coloured purple, wild 
type MEF plus Tamoxifen (FF – (no Cre) plus Tam) – coloured green, and mutant MEF 
(FFC plus TAM, deleted exon 9) – coloured blue, and 4 wells as blank control as 
standard procedure. Biological MEF replicates: wild type MEFs (no Tamoxifen) control 
N=3, wild type MEFs (with Tamoxifen) control N=2, Mutant MEF N= 3. They are divided 
in multiple technical replicates (at least 10 wells each) per run. Experiment was repeated 
3 times with different biological MEF cultures. 
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Figure 6.5.2: Figures of XF Cell Mito Stress Test. Multiple time points readings of A) 
Oxygen Consumption Rate (OCR), B) Oxygen Consumption Level (Measured) and C) 
Extracellular Acidification Rate (ECAR) for mouse embryonic fibroblast (MEF) at 
passage six post Tamoxifen at passage one. Total sample well N=92 for wild type MEF 
(FF noTAM) – coloured purple, wild type MEF plus Tamoxifen (FF – (no Cre) plus Tam) 
– coloured green, and mutant MEF (FFC plus TAM, deleted exon 9) – coloured blue, 
and 4 wells as blank control as standard procedure. Biological MEFs variation: wild type 
MEFs (no Tamoxifen) control N=3, wild type MEFs (with Tamoxifen) control N=2, Mutant 
MEF N= 3. They are divided in multiple technical replicates (at least 10 wells each). 
Experiment was repeated 3 times with different biological MEFs cultures. 
 
Using the Seahorse data, it is possible to calculate the difference of oligomycin-
insensitive OCR and basal OCR is equivalent to ATP-linked OCR at resting (Jekabsons 
and Nicholls, 2004) and the balance OCR is the proton leak and non-mitochondrial 
OCR. Both of these are unchanged (p >0.05) in MEF.  
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Figure 6.5.3: Box-Plot charts showing the important time points/sections of XF Cell Mito 
Stress Test. This is the calculation for significance of Figure 6.5.2-[A], in reference to 
Figure 6.5.1 as which part of the graph is called. A) Basal respiration, no different 
between groups (p > 0.05), B) Relative basal ATP content between groups (p > 0.05), 
C) Maximal respiration showing significant different between MEFs Cre-Floxed WT1 and 
controls (p < 0.05), D) Spare respiratory capacity showing significant different between 
MEFs Cre-Floxed WT1 and controls (p < 0.05), E) Proton leak / Electron transport chain, 
no different between groups (p > 0.05), and F) Non-mitochondrial respiration / cytosolic, 
no different between groups (p > 0.05).   
A) B) 
C) D) 
E) F) 
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 Subsequently, FCCP were injected, depleting the mitochondrial membrane 
potential by inhibited the proton movement across the inner membrane. The first was 
0.5uM showing no difference, followed by 1uM FCCP to completely uncouples the 
protons. This uncoupling resulted in electron to flow uninhibited through the 
mitochondrial respiratory chain. This will cause increment of oxygen consumption and its 
maximum limit by complex IV (cytochrome c oxidase). This process measures the OCR 
that which is not ATP/ADP transport dependant (Jekabsons and Nicholls, 2004). The 
maximal OCR was seen to be significantly higher compared to MEF wild type (p <0.05).  
 The difference of the basal OCR and maximal OCR (FCCP OCR) will compute for 
the mitochondrial spare respiratory capacity (reserve capacity), which is significantly 
high in mutant MEF (p < 0.05). This spare respiratory capacity is the available amount of 
oxygen consumption capacity when cells is in dire need of ATP increment or demand 
during cellular stress (Dranka et al., 2010). 
 The fourth and last sequence is the injection of both rotenone (complex I inhibitor) 
and antimycin A (complex III inhibitor), both are electron transport inhibitor, inhibiting 
electron from going through respective complex. This resulted in complete blocked of 
mitochondrial system preventing oxygen from being consumed at complex IV and the 
OCR reading is the result of non-mitochondrial OCR (cytosolic) (Jekabsons and 
Nicholls, 2004). 
 Equally important readings are the Extracellular acidification rate (ECAR) which 
can have the same rate and pattern as proton production rate (PPR) which was 
measured the exact time as respective OCR under the same time and condition. ECAR 
is an indirect indicator of glycolytic flux. In this experiment, at all-time points, ECAR does 
not show any significant changes. Even though not changed significantly, at point at 
which second FCCP (1uM) was introduced, there was no difference (p = 0.4).  
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6.6. Conditionally immortalised human podocyte cells 
In order to extend the findings of Wt1 mutation causing mitochondrial 
abnormalities in mouse kidneys and primary MEF cells, human podocyte cells were 
obtained. These human podocyte cells were derived by Saleem et al., 2002 from 
nephrectomy specimens from DDS patients, transfected with a temperature-sensitive 
SV-40 large T-antigen. At 33°C, podocytes are dedifferentiated, proliferate, and do not 
express podocyte-specific markers such as synaptopodin. Following 1 to 2 weeks of in 
vitro differentiation at 37°C, the immature podocytes acquire an arborized morphology 
and express synaptopodin, such of those found in mature podocyte in adults. 
Unfortunately, these cells quickly became infected and only a single experiment was 
possible. We are not sure of what infected these cells, or if it has been originally infected 
prior to arrival in our laboratory. However, initial culture showed no abnormal artifacts 
when viewed under microscope.   
In order to determine if these cells also have changes in the mitochondrial 
membranes, MitoTracker® staining was done. The MitoTracker® staining on those 
immature podocytes reveals multiple clustered signals, predominantly seen in the DDS 
patient cells. This further confirms what I previously saw in Cre-MEF cells.  
Previously double immunofluorescence of WT1 antibodies with COXIV show 
overlap signals that suggested direct interaction between the two proteins. This lead to 
the hypothesis that WT1 may actually directly involved in the mitochondrial system and 
processes. To further prove this, the MitoTracker® was double stained with WT1 
antibodies.  
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The double immunofluorescence shows overlap signals of MitoTracker® and WT1 
antibodies. This further strengthens my hypothesis of the localization of the WT1 and co-
localization with mitochondrial proteins. Aside from immunostaining, other experiment 
cannot be explored as all the cells were infected unfortunately. I do very much like to do 
Western blot, flowcytometry analysis, XF Cell Mito Stress Test and various expression 
analysis on these cell lines.  
  
 
 
DAPI X63 
WT1(6H-F2) FITC X63 MITOTRACKER X63 
DAPI+MITOTRACKER+WT1(6H-F2) FITC X63 
WILD TYPE CELLS DAPI X63 
WT1(6H-F2) FITC X63 MITOTRACKER X63 
DAPI+MITOTRACKER+WT1(6H-F2) FITC X63 
DDS CELLS 
Figure 6.6.1: Double immunofluorescence staining of MitoTracker® and WT1 antibody 
(6F-H2) of human podocyte cells from Saleem et al., 2002 from nephrectomy 
specimens from DDS patients. 6F-H2 shows overlapping signals with MitoTracker® 
and DDS cells show more clustering/fragmentation compared to wild type human cells.  
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6.7. Summary of key findings 
I. In silico, meta-analyses of provide evidence for the involvement of Wt1-regulated, 
nuclear-encoded mitochondrial genes in “mitochondrial” and “membrane” 
processes. 
II. Wt1 protein is found in mitochondria in developing kidney, primary mouse 
embryonic fibroblasts (MEF), and human podocyte cells. 
III. Wt1 mutation causes mitochondrial network abnormalities (Mitotracker)  
IV. Wt1 mutation causes elevated maximal oxygen consumption rate (OCR, 
Seahorse) in MEF.  
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6.8. Chapter discussions 
 In these experiments, MEF were introduced in with the intention of replacing 
kidneys as the source of tissues to investigate the effect of Wt1 mutation on cellular 
biology. In an optimised world, we do want to use kidneys as they would provide the 
direct effect seen without making any conjectures and the need to re-do experiment 
done on MEF. However, unfortunately the feasibility of getting pre-parturition kidneys will 
take a considerable time and lives of the mice, as for each time kidneys were needed, 
the pregnant mouse has to be killed. Usually these DDS/+ do not have more than 5 
littermates, with the most common are within the range of 1 to 3 and it is hard to get 
DDS/+ genotype as most of the time show wild type genotype. The advantages of MEFs 
are obvious. They are easy to culture and are physiological relevant to represent the 
changes that occur as the result of mutation. Although these MEFs were from different 
strain (DDS20), it is still physiologically relevant as the genes from the array were shown 
to be changes as the result of Wt1 mutation. To culture DDS/+ MEF, the mutation is 
already in place, not inducible as in DDS20 MEF. The initial mutation will cause 
unneeded secondary changes as MEF were prepared and cultured. Investigation of 
these cells might not be an indication of the actual causative effect of WT1 mutation, 
rather it will be the secondary effect of the initial change.  
Mutant and wild type SDH/COX staining uses slightly different age kidney. 
Instead of e17.5, there should not be much of a different in physiology of the kidneys at 
e18 (different of less than a day) as it is still in the fast pace of nephron development, 
and any changes in nephron will still be reflected and obviously seen in these stages of 
nephron growth. In overall, there should be not much of a different as we are focusing 
on the individual developing nephron itself, though preferable we like to do at e17.5 but 
limited to the timing and availability of kidney sections at the time frame. It was not our 
first choice to use kidneys at e18, but we were limited by the availability of the kidney at 
the time of the time of experiment as the mice have innate difficulty of breeding. 
Physiologically from sectioned and nephron developmental stages, there would not be 
much different between e17 and e18 kidneys.  
 The fractionation process to get each cellular fraction, the nuclear, cytoplasmic 
and mitochondrial fraction uses chemical and centrifugation methods. Whilst it is 
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effective, it also has some concerns that needed to be addressed. It is understandable 
that when fractionation is performed, there might be some parts of each fraction which 
contaminate one another. What we can do to minimise the effect is to strictly follow the 
protocol and use of appropriate amount of tissues or cells. Another way is by doing a 
comparison between wild type and mutant, while loading the similar amount of protein 
concentration. This would just be an indicator towards the change of protein expression. 
To get absolute amount, more rigorous technique such as protein mass spectrometry is 
needed to be done.   
Among the most significant changes in the array are of the mitochondrial related 
genes. Listed out when compared to MitoCarta 2.0 Mouse list are various mitochondrial 
genes, some of which reside in the mitochondria such as the tRNAs, and others are 
nuclear encoded protein coding mitochondrial genes (Figure 6.1.2.1). Some of these 
even have probable binding sequences for WT1 to regulate gene expression directly. 
Given the wide array of WT1 functions, this gene has been implicated to be among the 
most important in kidney development.  
 WT1 was seen to be co-localised with at least two mitochondrial markers, COXIV 
and MitoTracker® Red and Deep Red, in human cells and mouse. It was surprising to 
see as no studies to-date has shown this. Western blotting of isolated mitochondria both 
from developing kidneys and MEF have been shown to contain WT1 protein and 
differences in the bands are seen in MEF mutant. Although it is not confirmed if this 
mutant WT1 protein is functional or not, the changes of WT1 was seen to contribute 
significantly to the mitochondrial function as observed in the XF Cell Mito Stress Test, 
which reflects the actual live physiological conditions of cellular metabolic functions and 
mitochondrial metabolism.  
Mitochondrial metabolism is becoming an important topic in developmental 
biology and cancer metabolism. One particular is the intermediary macromolecules in 
tricarboxylic acid (TCA) cycle activity that are important for cellular macromolecules 
biosynthesis. There are increasing evidence that this synthesis requires energy from 
mitochondria to metabolize particular substrates (such as pyruvate and glutamine) in 
rapidly dividing cells (Halestrap and Price, 1999). The functional association of cellular 
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proliferative capacity and mitochondrial respiration has been ascertained (Dranka et al., 
2010). 
 In glycolytic metabolism, 2 ATP molecules are produced per glucose molecules 
where as in mitochondrial OXPHOS produced 38 ATP molecules, though the prior 
provides better advantage for growth (reviewed in Weinberg et al., 2010). Among the 
most significant is the rate of ATP production which is faster compared to OXPHOS, 
providing advantage for rapid energy requirement and rapid substrate biosynthesis 
during rapid proliferation (Spitz et al., 1990, Kim and Lemasters, 2011), plus advantage 
for cells when under low oxygen tension and hypoxic environment (Newsholme et al., 
1985).  
 This concept of different substrate for energy supplementation for rapidly dividing 
cells is supported by various reports. When compared to glucose, different substrates 
such as pyruvate and glutamine, supplemented through mitochondrial OXPHOS and 
TCA system shown to support cells growth with rapid proliferation such as cancer cells 
(Perez et al., 2010, Halestrap and Denton, 1975) though lactate alone as a substrate is 
not supportive of cell growth (Diers et al., 2012). The different substrate is even more 
important given the pathways provides substrates for various biosynthesis of nucleic 
acids, protein and lipids in rapidly dividing cells (Kim and Lemasters, 2011).  
 One of the ways to see how much different substrate influence the mitochondrial 
OXPHOS and TCA cycle is by analysing the extracellular acidification rate (ECAR). It is 
an indicator of glycolytic flux. It has been shown that rapidly dividing cells such as 
cancer cells, cells with complete media with glucose and pyruvate shown to have 
biggest reserve capacity (OCR), cells with pyruvate only media show small reserve 
capacity, whereas cells with glucose only media show no reserve capacity and lactose 
does not support any reserve capacity, whereas for ECAR, it was shown to increase in 
glucose containing medium and decrease with pyruvate media (Diers et al., 2012). In my 
XF Cell Mito stress test readings, even though there is a significant increase in 
maximum and reserve capacity, there are no significant difference in the ECAR reading 
at same time point. This may be due to the media containing both glucose and pyruvate. 
Even if the substrate changed, and there are changes in mitochondrial function, it is not 
equated to ATP and ADP levels (Diers et al., 2012). As mentioned before, alteration of 
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mitochondrial function correlates with proliferative potential, even more so, pyruvate is 
the preferred fuel to drive mitochondrial into overdrive for highly proliferative cells, had 
little effect on basal OCR, ATP linked OCR, ETC, non-mitochondrial OCR, no effect on 
cell viability, and not contribute to overt cell death (Diers et al., 2012). 
 The importance with regard to the ability of mitochondria to have the ability and 
have the extra reserve capacity will give the extra flexibility needed in those cells to 
response to multiple cellular stress (Sonveaux et al., 2008). It has been shown that 
losing the reserve capacity in cancer is associated with initiation of cells into 
mitochondrial activated apoptosis mechanism (Pinheiro et al., 2010) and cancer cell that 
gain the ability to increase its reserve capacity is less responsive to anticancer agents 
(Gerencser et al., 2009). In a condition where there is oxygen stress, this hypoxic cell 
rely more on glucose as fuel for oxidative metabolism, and shown to decrease cancer 
size (Diers et al., 2012). The combination of inadequacy of certain substrate plus 
hypoxia may drive cells into apoptosis, rather than proliferation. This thin balance just 
makes a difference between having one more cell or no cell at all (cell death). In MEF 
with Wt1 mutation in this study, the mutation most likely causes similar situation to 
occur, where in non-stressful condition, the cellular machinery already runs at a fast and 
demanding level. When stress is induced (e.g. increase in oxygen demand), the 
processes were pushed to ‘break-neck’ level and showed as higher rate of oxygen 
consumption (Figure 6.5.2-A). This kind of ‘break-neck’ performance of cellular 
machinery will most likely cause cells to die if demand is not met, or in the long run 
causes exhaustion of cellular processes, damaging the cells and tissues.  
From this study, it seems that the cells that are required for rapid proliferation, 
such as developmental cells and cancerous cells have this characteristic. This facilitates 
the energy and substrates requirement to grow and proliferate, but also at the same time 
they are predisposed to exaggerated response when stressed and go into death mode. 
Two important genes for pyruvate metabolism are changed in the array list. Those are 
Pck2 and Pdha2, which were upregulated. It is not surprising to see these genes 
changes if this mechanism does contribute to the inadequacy of nephron endowment. 
To explore this further, other specific experiments may possibly be done by introducing 
drugs that can block Pck2 and Pdha2 in the XF Cell Mito Stress Test. Other way is to 
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introduce RNAi or Crisper Cas9 to inhibit the function of these genes in vivo during 
nephrogenesis process and repeat the nephron counting to confirm the hypothesis.  
 
6.9. Conclusion  
Wt1 plays a role in mitochondrial function. However, it remains unclear if this is 
due to the regulation of nuclear-encoded mitochondrial genes or to a function of Wt1 
within the mitochondria, or a combination of both. 
Consideration of the Mitotracker and Seahorse data leads to a feasible 
explanation for the results observed. The elevated OCR corresponds to an increase in 
“reserve capacity” within mitochondria and this is consistent with stronger Mitotracker 
staining. Aggregation of the mitochondrial network can be caused by reduced 
membrane potential (and an increase in “reserve capacity”). Whilst these cells are not 
compromised, the reduced membrane potential results in increased Mitotracker staining. 
It is tempting to speculate that the decrease in tRNA levels reflect a 
compensatory mechanism to prevent overactivity/overproduction in the presence of a 
decreased membrane potential. 
It is noteworthy that Pck2 is elevated in the DDS/+ microarray, as Pck2 is a rate-
limiting factor in the production of glucose, such that an increased “reserve capacity” 
would require higher glucose, hence increased Pck2. 
The developing kidney can be considered to be under stress, potentially leading 
to amino acid limitation and thus increased Pck2. Increased glucose can lead to 
decreased membrane potential that results in reducing amino acid transport by 
decreasing levels of tRNAs. It is intriguing to note many members of the Slc25 family of 
solute carriers are down-regulated in DDS/+ kidneys. Some studies seem to clearly 
show that a decrease in membrane potential causes a rise in Pck2 expression and 
subsequent elevation of glucose levels. 
Thus, the most likely scenario is that Wt1 mutation affects mitochondria leading to 
a decrease in membrane potential triggering the effects seen in Wt1 mutant kidneys and 
cells. 
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CHAPTER 7. GENERAL DISCUSSION 
 
7.1 General discussion 
I have analysed and validated a microarray profile of e17.5 DDS/+ kidney and 
wild type and investigated the expression changes. The analysis revealed novel genes 
underlying development and relating to the role of the Wt1 gene during renal 
development. Changes seen in mitochondrial tRNA genes were surprising and those 
alterations gives clues towards more a complex interaction between nuclear genes and 
mitochondria and nephrogenesis. This analysis nevertheless confirmed some genes that 
have previously been found that are involved in nephron formation. More importantly, 
more new candidate genes suggest more complex molecular interactions than 
previously thought are involved. More investigation will help further in uncovering the 
various pathways involved in final nephron endowment, and potential candidates in 
management and early identification of risk factors for CKD.  
The role of multiple systemic disease processes in the pathogenesis of chronic 
kidney disease (CKD) has been recognised, for example in ageing DDS/+ mice (Patek 
et al., 2008), and the concept of a ‘first hit’ in renal disease is becoming widely accepted 
(Hershkovitz et. al., 2007). This concept has developed such that kidney diseases are 
now thought to often be associated with low nephron number (LNN), in particular as a 
mechanism involved in CKD development and progression. Multiple observations on 
intrauterine growth restricted (IUGR) babies initially led to this conceptual formulation 
(Hershkovitz et. al., 2007). Consistent with these observations, many studies in rats 
induced to have LNN by protein restriction diet resulted in animals with impaired renal 
function (Woods et. al., 2004, Bauer et. al., 2002). This positive correlation also has 
been documented from studies involving mortality of stillborn and infants within the first 
year of life (Manalich et. al., 2000). Thus, an individual with the ‘first hit’ LNN kidney then 
later becomes vulnerable to various forms of renal injury, the ‘second hits’, thus 
enhancing the development toward CKD.  
 
 
- 191 - 
 
 
In my study, nephron number is decreased at birth in DDS/+ mice as a result of 
abnormal development and not the disease state that leads to fewer nephrons in DDS/+ 
mice. Although DDS/+ kidneys do not differ in size from wild type at birth, there is a 
differential effect on different stages of nephrogenesis, indication of factors contributing 
to the nephron number start before parturition.  
Given the insight that the main mechanism of nephron formation and 
mesenchymal-epithelial transformation was disrupted, in the absence of obvious 
apoptosis event in foetal kidneys, the mechanism of controlled cell death during the 
kidney was not disrupted, it is unlikely that nephron niche dies to contribute to the lack of 
nephron number. WT1 was shown to exerts important function in renal progenitors 
(Figure 7.1.1), with a possibility of altering mechanisms in the early stage of nephron 
formation such as reduction of proliferation and survivality, thus altering the total 
nephron number at the end of nephrogenesis (Figure 7.1.2). 
 
 
Figure 7.1.1: A) and B) depicting the summation of role of WT1 in formation of 
pretubular aggregates / renal vesicle (PTA-RV). My study postulates that with the 
loss of normal WT1 function, the cascade of abnormally expressing gene would 
result in loss of nephron precursor (PTA-RV, pretubular aggregates/ renal vesicle) 
when introduced to stressed as a result from the tissue inability to adequately 
cope to the stressful event.  
A) B) 
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Figure 7.1.2: A model depicting the proposed mechanism of nephron endowment in 
DDS/+ mouse kidney. The total reduction shown in this diagram represented about 22% 
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reduction in numbers. Each branching morphogenesis step from top to bottom show 
increasing induced progenitors (yellow circle), decreasing uninduced progenitors (green 
circle), and appearance of PTA-RV formation (solid red circle) followed by committed 
nephron (red outlined circle with dull red centre). Final stage of nephron (triggered on 
parturition) involved induction of all remaining progenitors to be nephron.  
Various other mechanism of LNN development in kidney have been postulated by 
various studies. We hypothesise that in WT1 mutant (DDS/+), the observable reduction 
of nephron number and accelerated maturation of nephrons may induce a premature 
cessation of nephrogenesis leading to a reduced nephron number due to Wt1 
haploinsufficiency via a yet unknown mechanism. In addition, increasing cell turn over in 
IUGR babies, attempting to ’catch up’ by accelerated growth has been suggested to 
induce LNN kidney, shortening the telomeres (Jennings et. al., 1999, Hales 2001), and 
depleting the progenitor stem cells, increasing the risk for kidney diseases (Welham el. 
al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
- 194 - 
 
Figure 7.1.3: Potential mechanisms of factors related to low nephron number (LNN) and 
its subsequent progression towards adult kidney disease. (Adapted from Zandi-Nejad et. 
al., 2005, Hershkovitz et. al., 2007).  
 
Further correlation between nephron endowment and the increased tendency 
towards kidney disease can be seen in some clinical studied, where patients with a 
solitary kidney (lower nephron number per individual) show a higher incidence of chronic 
renal failure when compared to normal subjects (Rugiu et. al., 1986, Thorner et. al., 
1984, Zucchelli et. al., 1985). Solitary kidney transplants originating from ethnic groups 
having naturally lower nephron number show higher incidence of graft failures after 3 
years and allograft nephropathy (Terasaki et. al., 1994, Azuma et. al., 1997, Heemann 
et. al., 1994, Mackenzie et. al., 1996). Whilst these examples are rather extreme cases, 
it is likely that even a modest reduction in nephron number will increase the risk of 
developing CKD and the associated complications.  
I showed that loss of WT1 causes segregation or fragmentation of mitochondria and 
a profound metabolic state, which could drive the accelerated nephron maturation 
(differentiation). The WT1 mutation is postulated to cause stem-cell self-renewal 
deregulations and impairment of regenerative potential. Comparable deduction of my 
mitochondrial findings in nephron and MEF to a recent study in f rapid ageing 
hematopoietic stem cells (Ho et al., 2017), in which they showed that increased 
autophagy in this type of cells clears healthy mitochondria, in effect it maintains 
quiescence and stemness by supressing stem cell metabolism and functions to preserve 
the regenerative capacity in the ageing process.  
My findings have stimulating implications for WT1 as they recognize a novel 
cellular characteristic that has the potential to be directly targeted to improve kidney 
function and preserve the health of renal system. In this setting, understanding of 
why/how WT1 activates the mitochondrial system, as well as finding the extra drivers for 
this differential adaptive response, will help supplement our understanding of nephron 
endowment, and develop more targeted approaches for improving kidney health during 
development and disease. 
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7.2 Summary 
To summarize, nephron number is decreased at birth in DDS/+ mice. Thus, it is 
abnormal development and not the disease state that leads to fewer nephrons in DDS/+ 
mice with indication of factors contributing to the nephron number start before parturition 
(i.e. genotype or other factors).  
This study achieved the first objective of utilising WT1 mutant mice to uncover 
molecular mechanism underlying nephron number and second objective of 
understanding the pathway that would eventually lead these mice into a diseased state. 
Gene expression profile of e17.5 DDS/+ kidney and wild type revealed novel genes 
underlying development and biochemical interaction in foetal kidney development in 
relating to WT1 gene. Changes seen in mitochondrial tRNA and its alteration give clues 
towards more complex interaction between nuclear genes, mitochondria and 
WT1.Databases analysis including Ingenuity Pathway Analysis (IPA) shows confirmation 
of some genes that were found to be involved in nephron formation. There are also 
genes related to apoptosis dysregulated from microarray data.  Although no difference in 
the pattern of apoptosis was seen between wild type immature nephrons and DDS/+ P0 
kidney, there is disruption of normal cellular physiology in MEF (Tamoxifen) when in an 
unfavourable environment (different substrates and oxygen deprived). In silico, meta-
analyses provide evidence for the involvement of Wt1-regulated, nuclear-encoded 
mitochondrial genes in “mitochondrial” and “membrane” processes. Wt1 protein is found 
in mitochondria in developing kidney, primary mouse embryonic fibroblasts (MEF), and 
human podocyte cells. Wt1 mutation causes mitochondrial network abnormalities 
(Mitotracker). Wt1 mutation causes elevated maximal oxygen consumption rate (OCR, 
Seahorse) in MEF and various evidence suggesting this would lead to diseased state. 
The finding in this study highlighted the WT1 is crucial in determining the nephron 
number and it does this through pre-natal period. This indicates the important role of 
keeping pregnancy stress-free and the need to have better ex-vivo detection method to 
determine nephron number and indirectly higher risk of kidney disease. This would be 
one of the next steps of research. If given the chance, I would like to get a better 
understanding of WT1 molecular mechanism in MEF buy doing expression analysis. 
This would make MEF better served as an important mechanism and means to search 
- 196 - 
 
for potential markers and medium of trial of therapy for WT1-caused low nephron 
number in mammals.  
To conclude, this thesis has shown there is a previously uncharacterised 
significant developmental, role for WT1 role in the murine DDS/+ model. Analysis of 
DDS/+ mice has revealed novel functions of WT1 in normal kidney development, 
dysfunction of which contributes to kidney disease.  
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APPENDICES 
 
Table A-2.6.3: List of Primers used 
 
Gene / region Sequence 
1 Acaa2 F  CCCCAGCAAAACCAATGTGAG 
2 Acaa2 R TTTCCACCTCGACGCCTTAAC 
3 Ankfn1 F  CGACACCAGGCAAGGAACTT 
4 Ankfn1 R  GAGTGCGGGGTGTAAGGATT 
5 Arhgef12 FWRD SET1   CGACTTCCCTCCTCCTCTATTA 
6 Arhgef12 FWRD SET2  CCGAGAGTCACCAACAGATAAG 
7 Arhgef12 REV SET1 GCTCATCCTCACTCTGACTTTC 
8 Arhgef12 REV SET2   GCGCTGAACAAGACCATAGA 
9 Arhgef6 F  TGGCTCGGTGGAGAAGTATTG 
10 Arhgef6R ACCTTGGAGAAATTGGCCCC 
11 Asb15 F  GAATCCATTGAAGCGAGCCAG 
12 Asb15 R  AGCTCAAAAATGCGACCTTGC 
13 B-ACTIN F1 HUMAN  CTCGTCGCCCACATAGGAAT 
14 B-ACTIN F1 HUMAN  CGTGCTCAGGGCTTCTTGT 
15 B-ACTIN F2 HUMAN  CCACCAGAAGAGGTAGCGGG 
16 B-ACTIN R2 HUMAN  CGACATGGAGAAAATCTGGCAC 
17 Bmp4 F TCCGTCCCTGATGGGATTCTC 
18 Bmp4 R  GGAATGGCTCCATTGGTTCCT 
19 Ccdc141 FWRD  AGCCCTTTACAAGGCATCTC 
20 Ccdc141 FWRD SET2 CGTTGTGAGAGTTGGGAAGTA 
21 Ccdc141 REV  CCAGATCACCACAGGACATAAA 
22 Ccdc141 REV SET2  GGCACCGAGGGAGTAATAAA 
23 Ccnyl1 FRWD SET2   GACCAGGCTGTATGGAATGTAG 
24 Ccnyl1 FWRD SET1 GTGTTTGGAGCCATAGAGAGAG 
25 Ccnyl1 REV SET1 CAGAGGATGAGAAGCACCATTAG 
26 Ccnyl1 REV SET2 ACTGGAGTAGCTCCAAGAAATG 
27 CD55 F1 HUMAN  GTGCCGTCCAGGTTACAGAA 
28 CD55 F2 HUMAN  TGCCGTCCAGGTTACAGAAG 
29 CD55 F3 HUMAN  CCATCTGGTGTTTGGGGGAA 
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30 CD55 R1 HUMAN  TTTCCCCCAAACACCAGATG 
31 CD55 R2 HUMAN ATTTCCCCCAAACACCAGATG 
32 CD55 R3 HUMAN  TGACACTCATGGTCCTATCAAGA 
33 CD55-F  GACAGACAGACAGACAGACATAC 
34 CD55-R  GTCTCCAACCACTTCCTCTTAAT 
35 CITED1 F CTTCTGAGCACCTGAGACCAAC 
36 CITED1 R  GTGCAGGCCTCGACATAGTT 
37 Cldn16 FWRD SET1  CCTACCTGATGACCCACAAATTA 
38 Cldn16 FWRD SET2 GCAAGAGGGATGTGAGGAAA 
39 Cldn16 REV SET1 CCACAGCATACCACACAGAA 
40 Cldn16 REV SET2  CTATGGGCCTCTGTTGCTATT 
41 Clec4g F  TCTCCAGAGGGCAATTGGGA 
42 Clec4g R  GTGCTCAGAATGAGAGCCCA 
43 Clic5 F  CCAAACAACAGAACAATGCTG 
44 Clic5 R  GTTGGTGTCAATCTCCTCTG 
45 Cre1R (DDS20/MEF) TGTTCTGAATCTCCTGGACA 
46 Ex9F2 (DDS20/MEF) AGACCTTCTCTGTCCGTTTAG 
47 neo52 (DDS20/MEF) GATGCCTGCTTGCCGAATATCATGG 
48 Crym F  CCACAAAGCTGTTGAAGCCC 
49 Crym R  GCGGTTCCACATTCTCACCT 
50 Ddn F  TTATAGTCGTCGCGCTCCTTC 
51 Ddn R  CCTACACGTGCGGCTCTG 
52 Dlg1 F  GTTCCTCCCTCCTCTCCCAT 
53 Dlg1 R  GGAGGAGGATTTGCCTGTGG 
54 Etos F  AGGACTACCTCAGTCTCATACC 
55 Etos R  TCCTCCAGTATCTGCCTTACT 
56 EYA1 F CCCACATATTCTCCCTACCCCT 
57 EYA1 R  GCCCACAATGCACCATAGGA 
58 GAPDH F1 HUMAN  CCACACTGAATCTCCCCTCC 
59 GAPDH F2 HUMAN  CCCACCACACTGAATCTCCC 
60 GAPDH F3 HUMAN  GAGCCGCACCTTGTCATGTA 
61 GAPDH R1 HUMAN  CTTGACACAAGCCCAGCTTC 
62 GAPDH R2 HUMAN  TCTGCCCCAGACCCTAGAAT 
63 GAPDH R3 HUMAN  CTCACCTTGACACAAGCCCA 
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64 GDNF F  TGGGTCTCCTGGATGGGATT 
65 GDNF R CGGCGGCACCTCGGAT 
66 Gm5346-F  TCAGCAAGTCTGTTCTGGTAAG 
67 Gm5346-R  GGTGGTTCCCATGTGTTAGT 
68 intronID10338497-F  GGAGTCCAGAGAACACAAGAAA 
69 intronID10338497-R  CCATGGTGCTCATGTGAAGA 
70 Iyd F  CACTGCAGAATGCAGGGCT 
71 Iyd R  CCACAGGAAGTAGCACCAACA 
72 Jarid1_sexChrom_Revs   CCACTGCCAAATTCTTTGG 
73 Jarid1_sexCrom_Fwd  CTGAAGCTTTTGGCTTTGAG 
74 Llph F  TGTCTCTCAGGTGAAGCATGG 
75 Llph R  TTAGAGCATCCCCGTCCACT 
76 Mafb F  CAGGGCTGGTTTGGAATCCT 
77 Mafb R  TTGGCTCAATGGGAGCTCAG 
78 Magi2 F  AAGTAGGCGTCCAGATTATAAGG 
79 Magi2 R  GCTGTCCAGGTTCATCTCCC 
80 mAldh1a2 ex2 for  GAGCAAGTGTGTGAAGTTCA 
81 mAldh1a2 ex4 rev  AGCTTGCAGGAATGGCTTAC 
82 Mcu F  TTGTGCCCTCTGATGACGTG 
83 Mcu R  CCTCCTCTTGCAGTTGTCGT 
84 Me3 F  CATGAGCGCCCTATCGTCTT 
85 Me3 R  CAAAGATTCCTCGGCCCTCG 
86 Mfap5 F  TTCACCAGTTTACGGCGCAT 
87 Mfap5 R  ACAGGGAGGAAGTCGGAAGT 
88 Micu3 F  TGACACTGACGGAAATGAGATGG 
89 Micu3 R  CCATAAAGTTGAAGACGCAGCAT 
90 Mir24-2 FWRD  CCTCCCGTGCCTACTGA 
91 Mir24-2 REV  GGGCTGGACTCCTGTTC 
92 Mrpl54 F  GTACCCCACATGGCTGTTCC 
93 Mrpl54 R  CTGTTTGCGAAGTAGTCGCC 
94 mWnt4 ex2 for  CAGGTGCAGATGTGCAAAC 
95 mWnt4 ex3 rev  GCTGAAGAGATGGCGTATAC 
96 Myo18b FWRD SET1  CTGGTTCGAGAGACAGAGAAAG 
97 Myo18b FWRD SET2  CATCATCTGTGACCTGGAGAAC 
- 200 - 
 
98 Myo18b REV SET1  GAACTGCTGGGATCTCTACTTC 
99 Myo18b REV SET2 GAGACAACTCTTCACCCATCTT 
100 ND1 mito FWD GCCGTAGCCCAAACAATTTC 
101 ND1 mito RVS  CAGGCTGGCAGAAGTAATCATA 
102 ND4 mito FWD  CTCAGTTAGCCACATAGCACTT 
103 ND4 mito RVS  GGAGTTTGCTAGGCAGAATAGG 
104 ND5 F1 HUMAN  CACACCGCACAATCCCCTAT 
105 ND5 F2 HUMAN  TCGCTTCCCCACCCTTACTA 
106 ND5 mito FWD  CTGGCAGACGAACAAGACA 
107 ND5 mito RVS GCTTCCGATTACTAGGCATGAT 
108 ND5 R1 HUMAN  TGGAGGTGGAGATTTGGTGC 
109 ND5 R2 HUMAN ATCCTGCGAATAGGCTTCCG 
110 Nebl F  CGGGGGATGTCACAGCG 
111 Nebl R  GTAGTGTGCATTGCAATAGGGCT 
112 Nes (Nestin) F  GCTACATACAGGACTCTGCTGG 
113 Nes (Nestin) R  GGTGCTGGTCCTCTGGTATC 
114 NME5 F  ATGAGCTCTGGACCTCTTGTTG 
115 NME5 R  CCCTTAAGCTGTCCGGGTG 
116 Nxph1-F  CCTGCGGAGTTAAAGGTCATAG 
117 Nxph1-R  CAACAAGAGCAGCAAGGTAGA 
118 Olfr1174psedo1 FWRD SET1 GGCTGTGTCATGCAATTCTTC 
119 Olfr1174psedo1 FWRD SET2  GCTCCACACTCCCATGTATTT 
120 Olfr1174psedo1 REV SET1 GGTTGCATACTGCCACAAATC 
121 Olfr1174psedo1 REV SET2  AGATCCTTCTGTCTTCCACAATC 
122 P1F-EX7-GENOME  TGAAACCAGTGAGAAACGTCCT 
123 P1R-EX10-GENOME  GCATGTTGTGATGGCGGAC 
124 P2F-EX7-GENOME  GTGCGGCGTGTATCTGGA 
125 P2R-EX10-GENOME  TCCGGCAAACCTGATAGGATG 
126 P3F-EX7-mRNA   CCGGTCAGCATCTGAAACCA 
127 P3R-EX10-mRNA CTCCTTCCGGCAAACCTGAT 
128 P4F-EX7-mRNA TGCATACCCAGGCTGCAATA 
129 P4R-EX10-mRNA  TGTTGTGATGGCGGACCAAT 
130 Pax2 (m) qPCR F Ex2  GCTGCACCCACGACAGAAGG 
131 Pax2 (m) qPCR R Ex3  GTCTCAATCGGACGGCAGTAG 
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132 PAX2 F  CCTGTTTCCAGCGCCTCTAA 
133 PAX2 R  CAGACACATCTTCCTCGCGT 
134 Pax2 set1 F   TCCCAGTGTCTCATCCATCA 
135 Pax2 set1 R  GTTAGAGGCGCTGGAAACAG 
136 Pax2 set2 F GCAGGTACTACGAGACTGGC 
137 Pax2 set2 R CAGGCGAACATAGTCGGGTT 
138 Pck2 F  TGCGGAGCACAAAGGAAAGA 
139 Pck2 R  AACCAGTGTTCCAGGTAGCG 
140 Pcp4 F  TGAGTGAGAGACAAAGTGCCG 
141 Pcp4 R  TCTCTGGTGCATCCATGTCG 
142 Plce1 F  GCTGGTCTCCTATGGCCTTG 
143 Plce1 R  GGCACTGTAGATCAGGCACC 
144 Prol1 F  AAGCAACAACTGACTGTTCCA 
145 Prol1 R  GATGACTTTCACCAGGCATGAA 
146 Prp2 FWRD SET1 ATGCTGGTGGTCCTGTTTAC 
147 Prp2 FWRD SET2  CCCGTGAAGAACTTCAGAATCA 
148 Prp2 REV SET1  GAAGGAGGTGGCCTTTGATT 
149 Prp2 REV SET2  CTTGCTGGCTCCCATTAACA 
150 Ptpn11 F  GGGGTCATGCGTGTTAGGAA 
151 Ptpn11 R  CCTGGAGTAGAGCTTGTCCGA 
152 Ptpro F  GGCAGTCTTTGTGGGTGGAT 
153 Ptpro R  GGCTGGTTAGGCAGGTAGC 
154 Reep1 F  TCATACAAGGCTGTGAAGTCCAA 
155 Reep1 R  AGAATGGAAACCAGCAAAGGAAGA 
156 RNASE12 F1 HUMAN  GACTCGGGAGCTGATCTTGA 
157 RNASE12 F2 HUMAN  GCCAAGGAAACTATCTGGCCT 
158 RNASE12 R1 HUMAN  CCCACAGAGGGGTTTGTTCT 
159 RNASE12 R2 HUMAN  GCAGGTACCACTATTCCCCC 
160 Rnf39 F  TCCCCACGGAGAGGATATGA 
161 Rnf39 R TGTCAGCCTGTGAAGCATGT 
162 SALL1 F  AAGCAAGCGAAGCCTCAACA 
163 SALL1 R  ACCCTTCTCTGTGTCCCCATC 
164 Slc25a18 F  GTACCGAGGGGCTGCAGTAA 
165 Slc25a18 R  CATATTCCAGCCCCACACCC 
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166 Snap91 F  TGGGGAGACCTTTTGGGAGA 
167 Snap91 R  AGTAGGAGGGGAAGGCTCTG 
168 Sp140 FWRD SET1  CGGAGCAGAAGTTTCAGGAATA 
169 Sp140 FWRD SET2  GGAGGCTATGGAAAGTCAAAGA 
170 Sp140 REV SET1 CTTTCAGAAGATCCCGGCTAAA 
171 Sp140 REV SET2  CGATGTATCCGTGGAGGATTG 
172 Stap2 F  GGACCCTGTGACCAGGATTA 
173 Stap2 R GCAGAGCCTCATCTCTGAGC 
174 Sulf1-F(Heidet)  CACCTCCCACTCCTCCTTTTG 
175 Sulf1-R(Heidet)  GAACTCCCCAGCCAAGTAACCT 
176 Tbc1d10a F  CTGGGAAGTTTGATGAGCTGG 
177 Tbc1d10a R CTTCAGCACACGGAACAGGT 
178 Tgfb1 F  CTTTGTACAACAGCACCCGC 
179 Tgfb1 R  ATAGATGGCGTTGTTGCGGT 
180 Tgfbr3 F  AGCTGCCAAAGTGTGTGACT 
181 Tgfbr3 R  CCAGGGGCTTGGTGAATGTC 
182 tRNA-ala F1 human GGGCTTAGCTTAATTAAAGTGGCT 
183 tRNA-ala F2 human  GGGCTTAGCTTAATTAAAGTGGCTG 
184 tRNA-ala F3 human AGGGCTTAGCTTAATTAAAGTGGCT 
185 tRNA-ala NC_005089 FWD  GAGGTCTTAGCTTAATTAAAGC 
186 tRNA-ala NC_005089 RVS  TAAGGACTGTAAGACTTCATCC 
187 tRNA-ala R1 human  ACCCCACTCTGCATCAACTG 
188 tRNA-ala R2 human  AGGACTGCAAAACCCCACTC 
189 tRNA-ala R3 human  GCAAAACCCCACTCTGCATC 
190 tRNA-arg NC_005089 FWD  TGGTAATTAGTTTAAAAAAAATT 
191 tRNA-arg NC_005089 RVS  TTGGTAATTATGAACATCATCA 
192 tRNA-his NC_005089 FWD  TGAATATAGTTTACAAAAAACA 
193 tRNA-his NC_005089 RVS  GGTGAATAAGGAGGTTTATTTC 
194 tRNA-PHE F1 human GTAGCTTACCTCCTCAAAGCA 
195 tRNA-PHE F2 human  TGTAGCTTACCTCCTCAAAGCAA 
196 tRNA-phe NC_005089 FWD  GTTAATGTAGCTTAATAACAAAGC 
197 tRNA-phe NC_005089 RVS  TGTTTATGGGATACAATTATCC 
198 tRNA-PHE R1 human GTTTATGGGGTGATGTGAGCC 
199 tRNA-PHE R2 human  GGTGATGTGAGCCCGTCTAAA 
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200 tRNA-TYR F1 human  AAAAAGAGGCCTAACCCCTGT 
201 tRNA-TYR F2 human  AGAGGCCTAACCCCTGTCTT 
202 tRNA-TYR F3 human AAGAGGCCTAACCCCTGTCT 
203 tRNA-tyr NC_005089 FWD  GGTAAAATGGCTGAGTAAGCAT 
204 tRNA-tyr NC_005089 RVS  TGGTAAAAAGAGGATTTAAACC 
205 tRNA-TYR R1 human  TGGCTGAGTGAAGCATTGGA 
206 tRNA-TYR R2 human  GGTAAAATGGCTGAGTGAAGCA 
207 tRNA-TYR R3 human  AAATGGCTGAGTGAAGCATTGG 
208 Vegfa (m) qPCR F Ex6  GCGTCCTTCCTATCCCGATGTC 
209 Vegfa (m) qPCR R Ex7  CTTGACTTCATCAAGCCCAGG 
210 VEGFa set1 F CAGGCTGCTGTAACGATGAA 
211 VEGFa set1 R  GCCTTGGCTTGTCACATTTT 
212 VEGFa set2 F  ATCTTCAAGCCGTCCTGTGT 
213 VEGFa set2 R  GCATTCACATCTGCTGTGCT 
214 Vegfa splicing primers F  CACAGCAGATGTGAATGCAG 
215 Vegfa splicing primers R  CCTTCCTGCAGCCTGGCTC 
216 Wnt10a FWRD SET1 CTCTGCTCCTGTCTTTCACTT 
217 Wnt10a FWRD SET2  ACTCCGACCTGGTCTACTTT 
218 Wnt10a REV SET1  GTCCCTTAATCAGCCTGTAGAC 
219 Wnt10a REV SET2  ACCCGTGCTGCTCTTATTG 
220 WNT11 F  GCAACCTCGCAGGCGG 
221 WNT11 R  AAGAGCAGAGCCTCGCAGA 
222 WNT4 F GCGAGCAATTGGCTGTACCT 
223 WNT4 R  GCCTTTGAGTTTCTCGCACG 
224 Wnt5a F  AGCCCTGCTTTGGATTGTCC 
225 Wnt5a R  TCCAATGGGCTTCTTCATGGC 
226 WT1 F  TTAAAGGGAATGGCTGCTGGG 
227 WT1 R  CTCTCATACCCTGTGCCGTG 
228 Zbtb20 F  ACTTCCAGGGAGACACCGAT 
229 Zbtb20 R  AAGGAAACACCTTCAGCCTTCA 
230 zfp507 FRWD SET2 AGCCTTACCAGTGTCCTATCT 
231 zfp507 FWRD SET1  CCACCGTCTTCATCTCCTTTAG 
232 zfp507 REV SET1   TCCAGCATTTCTTCCTCGTTAG 
233 zfp507 REV SET2  GCACTGCTTACATTGGTGTATTC 
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234 Gapdh F AACTTTGGCATTGTGGAAGG 
235 Gapdh R ACACATTGGGGGTAGGAACA 
236 B-actin F TGCCGCATCCTCTTCCTC 
237 B-actin R  CCACAGGATTCCATACCCAAG 
238 Hprt F TGATTAGCGATGATGAACCAGG 
239 Hprt R CCTTCATGACATCTCGAGCAAG 
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Appendix for Chapter 3 
Length Pole-
to-pole (LPP) 
longitudinal 
cross-sectional 
area 
Nnephron Nglomeruli NComma NS-
Shaped 
Genotype 
3205.38 5318570.23 4496 3264 976 256 1 - wt 
3333.45 5840747.75 4024 2952 832 240 1 
3482.24 6620300.26 4136 2992 824 320 1 
3985.87 8407056.84 4768 3504 968 296 1 
3620.90 7206341.69 3744 2656 856 232 1 
3414.43 6478782.14 4392 3192 1008 192 1 
3863.48 7592049.22 4320 2920 1056 344 1 
3161.38 5440921.28 3616 2664 824 128 2 - Het 
3788.89 7515193.93 3392 2544 752 96 2 
3907.12 7062746.49 2740 2120 560 60 2 
3201.43 5841391.91 3912 2904 888 120 2 
3327.65 5508807.91 3552 2440 944 168 2 
3536.84 6445916.81 4192 3248 864 80 2 
3585.75 6190513.75 3528 2752 664 112 2 
 
Table A-3.2.1: All values and counts of all variables (as per describe in table headings) 
involved in calculations.  
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Table A-3.2.2: Inclusions of data for testing normality.  
 
 
Table A-3.2.3: Beta values for Comma-shaped bodies and glomeruli numbers. The beta 
coefficients are significant, correlating the two variables, with increment of 0.6 unit of 
outcome variable per increment of predictor variable.  
 
R R Square
Adjusted R 
Square
Std. Error of the 
Estimate
1 .692
a .479 .436 397.88536
Model Summary
b
Model
a. Predictors: (Constant), Genotypes
b. Dependent Variable: TotalNephronNumber
 
R R Square
Adjusted R 
Square
Std. Error of the 
Estimate
1 .562
a .316 .259 319.06053
Model Summary
b
Model
a. Predictors: (Constant), Genotypes
b. Dependent Variable: GlomeruliNumber
 
 
Case Processing Summary 
 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
LengthPoleToPole 14 100.0% 0 0.0% 14 100.0% 
LongCrossSection 14 100.0% 0 0.0% 14 100.0% 
TotalNephronNumber 14 100.0% 0 0.0% 14 100.0% 
GlomeruliNumber 14 100.0% 0 0.0% 14 100.0% 
CommaBodies 14 100.0% 0 0.0% 14 100.0% 
SshapedBodies 14 100.0% 0 0.0% 14 100.0% 
Genotypes 14 100.0% 0 0.0% 14 100.0% 
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Standardized 
Coefficients
B Std. Error Beta Lower Bound Upper Bound Zero-order Partial Part Tolerance VIF
(Constant) 4975.429 336.275 14.796 .000 4242.749 5708.108
Genotypes -706.857 212.679 -.692 -3.324 .006 -1170.244 -243.470 -.692 -.692 -.692 1.000 1.000
1
a. Dependent Variable: TotalNephronNumber
Coefficients
a
Model
Unstandardized Coefficients
t Sig.
95.0% Confidence Interval for B Correlations Collinearity Statistics
 
Standardized 
Coefficients
B Std. Error Beta Lower Bound Upper Bound Zero-order Partial Part Tolerance VIF
(Constant) 3469.714 269.655 12.867 .000 2882.186 4057.243
Genotypes -401.143 170.545 -.562 -2.352 .037 -772.729 -29.557 -.562 -.562 -.562 1.000 1.000
1
a. Dependent Variable: GlomeruliNumber
Coefficients
a
Model
Unstandardized Coefficients
t Sig.
95.0% Confidence Interval for B Correlations Collinearity Statistics
 
 
 
 
 
 
 
 
 
T-test 
Group Statistics 
 Genotypes N Mean Std. Deviation Std. Error Mean 
LengthPoleToPole 1.00 7 3557.9643 283.27332 107.06725 
2.00 7 3501.2943 286.18605 108.16816 
LongCrossSection 1.00 7 6780549.7329 1050611.80473 397093.93711 
2.00 7 6286498.8686 781537.37773 295393.36311 
TotalNephronNumber 1.00 7 4268.5714 334.56382 126.45324 
2.00 7 3561.7143 452.42963 171.00233 
GlomeruliNumber 1.00 7 3068.5714 275.30762 104.05650 
2.00 7 2667.4286 357.49819 135.12161 
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CommaBodies 1.00 7 931.4286 92.93521 35.12621 
2.00 7 785.1429 135.40486 51.17823 
SshapedBodies 1.00 7 268.5714 53.63723 20.27297 
2.00 7 109.1429 35.07814 13.25829 
 
Robust Tests of Equality of Means 
 Statistica df1 df2 Sig. 
LengthPoleToPole Welch .139 1 11.999 .716 
Brown-Forsythe .139 1 11.999 .716 
LongCrossSection Welch .997 1 11.084 .339 
Brown-Forsythe .997 1 11.084 .339 
TotalNephronNumber Welch 11.046 1 11.051 .007 
Brown-Forsythe 11.046 1 11.051 .007 
GlomeruliNumber Welch 5.532 1 11.265 .038 
Brown-Forsythe 5.532 1 11.265 .038 
CommaBodies Welch 5.554 1 10.626 .039 
Brown-Forsythe 5.554 1 10.626 .039 
SshapedBodies Welch 43.317 1 10.339 .000 
Brown-Forsythe 43.317 1 10.339 .000 
 
a. Asymptotically F distributed. 
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Independent Samples Test 
 
Levene's Test for Equality of 
Variances 
t-test for 
Equality 
of Means 
F Sig. t 
LengthPoleToPole Equal variances assumed .004 .949 .372 
Equal variances not 
assumed 
  .372 
LongCrossSection Equal variances assumed .574 .463 .998 
Equal variances not 
assumed 
  .998 
TotalNephronNumber Equal variances assumed .074 .790 3.324 
Equal variances not 
assumed 
  3.324 
GlomeruliNumber Equal variances assumed .173 .685 2.352 
Equal variances not 
assumed 
  2.352 
CommaBodies Equal variances assumed .951 .349 2.357 
Equal variances not 
assumed 
  2.357 
SshapedBodies Equal variances assumed 2.162 .167 6.582 
Equal variances not 
assumed 
  6.582 
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Independent Samples Test (continue) 
 
t-test for Equality of Means 
df Sig. (2-tailed) Mean Difference 
LengthPoleToPole Equal variances assumed 12 .716 56.67000 
Equal variances not assumed 11.999 .716 56.67000 
LongCrossSection Equal variances assumed 12 .338 494050.86429 
Equal variances not assumed 11.084 .339 494050.86429 
TotalNephronNumber Equal variances assumed 12 .006 706.85714 
Equal variances not assumed 11.051 .007 706.85714 
GlomeruliNumber Equal variances assumed 12 .037 401.14286 
Equal variances not assumed 11.265 .038 401.14286 
CommaBodies Equal variances assumed 12 .036 146.28571 
Equal variances not assumed 10.626 .039 146.28571 
SshapedBodies Equal variances assumed 12 .000 159.42857 
Equal variances not assumed 10.339 .000 159.42857 
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Independent Samples Test 
 
t-test for Equality of Means 
Std. Error 
Difference 
95% Confidence Interval of the 
Difference 
Lower Upper 
LengthPoleToPole Equal variances assumed 152.19641 -274.93749 388.27749 
Equal variances not assumed 152.19641 -274.94134 388.28134 
LongCrossSection Equal variances assumed 494914.97639 -584276.23588 1572377.96445 
Equal variances not assumed 494914.97639 -594246.75959 1582348.48817 
TotalNephronNumber Equal variances assumed 212.67867 243.47012 1170.24416 
Equal variances not assumed 212.67867 239.02044 1174.69385 
GlomeruliNumber Equal variances assumed 170.54502 29.55717 772.72854 
Equal variances not assumed 170.54502 26.84984 775.43587 
CommaBodies Equal variances assumed 62.07303 11.04020 281.53123 
Equal variances not assumed 62.07303 9.07539 283.49604 
SshapedBodies Equal variances assumed 24.22345 106.65021 212.20693 
Equal variances not assumed 24.22345 105.69410 213.16304 
 
Figure A.3.1: Redual analysis 
for data normalisation.  
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Appendix for Chapter 4 
4932411E22Rik 1700041G16Rik 1700010H22Rik 1700108M19Rik A930002I21Rik 
6530418L21Rik 2310015B20Rik 4430402I18Rik Abca15 Adam11 
Ankrd13c A930004D18Rik 9830107B12Rik Akap2 Adamtsl3 
Ap1s1 Anxa3 Alpk1 Ankfn1 Adora1 
Asb15 Arhgap18 Ano4 Ano6 Afap1l2 
B3galt5 Arhgap28 Arhgef3 Anxa2 Agps 
C1qtnf6 Arhgef4 Calcrl Art3 Arhgap25 
Ccdc92 Armc4 Cdk15 Atp9b Ccdc62 
Cd34 Ascl1 Clec14a Cdc20b Cdc14a 
Cd5 Atp2b1 Clic5 Chn2 Cdhr3 
Csmd3 Atp2b4 Crip2 Csrp1 Chgb 
Daam1 B3galt1 Csdc2 Dhrs7c Clcn3 
Dtd1 Chrdl2 Cxxc4 E230008N13Rik Creb3 
Dtx4 Chst15 Cyp4a12b Eftud1 D6Ertd474e 
Edaradd E230008N13Rik Dub1 Enc1 Dnahc7b 
Entpd3 E230008N13Rik Elf4 Esyt2 Dock4 
Fabp12 Elmo1 Elovl5 Fat3 Dpp6 
Fgf20 Fndc3b Enox1 Filip1 E330009J07Rik 
Gipc1 Grin2a Fat3 Gm766 Ect2l 
Gm973 Hdac5 Gm10637 Greb1l Fhad1 
Gnal Il15 Gm1110 L1cam Foxo6 
Hmcn1 Kat2b Grik4 Lhx9 Gas5 
Inpp5d Lamb1 Hs3st3b1 Nebl Il1rapl1 
Klk15 Map4k3 Lrrk1 Net1 Kank4 
Magi2 Mast1 Mmrn2 Nlrc5 Lyrm4 
Mgat1 Mesdc1 Mylk4 Pcp4 Myof 
Ngf Npr3 Nt5c2 Pcsk6 Nes 
Nlrc5 Pknox2 Pde4d Pld1 Nlrc5 
Npas3 Reln Pex5l Ptpro Nmu 
Plb1 Scn3a Pgm2 Rab3il1 Nrxn2 
Plce1 Selm Plekhm3 Rasa4 Pard3b 
Rgag4 Sema3f Ptprr Rgs8 Parvb 
Sat2 Sema6d Scn4a Rp1 Pde10a 
Sfmbt2 Slc26a7 Slc4a10 S100a10 Prkch 
Sh2d4a Slc35f4 Sqstm1 Senp5 Prss16 
Shb Smoc1 Stac2 Slc12a6 Ptplad2 
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Slc25a14 Snap91 Tgfbr3 Slc25a40 Rcsd1 
Slc9a9 Soat1 Tmprss11f Slc45a3 Slc4a8 
Spats2 Specc1 Tpm4 Spnb1 Susd4 
Sulf1 St3gal4 Tspan2 Tchh Unc13c 
Tbc1d10a Stom Txndc5 Tgfbr2 Wt1 
Tiam2 Tec Wwc2 Ttc4 Zfp385b 
Yipf1 Txnrd2 Zfp353 Zbtb20 
 
 
 
 
Genes 
WT1 Target 
Domain 
Descriptions 
Slc25a40 yes 
NM_178766 ::: Mus musculus solute carrier family 25, member 40 
(Slc25a40), nuclear gene encoding mitochondrial protein, mRNA. 
Clic5 yes 
NM_172621 ::: Mus musculus chloride intracellular channel 5 (Clic5), 
nuclear gene encoding mitochondrial protein, mRNA. 
Slc25a14 yes 
NM_011398 ::: Mus musculus solute carrier family 25 (mitochondrial 
carrier, brain), member 14 (Slc25a14), nuclear gene encoding 
mitochondrial protein, transcript variant 2, mRNA. 
Txnrd2 yes 
NM_013711 ::: Mus musculus thioredoxin reductase 2 (Txnrd2), nuclear 
gene encoding mitochondrial protein, mRNA. 
Dtd1 yes 
NM_025314 ::: Mus musculus D-tyrosyl-tRNA deacylase 1 homolog (S. 
cerevisiae) (Dtd1), nuclear gene encoding mitochondrial protein, 
mRNA. 
Maob no 
NM_172778 ::: Mus musculus monoamine oxidase B (Maob), nuclear 
gene encoding mitochondrial protein, mRNA. 
Reep1 no 
NM_178608 ::: Mus musculus receptor accessory protein 1 (Reep1), 
nuclear gene encoding mitochondrial protein, mRNA. 
Tufm no 
NM_001163713 ::: Mus musculus Tu translation elongation factor, 
mitochondrial (Tufm), nuclear gene encoding mitochondrial protein, 
transcript variant 2, mRNA. 
Opa1 yes 
NM_133752 ::: Mus musculus optic atrophy 1 homolog (human) 
(Opa1), nuclear gene encoding mitochondrial protein, mRNA. 
Cps1 no 
NM_001080809 ::: Mus musculus carbamoyl-phosphate synthetase 1 
(Cps1), nuclear gene encoding mitochondrial protein, mRNA. 
Table A-4.6.2: List of 216 genes that contain WT1 target sequence (intragenic) from my 
array 
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Pck2 no 
NM_028994 ::: Mus musculus phosphoenolpyruvate carboxykinase 2 
(mitochondrial) (Pck2), nuclear gene encoding mitochondrial protein, 
mRNA. 
Slc25a18 no 
NM_001081048 ::: Mus musculus solute carrier family 25 (mitochondrial 
carrier), member 18 (Slc25a18), nuclear gene encoding mitochondrial 
protein, mRNA. 
 
 
 
 
 
Figure A.4.6.1: A Venn diagram showing overlap of comparison database of 3 
microarrays (p<0.05). [A] is E17.5 whole kidney microarray, [O] is DDS/+ heterozygous 
adult isolated podocyte glomerulus kidney microarray from Ratelade et al., 2010, and [P] 
is WT1 heterozygous mutant adult isolated glomerulus kidney microarray from 
Schumacher et al., 2011. Adjacent tables showing the respective overlap list of 
differentially expressed genes in mutant mice together with regulation status and listed 
indication for presence of WT1 transcriptional binding.  
 
Table A-4.6.3 :  List of mitochondrial related genes (nuclear gene 
encoding mitochondrial protein, mRNA) (p < 0.05) from my array, 
excluding the tRNAs.  
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Figure A.4.6.2: An extension of previous Venn diagram to include a gene list from 
MitoMiner website, [M] MitoCarta2.0 that recently updated listing the known genes that 
directly related to the mitochondrial. Adjacent tables showing the respective overlap list 
of differentially expressed genes in mutant mice together with regulation status and 
listed indication for presence of WT1 transcriptional binding.  
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Figure A.4.6.3: A Venn diagram showing overlap of comparison database of 3 
microarrays (p<0.05). [A] is E17.5 whole kidney microarray, [O] is DDS/+ heterozygous 
adult isolated podocyte glomerulus kidney microarray from Ratelade et al., 2010, and [P] 
is WT1 heterozygous mutant adult isolated glomerulus kidney microarray from 
Schumacher et al., 2011, and [M] MitoCarta2.0 that listing genes that directly related to 
the mitochondrial. Adjacent tables showing the respective overlap list of differentially 
expressed genes in mutant mice together with regulation status and listed indication for 
presence of WT1 transcriptional binding. 
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Appendix Chapter 6 
Genes Full name and annotated functions if any 
Clpb ClpB caseinolytic peptidase B; May function as a regulatory ATPase and be related to 
secretion/protein trafficking process (677 aa) 
Ltbp1 latent transforming growth factor beta binding protein 1 (1712 aa) 
Tgfb1 transforming growth factor, beta 1; Multifunctional protein that controls proliferation, 
differentiation and other functions in many cell types. Many cells synthesize TGFB1 and 
have specific receptors for it. It positively and negatively regulates many other growth 
factors. It plays an important role in bone remodeling as it is a potent stimulator of 
osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in 
committed osteoblasts (390 aa) 
Ciao1 cytosolic iron-sulfur protein assembly 1; Key component of the cytosolic iron-sulfur protein 
assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-
sulfur cluster into extramitochondrial Fe/S proteins. Seems to specifically modulate the 
transactivation activity of WT1. As part of the mitotic spindle-associated MMXD complex it 
may play a role in chromosome segregation (By similarity) (339 aa) 
Pdk1 pyruvate dehydrogenase kinase, isoenzyme 1; Serine/threonine kinase that plays a key 
role in regulation of glucose and fatty acid metabolism and homeostasis via 
phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This 
inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through 
the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation 
of acetyl-coenzyme A from pyruvate. Plays an important role in cellular responses to 
hypoxia and is important for cell proliferation under hypoxia. Protects cells against apo [...] 
(434 aa) 
Wtap Wilms’ tumour 1-associating protein; Regulates G2/M cell-cycle transition by binding to the 
3’ UTR of CCNA2, which enhances its stability. Impairs WT1 DNA- binding ability and 
inhibits expression of WT1 target genes. May be involved in mRNA splicing regulation (By 
similarity) (396 aa) 
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4; Serine/threonine kinase that plays a key 
role in regulation of glucose and fatty acid metabolism and homeostasis via 
phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This 
inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through 
the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation 
of acetyl-coenzyme A from pyruvate. Inhibition of pyruvate dehydrogenase decreases 
glucose utilization and increases fat metabolism in response to prolonged fasting and 
starv [...] (412 aa) 
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Tab1 TGF-beta activated kinase 1/MAP3K7 binding protein 1; May be an important signaling 
intermediate between TGFB receptors and MAP3K7/TAK1. May play an important role in 
mammalian embryogenesis (502 aa) 
Uqcrc1 ubiquinol-cytochrome c reductase core protein 1; This is a component of the ubiquinol-
cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part 
of the mitochondrial respiratory chain. This protein may mediate formation of the complex 
between cytochromes c and c1 (By similarity) (480 aa) 
Cps1 carbamoyl-phosphate synthetase 1; Involved in the urea cycle of ureotelic animals where 
the enzyme plays an important role in removing excess ammonia from the cell (1500 aa) 
Mterfd2 MTERF domain containing 2; Required for the targeting of the methyltransferase NSUN4 
to mitochondrial large ribosomal subunit and efficient rRNA methylation (346 aa) 
Yme1l1 YME1-like 1 (S. cerevisiae); Putative ATP-dependent protease which plays a role in 
mitochondrial protein metabolism. Ensures cell proliferation, maintains normal cristae 
morphology and complex I respiration activity, promotes antiapoptotic activity, and 
protects mitochondria from the accumulation of oxidatively damaged membrane proteins. 
Requires to control the accumulation of nonassembled respiratory chain subunits 
(NDUFB6, OX4 and ND1). Seems to act in the processing of OPA1 (By similarity) (715 
aa) 
Stom stomatin; Thought to regulate cation conductance. May regulate ASIC2 and ASIC3 gating 
(284 aa) 
Park7 Parkinson disease (autosomal recessive, early onset) 7; Protects cells against oxidative 
stress and cell death. Plays a role in regulating expression or stability of the mitochondrial 
uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia 
nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the 
neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and 
protects cells against hydrogen peroxide-induced cell death. May act as an atypical 
peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Follow [...] (189 aa) 
Pdk3 pyruvate dehydrogenase kinase, isoenzyme 3; Inhibits pyruvate dehydrogenase activity 
by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism 
and aerobic respiration. Can also phosphorylate PDHA2. Decreases glucose utilization 
and increases fat metabolism in response to prolonged fasting, and as adaptation to a 
high-fat diet. Plays a role in glucose homeostasis and in maintaining normal blood glucose 
levels in function of nutrient levels and under starvation. Plays a role in the generation of 
reactive oxygen species (By similarity) (415 aa) 
Opa1 optic atrophy 1; Dynamin-related GTPase required for mitochondrial fusion and regulation 
of apoptosis. May form a diffusion barrier for proteins stored in mitochondrial cristae. 
Proteolytic processing in response to intrinsic apoptotic signals may lead to disassembly 
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of OPA1 oligomers and release of the caspase activator cytochrome C (CYCS) into the 
mitochondrial intermembrane space (978 aa) 
Letmd1 LETM1 domain containing 1; Involved in tumorigenesis and may function as a negative 
regulator of the p53/TP53 (360 aa) 
Scube3 signal peptide, CUB domain, EGF-like 3; Binds to TGFBR2 and activates TGFB signaling 
(By similarity) (993 aa) 
Pck2 phosphoenolpyruvate carboxykinase 2 (mitochondrial); Catalyzes the conversion of 
oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic 
pathway that produces glucose from lactate and other precursors derived from the citric 
acid cycle (By similarity) (667 aa) 
Foxred1 FAD-dependent oxidoreductase domain containing 1 (493 aa) 
Map3k7 mitogen-activated protein kinase kinase kinase 7; Serine/threonine kinase which acts as 
an essential component of the MAP kinase signal transduction pathway. Plays an 
important role in the cascades of cellular responses evoked by changes in the 
environment. Mediates signal transduction of TRAF6, various cytokines including 
interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like 
BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-
cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, 
acts as a [...] (606 aa) 
Maob monoamine oxidase B; Catalyzes the oxidative deamination of biogenic and xenobiotic 
amines and has important functions in the metabolism of neuroactive and vasoactive 
amines in the central nervous system and peripheral tissues. MAOB preferentially 
degrades benzylamine and phenylethylamine (By similarity) (520 aa) 
Chchd4 coiled-coil-helix-coiled-coil-helix domain containing 4; Functions as chaperone and 
catalyzes the formation of disulfide bonds in substrate proteins, such as COX17. Required 
for the import and folding of small cysteine-containing proteins (small Tim) in the 
mitochondrial intermembrane space (IMS). Precursor proteins to be imported into the IMS 
are translocated in their reduced form into the mitochondria. The oxidized form of 
CHCHD4/MIA40 forms a transient intermolecular disulfide bridge with the reduced 
precursor protein, resulting in oxidation of the precursor protein that now contain [...] (139 
aa) 
Pdk2 pyruvate dehydrogenase kinase, isoenzyme 2; Serine/threonine kinase that plays a key 
role in the regulation of glucose and fatty acid metabolism and homeostasis via 
phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This 
inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through 
the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation 
of acetyl-coenzyme A from pyruvate. Inhibition of pyruvate dehydrogenase decreases 
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glucose utilization and increases fat metabolism. Mediates cellular responses to insuli [...] 
(407 aa) 
Rnmtl1 RNA methyltransferase like 1; Probable RNA methyltransferase (By similarity) (418 aa) 
Oma1 OMA1 homolog, zinc metallopeptidase (S. cerevisiae); Metalloprotease that is part of the 
quality control system in the inner membrane of mitochondria. Following stress conditions 
that induce loss of mitochondrial membrane potential, mediates cleavage of OPA1 at S1 
position, leading to OPA1 inactivation and negative regulation of mitochondrial fusion. Its 
role in mitochondrial quality control is essential for regulating lipid metabolism as well as to 
maintain body temperature and energy expenditure under cold-stress conditions (521 aa) 
Parl presenilin associated, rhomboid-like; Required for the control of apoptosis during postnatal 
growth. Essential for proteolytic processing of an antiapoptotic form of OPA1 which 
prevents the release of mitochondrial cytochrome c in response to intrinsic apoptoptic 
signals (By similarity) (377 aa) 
Wtip WT1-interacting protein; Adapter or scaffold protein which participates in the assembly of 
numerous protein complexes and is involved in several cellular processes such as cell 
fate determination, cytoskeletal organization, repression of gene transcription, cell-cell 
adhesion, cell differentiation, proliferation and migration. Positively regulates microRNA 
(miRNA)-mediated gene silencing. Negatively regulates Hippo signaling pathway and 
antagonizes phosphorylation of YAP1. Acts as a transcriptional corepressor for SNAI1 and 
SNAI2/SLUG-dependent repression of E-cadherin transcription. A [...] (398 aa) 
Cox17 cytochrome c oxidase, subunit XVII assembly protein homolog (yeast) (63 aa) 
Tmem11 transmembrane protein 11; Plays a role in mitochondrial morphogenesis (By similarity) 
(190 aa) 
Pdha2 pyruvate dehydrogenase E1 alpha 2; The pyruvate dehydrogenase complex catalyzes the 
overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic 
pathway to the tricarboxylic cycle (By similarity) (391 aa) 
Lyrm4 LYR motif containing 4; Required for nuclear and mitochondrial iron-sulfur protein 
biosynthesis (By similarity) (91 aa) 
Eid2 EP300 interacting inhibitor of differentiation 2; Interacts with EP300 and acts as a 
repressor of MYOD- dependent transcription and muscle differentiation. Inhibits EP300 
histone acetyltransferase activity. Acts as a repressor of TGFB/SMAD transcriptional 
responses. May act as a repressor of the TGFB/SMAD3-dependent signaling by 
selectively blocking formation of TGFB-induced SMAD3-SMAD4 complex (By similarity) 
(236 aa) 
Slc25a40 solute carrier family 25, member 40 (337 aa) 
Sirt5 sirtuin 5 (silent mating type information regulation 2 homolog) 5 (S. cerevisiae); NAD-
dependent lysine demalonylase and desuccinylase that specifically removes malonyl and 
succinyl groups on target proteins. Activates CPS1 and contributes to the regulation of 
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blood ammonia levels during prolonged fasting- acts by mediating desuccinylation of 
CPS1, thereby increasing CPS1 activity in response to elevated NAD levels during fasting. 
Has weak NAD- dependent protein deacetylase activity; however this activity may not be 
physiologically relevant in vivo. Can deacetylate cytochrome c (CYCS) [...] (310 aa) 
Tgif2lx2 TGFB-induced factor homeobox 2-like, X-linked 2 (231 aa) 
Tgif2lx1 TGFB-induced factor homeobox 2-like, X-linked 1 (231 aa) 
mt-Co3 mitochondrially encoded cytochrome c oxidase III; Subunits I, II and III form the functional 
core of the enzyme complex (By similarity) (261 aa) 
mt-Nd3 mitochondrially encoded NADH dehydrogenase 3; Core subunit of the mitochondrial 
membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong 
to the minimal assembly required for catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The immediate electron acceptor for the 
enzyme is believed to be ubiquinone (By similarity) (115 aa) 
mt-Nd4 mitochondrially encoded NADH dehydrogenase 4; Core subunit of the mitochondrial 
membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong 
to the minimal assembly required for catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The immediate electron acceptor for the 
enzyme is believed to be ubiquinone (By similarity) (459 aa) 
mt-Nd5 mitochondrially encoded NADH dehydrogenase 5; Core subunit of the mitochondrial 
membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong 
to the minimal assembly required for catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The immediate electron acceptor for the 
enzyme is believed to be ubiquinone (By similarity) (607 aa) 
mt-Nd4l mitochondrially encoded NADH dehydrogenase 4L; Core subunit of the mitochondrial 
membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong 
to the minimal assembly required for catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The immediate electron acceptor for the 
enzyme is believed to be ubiquinone (By similarity) (98 aa) 
Pawr PRKC, apoptosis, WT1, regulator; Pro-apoptopic protein capable of selectively inducing 
apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing 
regression of tumors in animal models. Induces apoptosis in certain cancer cells by 
activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B 
transcriptional activity. Inhibits the transcriptional activation and augments the 
transcriptional repression mediated by WT1. Down- regulates the anti-apoptotic protein 
BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by [...] 
(333 aa) 
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Tufm Tu translation elongation factor, mitochondrial; This protein promotes the GTP-dependent 
binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis (By 
similarity) (452 aa) 
Thsd4 thrombospondin, type I, domain containing 4; Promotes FBN1 matrix assembly. 
Attenuates TGFB signaling, possibly by accelerating the sequestration of large latent 
complexes of TGFB or active TGFB by FBN1 microfibril assembly, thereby negatively 
regulating the expression of TGFB regulatory targets, such as POSTN (1018 aa) 
Tgif2 TGFB-induced factor homeobox 2; Transcriptional repressor, which probably repress 
transcription by binding directly the 5’-CTGTCAA-3’ DNA sequence or by interacting with 
TGF-beta activated SMAD proteins. Probably represses transcription via the recruitment 
of histone deacetylase proteins (By similarity) (237 aa) 
Oxr1 oxidation resistance 1; May be involved in protection from oxidative damage (866 aa) 
Slc25a18 solute carrier family 25 (mitochondrial carrier), member 18; Involved in the transport of 
glutamate across the inner mitochondrial membrane. Glutamate is cotransported with H(+) 
(By similarity) (320 aa) 
Slc25a14 solute carrier family 25 (mitochondrial carrier, brain), member 14; Participates in the 
mitochondrial proton leak measured in brain mitochondria (325 aa) 
Txnrd2 thioredoxin reductase 2; Maintains thioredoxin in a reduced state. Implicated in the 
defenses against oxidative stress. May play a role in redox- regulated cell signaling (524 
aa) 
AI037035 Cytochrome c oxidase copper chaperone ; Copper chaperone for cytochrome c oxidase 
(COX). Binds two copper ions and deliver them to the Cu(A) site of COX (By similarity) (63 
aa) 
Wt1 Wilms tumor 1 homolog; Transcription factor that plays an important role in cellular 
development and cell survival. Regulates the expression of numerous target genes, 
including EPO. Plays an essential role for development of the urogenital system. 
Recognizes and binds to the DNA sequence 5’-CGCCCCCGC-3’. It has a tumor 
suppressor as well as an oncogenic role in tumor formation. Function may be isoform-
specific- isoforms lacking the KTS motif may act as transcription factors. Isoforms 
containing the KTS motif may bind mRNA and play a role in mRNA metabolism or 
splicing. Isoform 1 has lo [...] (517 aa) 
Tgif1 TGFB-induced factor homeobox 1; Binds to a retinoid X receptor (RXR) responsive 
element from the cellular retinol-binding protein II promoter (CRBPII- RXRE). Inhibits the 
9-cis-retinoic acid-dependent RXR alpha transcription activation of the retinoic acid 
responsive element. May participate in the transmission of nuclear signals during 
development and in the adult, as illustrated by the down- modulation of the RXR alpha 
activities (By similarity) (305 aa) 
Table A-6.1.3.1: STRING genes list and annotated functions 
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Figure A-6.5.3: Box-plot of individual major time points of XF Cell Mito Stress Test. 
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